journals.lww.com
Open in
urlscan Pro
104.18.40.144
Public Scan
Submitted URL: https://doi.org/10.1002/hep.31812
Effective URL: https://journals.lww.com/hep/fulltext/2021/09000/analysis_and_validation_of_human_targets_and.24.aspx
Submission: On June 20 via api from HK — Scanned from DE
Effective URL: https://journals.lww.com/hep/fulltext/2021/09000/analysis_and_validation_of_human_targets_and.24.aspx
Submission: On June 20 via api from HK — Scanned from DE
Form analysis 1 forms found in the DOM
POST /hep/fulltext/2021/09000/analysis_and_validation_of_human_targets_and.24.aspx
<form method="post" action="/hep/fulltext/2021/09000/analysis_and_validation_of_human_targets_and.24.aspx" onsubmit="javascript:return WebForm_OnSubmit();" id="aspnetForm">
<div class="aspNetHidden">
<input type="hidden" name="_wpcmWpid" id="_wpcmWpid" value="">
<input type="hidden" name="wpcmVal" id="wpcmVal" value="">
<input type="hidden" name="MSOWebPartPage_PostbackSource" id="MSOWebPartPage_PostbackSource" value="">
<input type="hidden" name="MSOTlPn_SelectedWpId" id="MSOTlPn_SelectedWpId" value="">
<input type="hidden" name="MSOTlPn_View" id="MSOTlPn_View" value="0">
<input type="hidden" name="MSOTlPn_ShowSettings" id="MSOTlPn_ShowSettings" value="False">
<input type="hidden" name="MSOGallery_SelectedLibrary" id="MSOGallery_SelectedLibrary" value="">
<input type="hidden" name="MSOGallery_FilterString" id="MSOGallery_FilterString" value="">
<input type="hidden" name="MSOTlPn_Button" id="MSOTlPn_Button" value="none">
<input type="hidden" name="__EVENTTARGET" id="__EVENTTARGET" value="">
<input type="hidden" name="__EVENTARGUMENT" id="__EVENTARGUMENT" value="">
<input type="hidden" name="__REQUESTDIGEST" id="__REQUESTDIGEST" value="0x90F685307FA1DC88B17541C12D3D0E7B908331ACFDACA6B3355C3068F9FF69F8D3E502DEC19B0DD81137F9861930CF76FD748A74B7F8482C8BDEF7B59E347D86,20 Jun 2024 03:11:54 -0000">
<input type="hidden" name="MSOSPWebPartManager_DisplayModeName" id="MSOSPWebPartManager_DisplayModeName" value="Browse">
<input type="hidden" name="MSOSPWebPartManager_ExitingDesignMode" id="MSOSPWebPartManager_ExitingDesignMode" value="false">
<input type="hidden" name="MSOWebPartPage_Shared" id="MSOWebPartPage_Shared" value="">
<input type="hidden" name="MSOLayout_LayoutChanges" id="MSOLayout_LayoutChanges" value="">
<input type="hidden" name="MSOLayout_InDesignMode" id="MSOLayout_InDesignMode" value="">
<input type="hidden" name="_wpSelected" id="_wpSelected" value="">
<input type="hidden" name="_wzSelected" id="_wzSelected" value="">
<input type="hidden" name="MSOSPWebPartManager_OldDisplayModeName" id="MSOSPWebPartManager_OldDisplayModeName" value="Browse">
<input type="hidden" name="MSOSPWebPartManager_StartWebPartEditingName" id="MSOSPWebPartManager_StartWebPartEditingName" value="false">
<input type="hidden" name="MSOSPWebPartManager_EndWebPartEditing" id="MSOSPWebPartManager_EndWebPartEditing" value="false">
<input type="hidden" name="listContainerControlstate" id="listContainerControlstate" value="AAEAAAD/////AQAAAAAAAAAEAQAAAA5TeXN0ZW0uQm9vbGVhbgEAAAAHbV92YWx1ZQABAAs=">
<input type="hidden" name="hiddenDisplayItemView" id="hiddenDisplayItemView" value="Citation">
<input type="hidden" name="hiddenSortBy" id="hiddenSortBy" value="">
<input type="hidden" name="__LASTFOCUS" id="__LASTFOCUS" value="">
<input type="hidden" name="__VIEWSTATE" id="__VIEWSTATE"
value="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">
</div>
<script type="text/javascript">
//<![CDATA[
var theForm = document.forms['aspnetForm'];
if (!theForm) {
theForm = document.aspnetForm;
}
function __doPostBack(eventTarget, eventArgument) {
if (!theForm.onsubmit || (theForm.onsubmit() != false)) {
theForm.__EVENTTARGET.value = eventTarget;
theForm.__EVENTARGUMENT.value = eventArgument;
theForm.submit();
}
}
//]]>
</script>
<script src="/WebResource.axd?d=dnaDAFNiQGyAS-8AAnEusSAvRcEvxsZnbowJJdr_Pi9Oz7lzs5k45FStkRo1xlEHk9NeovbY1Hwq_CwXR_md87LXDXM1L2hMpaL8ksMyAA01&t=637811513229275428" type="text/javascript"></script>
<script type="text/javascript">
//<![CDATA[
var MSOWebPartPageFormName = 'aspnetForm';
var g_presenceEnabled = true;
var g_wsaEnabled = false;
var g_correlationId = 'df5c34a1-722d-f0c3-dd35-8feefc4ce9ac';
var g_wsaQoSEnabled = false;
var g_wsaQoSDataPoints = [];
var g_wsaRUMEnabled = false;
var g_wsaLCID = 1033;
var g_wsaListTemplateId = 850;
var g_wsaSiteTemplateId = 'EJOURNALS#7';
var _spPageContextInfo = {
"webServerRelativeUrl": "/hep",
"webAbsoluteUrl": "https://journals.lww.com/hep",
"viewId": "",
"listId": "{b807cb8a-3cdf-4126-b475-cf89c1612eb3}",
"listPermsMask": {
"High": 0,
"Low": 200769
},
"listUrl": "/hep/Pages",
"listTitle": "Pages",
"listBaseTemplate": 850,
"viewOnlyExperienceEnabled": false,
"blockDownloadsExperienceEnabled": false,
"idleSessionSignOutEnabled": false,
"cdnPrefix": "",
"siteAbsoluteUrl": "https://journals.lww.com/hep",
"siteId": "{2c6587f4-72ed-421d-b7cf-8bc89dbb8af8}",
"showNGSCDialogForSyncOnTS": false,
"supportPoundStorePath": true,
"supportPercentStorePath": true,
"siteSubscriptionId": null,
"CustomMarkupInCalculatedFieldDisabled": true,
"AllowCustomMarkupInCalculatedField": false,
"isSPO": false,
"farmLabel": null,
"serverRequestPath": "/hep/pages/articleviewer.aspx",
"layoutsUrl": "_layouts/15",
"webId": "{fad62b21-61f6-402d-b613-d5e24dd4ad5b}",
"webTitle": "Hepatology",
"webTemplate": "20200",
"webTemplateConfiguration": "EJOURNALS#7",
"webDescription": "",
"tenantAppVersion": "0",
"isAppWeb": false,
"webLogoUrl": "_layouts/15/images/siteicon.png",
"webLanguage": 1033,
"currentLanguage": 1033,
"currentUICultureName": "en-US",
"currentCultureName": "en-US",
"currentCultureLCID": 1033,
"env": null,
"nid": 0,
"fid": 0,
"serverTime": "2024-06-20T03:11:54.6927013Z",
"siteClientTag": "0$$16.0.10409.20027",
"crossDomainPhotosEnabled": false,
"openInClient": false,
"Has2019Era": true,
"webUIVersion": 15,
"webPermMasks": {
"High": 0,
"Low": 196609
},
"pageListId": "{b807cb8a-3cdf-4126-b475-cf89c1612eb3}",
"pageItemId": 77,
"pagePermsMask": {
"High": 0,
"Low": 200769
},
"pagePersonalizationScope": 1,
"userEmail": "",
"userId": 0,
"userLoginName": null,
"userDisplayName": null,
"isAnonymousUser": true,
"isAnonymousGuestUser": false,
"isEmailAuthenticationGuestUser": false,
"isExternalGuestUser": false,
"systemUserKey": null,
"alertsEnabled": true,
"siteServerRelativeUrl": "/hep",
"allowSilverlightPrompt": "True",
"themeCacheToken": "/hep::1:",
"themedCssFolderUrl": null,
"themedImageFileNames": null,
"modernThemingEnabled": true,
"isSiteAdmin": false,
"ExpFeatures": [480216468, 1884350801, 1158731092, 62197791, 538521105, 335811073, 4194306, 34614301, 268500996, -1946025984, 28445328, -2147475455, 134291456, 65536, 288, 950272, 1282, 808326148, 134217873, 0, 0, -1073217536, 545285252,
18350656, -467402752, 6291457, -2147483644, 1074794496, -1728053184, 1845537108, 622628, 4102, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0
],
"killSwitches": {},
"InternalValidAuthorities": ["journals.na.lww.com", "journals.lww.com", "journals.na.lww.com", "journals.lww.com", "cloud-journals.lww.com", "cloud-journals.lww.com"],
"CorrelationId": "df5c34a1-722d-f0c3-dd35-8feefc4ce9ac",
"hasManageWebPermissions": false,
"isNoScriptEnabled": false,
"groupId": null,
"groupHasHomepage": true,
"groupHasQuickLaunchConversationsLink": false,
"departmentId": null,
"hubSiteId": null,
"hasPendingWebTemplateExtension": false,
"isHubSite": false,
"isWebWelcomePage": false,
"siteClassification": "",
"hideSyncButtonOnODB": false,
"showNGSCDialogForSyncOnODB": false,
"sitePagesEnabled": false,
"sitePagesFeatureVersion": 0,
"DesignPackageId": "00000000-0000-0000-0000-000000000000",
"groupType": null,
"groupColor": "#757575",
"siteColor": "#757575",
"headerEmphasis": 0,
"navigationInfo": null,
"guestsEnabled": false,
"MenuData": {
"SignInUrl": "/hep/_layouts/15/Authenticate.aspx?Source=%2Fhep%2Ffulltext%2F2021%2F09000%2Fanalysis%5Fand%5Fvalidation%5Fof%5Fhuman%5Ftargets%5Fand%2E24%2Easpx"
},
"RecycleBinItemCount": -1,
"PublishingFeatureOn": true,
"PreviewFeaturesEnabled": false,
"disableAppViews": false,
"disableFlows": false,
"serverRedirectedUrl": null,
"formDigestValue": "0x90F685307FA1DC88B17541C12D3D0E7B908331ACFDACA6B3355C3068F9FF69F8D3E502DEC19B0DD81137F9861930CF76FD748A74B7F8482C8BDEF7B59E347D86,20 Jun 2024 03:11:54 -0000",
"maximumFileSize": 10240,
"formDigestTimeoutSeconds": 1800,
"canUserCreateMicrosoftForm": false,
"canUserCreateVisioDrawing": true,
"readOnlyState": null,
"isTenantDevSite": false,
"preferUserTimeZone": false,
"userTimeZoneData": null,
"userTime24": false,
"userFirstDayOfWeek": null,
"webTimeZoneData": null,
"webTime24": false,
"webFirstDayOfWeek": null,
"isSelfServiceSiteCreationEnabled": null,
"alternateWebAppHost": "",
"aadTenantId": "",
"aadUserId": "",
"aadInstanceUrl": "",
"msGraphEndpointUrl": "https://",
"allowInfectedDownload": true
};
_spPageContextInfo.updateFormDigestPageLoaded = new Date();
_spPageContextInfo.clientServerTimeDelta = new Date(_spPageContextInfo.serverTime) - new Date();
if (typeof(define) == 'function') {
define('SPPageContextInfo', [], function() {
return _spPageContextInfo;
});
}
var L_Menu_BaseUrl = "/hep";
var L_Menu_LCID = "1033";
var L_Menu_SiteTheme = "null";
document.onreadystatechange = fnRemoveAllStatus;
function fnRemoveAllStatus() {
removeAllStatus(true)
}; //]]>
</script>
<script src="https://lww.com/_layouts/15/1033/Scripts/wk/alerts-subscription.min.js?v=05.20.00.150" type="text/javascript"></script>
<script type="text/javascript">
//<![CDATA[
Flighting.ExpFeatures = [480216468, 1884350801, 1158731092, 62197791, 538521105, 335811073, 4194306, 34614301, 268500996, -1946025984, 28445328, -2147475455, 134291456, 65536, 288, 950272, 1282, 808326148, 134217873, 0, 0, -1073217536, 545285252,
18350656, -467402752, 6291457, -2147483644, 1074794496, -1728053184, 1845537108, 622628, 4102, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0
];
(function() {
if (typeof(window.SP) == "undefined") window.SP = {};
if (typeof(window.SP.YammerSwitch) == "undefined") window.SP.YammerSwitch = {};
var ysObj = window.SP.YammerSwitch;
ysObj.IsEnabled = false;
ysObj.TargetYammerHostName = "www.yammer.com";
})();
var _spWebPartComponents = new Object();
function openEmtcIfAuthenticated(resourceId) {
logCounterDataEmailToColleagueByAN('01515467-202109000-00024', false);
window.location.assign('https://journals.lww.com/hep/pages/login.aspx?ReturnUrl=%2fhep%2ffulltext%2f2021%2f09000%2fanalysis_and_validation_of_human_targets_and.24.aspx');
}
function slideShow_NavigateToUrl(urlToNavigate) {
$('#ArticleImageModal').modal('hide');
logCounterDataImageGalleryByAN('01515467-202109000-00024');
window.location = urlToNavigate;
}
function HideSlideShow() {
$('#ArticleImageModal').modal('hide');
} //]]>
</script>
<script src="https://lww.com/_layouts/15/1033/Scripts/wk/ListContainerControlBase.js?v=05.20.00.150" type="text/javascript"></script>
<script type="text/javascript">
//<![CDATA[
function getSelectedItemsField() {
return $get("selectedItems");
}
function getCheckBoxListContainer() {
return $get("checkBoxListContainer");
}
function getListActionsContainerTop() {
return $get("listActionsContainerTop");
}
function getListActionsContainerBottom() {
return $get("listActionsContainerBottom");
}
function getSelectedItemsCount() {
{
return getSelectedItemsField().value.split(';').length - 1;
}
}
function article_AddSelectedItem() {
addToMyCollectionsLinkClicked('00024');
}
function getEmailRegularExpression() {
return /^(([a-zA-Z0-9_\-\.]+)@([a-zA-Z0-9_\-\.]+)\.([a-zA-Z]{2,5}){1,25})$/;
}
function getMultipleEmailsRegularExpression() {
return /^(([a-zA-Z0-9_\-\.]+)@([a-zA-Z0-9_\-\.]+)\.([a-zA-Z]{2,5}){1,25})+([;.](([a-zA-Z0-9_\-\.]+)@([a-zA-Z0-9_\-\.]+)\.([a-zA-Z]{2,5}){1,25})+)*$/;
}
function getMailMessage() {
return 'Thought you might appreciate this item(s) I saw in Hepatology.';
}
function getImageCountStatus() {
return $get("ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_imageCountStatus");
}
function getCallshowImage() {
return $get("ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_callShowImage");
}
function getImageUrl() {
return $get("ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_image_url");
}
function getDescription() {
return $get("ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_image_description");
}
function getImageSourceTitle() {
return $get("ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_image_sourceTitle");
}
function getImageSourceUrl() {
return $get("ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_image_sourceUrl");
}
function getImageSourceInfo() {
return $get("ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_image_sourceInfo");
}
function getImageKey() {
return $get("ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_image_key");
}
function getImageFullSizeUrl() {
return $get("ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_image_fullSizeUrl");
}
function getImageGalleryUrl() {
return $get("ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_image_imageGalleryUrl");
}
function getEmailTOColleaguePopupID() {
return "ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague";
}
function image(id, nextImageId, previousImageId, title, description, rolloverUrl, popupUrl, fullSizeUrl, originalUrl, imageGalleryUrl, windowId) {
this.id = id;
this.title = title;
this.description = description;
this.rolloverUrl = rolloverUrl;
this.popupUrl = popupUrl;
this.nextImageId = nextImageId;
this.previousImageId = previousImageId;
this.fullsizeUrl = fullSizeUrl;
this.originalUrl = originalUrl;
this.imageGalleryUrl = imageGalleryUrl;
this.windowId = windowId
}
function Global_GetImagesCollection() {
var images = new Object();
images["hep31812-fig-0001"] = new image("hep31812-fig-0001", "hep31812-fig-0002", "", "FIG. 1",
"Human immune system–promoted HCC proliferation and angiogenesis in the Humice model. (A) Representative images of HCC‐PDX tumor 1# and spleens, and the statistical analysis of HCC‐PDX tumor 1# weight from NSG (n\u00A0=\u00A05), Humice (n\u00A0=\u00A05), and Humice treated with anti–hCD45 Ab (50 ug/mouse/week for 4 weeks; n\u00A0=\u00A05). (B) Immunohistochemistry staining of Ki67 in HCC‐PDX tumor 1# tissues and the statistical analysis of the proportion of Ki67<sup xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">+</sup> cells (n\u00A0=\u00A020, four randomly selected photographs/each sample [total of five samples]). (C) The EDU staining of the HCC‐PDX tumor 1# cells isolated from NSG Humice and Humice treated with anti‐hCD45 Ab and the statistical analysis of EDU<sup xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">+</sup> cells (n\u00A0=\u00A05). (D) Immunohistochemistry staining of CD31 in tumor tissues and the statistical analysis of the MVD and VCSA (n\u00A0=\u00A05 samples/group; four images were randomly selected for each sample for quantification [total of 20]). (E) Five million cells from the HCC cell line LM3 were engrafted into different groups. The tumor weight was analyzed after 3\u00A0weeks (n\u00A0=\u00A04). (F) The methodology and workflow for RNA sequencing of isolating LM3 tumor cells from different mice groups. (G) PCA of LM3 tumor cells from different groups. (H) The heatmap of top DE genes in RNA‐sequencing results. (I) The signal pathway analysis of DE genes from LM3 tumor cells between Humice and NSG mice or Humice and Humice treated with anti‐hCD45 Abs. (J) Immunohistochemistry staining of p‐STAT3, p‐JAK2, p‐ERK1/2, p‐p38, and p‐AKT using HCC‐PDX tumor 1#. (K) Western blot analysis of p‐STAT3, p‐JAK2, p‐ERK1/2, p‐p38, and p‐AKT from isolated HCC‐PDX tumor cells from different groups. Abbreviations: APC, allophycocyanin; ERK, extracellular signal‐regulated kinases; GAPDH, glyceraldehyde 3‐phosphate dehydrogenase; Humice, humanized mice; n.s, not significant; TREM1, triggering receptor expressed on myeloid cells 1. *<em xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">P</em> < 0.05; **<em xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">P</em> < 0.01.",
"https://images.journals.lww.com/hep/Rollover.01515467-202109000-00024.hep31812-fig-0001.jpeg", "https://images.journals.lww.com/hep/Gallery.01515467-202109000-00024.hep31812-fig-0001.jpeg",
"https://journals.lww.com/hep/_layouts/oaks.journals/ImageView.aspx?k=hep:2021:09000:00024&i=hep31812-fig-0001&year=2021&issue=09000&article=00024&type=Fulltext",
"https://images.journals.lww.com/hep/Original.01515467-202109000-00024.hep31812-fig-0001.jpeg", "/hep/pages/imagegallery.aspx?year=2021&issue=09000&article=00024", "hep_2021_09000_00024_hep31812-fig-0001");
images["hep31812-fig-0002"] = new image("hep31812-fig-0002", "hep31812-fig-0003", "hep31812-fig-0001", "FIG. 2",
"hCD14<sup xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">+</sup> TILs are one of the major players in HCC proliferation and angiogenesis. (A) The average proportion of multiple human immune cells (hCD45<sup xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">+</sup>) in blood, spleen, BM, and TILs from HepG2 or LM3‐engrafted Humice, which were used in an HepG2 or LM3 co‐culture <em xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">in vitro</em> experiment. (B) The HCC clone‐formation analysis. HepG2 or LM3 cells are co‐cultured with human immune cells from blood, spleen, BM, and TILs of HepG2‐engrafted Humice for 10\u00A0days. The ratio was 1:10, exchanging new medium and adding new human immune cells every two days. The statistical analysis of the size of clone is shown (n\u00A0=\u00A050). (C) Total RNA was extracted from blood or hCD45<sup xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">+</sup> TILs from Humice without the HCC‐PDX tumor and HCC‐PDX tumor 1#–bearing Humice. Gene expression profiles are analyzed using RT–quantitative real‐time PCR (n\u00A0=\u00A03). A heat map of the gene expression is shown. (D) HCC‐PDX tumor 1# was engrafted into NSG and Humice, which were treated with saline, anti–hCD4 Abs, anti‐hCD8 Abs, anti‐hCD19 Abs, anti‐hCD14 Abs, and anti‐hCD56 Abs. (E) The HCC‐PDX tumor 1# cells from different groups were analyzed using EDU staining (n\u00A0=\u00A05). (F‐J) Immunohistochemistry staining of Ki67, CD31, p‐JAK2 and p‐STAT3 were performed in HCC‐PDX tumor tissues. The statistical results of (F) Ki67<sup xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">+</sup>, (G) MVD, (H) VCSA, (I) p‐JAK2, and (J) p‐STAT3 are shown (n\u00A0=\u00A05 samples/group; four images were randomly selected for each sample for quantification [total of 20]). (K) Western blot analysis of the p‐STAT3 and p‐JAK2 level in isolated HCC‐PDX tumor cells from different groups. (L‐M) The changes in human immune cells’ proportion in TILs after saline and (L) anti‐hCD14 Ab or (M) anti‐hCD19 Ab injection (n\u00A0=\u00A05). Abbreviations: e‐MDSC, early‐stage MDSC; Humice, humanized mice; k, thousand; PMN‐MDSC, polymorphonuclear leukocyte–MDSC; T<sub xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">c</sub>E, effector T<sub xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">c</sub> cell; TcN, naive cytotoxic T cells; T<sub xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">h</sub>E, effector T<sub xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">h</sub> cell; ThN, naive T helper cells; Treg, regulatory T cell; W, with; W/O, without. *<em xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">P</em> < 0.05; **<em xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">P</em> < 0.01.",
"https://images.journals.lww.com/hep/Rollover.01515467-202109000-00024.hep31812-fig-0002.jpeg", "https://images.journals.lww.com/hep/Gallery.01515467-202109000-00024.hep31812-fig-0002.jpeg",
"https://journals.lww.com/hep/_layouts/oaks.journals/ImageView.aspx?k=hep:2021:09000:00024&i=hep31812-fig-0002&year=2021&issue=09000&article=00024&type=Fulltext",
"https://images.journals.lww.com/hep/Original.01515467-202109000-00024.hep31812-fig-0002.jpeg", "/hep/pages/imagegallery.aspx?year=2021&issue=09000&article=00024", "hep_2021_09000_00024_hep31812-fig-0002");
images["hep31812-fig-0003"] = new image("hep31812-fig-0003", "hep31812-fig-0004", "hep31812-fig-0002", "FIG. 3",
"Human immune cells from TILs were modulated by HCC tumors. Multiple kinds of human immune cells are isolated from spleen (in HCC‐PDX tumor 1#–bearing humanized mice and non–HCC humanized mice) and HCC‐PDX tumor 1# tissue. PCA and heatmap analysis are performed using RNA‐sequencing results. (A) The workflow of isolation of multiple kinds of human immune cells for RNA sequencing. (B) Results of hCD4<sup xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">+</sup> cells (human T<sub xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">h</sub> cells). (C) Results of hCD8<sup xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">+</sup> cells (human T<sub xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">c</sub> cells). (D) Results of hCD14<sup xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">+</sup> cells (human monocytes). (E) Results of hCD19<sup xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">+</sup> cells (human B cells). (F) Results of hCD56<sup xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">+</sup> cells (human NK cells). Abbreviations: W, with; W/O, without.",
"https://images.journals.lww.com/hep/Rollover.01515467-202109000-00024.hep31812-fig-0003.jpeg", "https://images.journals.lww.com/hep/Gallery.01515467-202109000-00024.hep31812-fig-0003.jpeg",
"https://journals.lww.com/hep/_layouts/oaks.journals/ImageView.aspx?k=hep:2021:09000:00024&i=hep31812-fig-0003&year=2021&issue=09000&article=00024&type=Fulltext",
"https://images.journals.lww.com/hep/Original.01515467-202109000-00024.hep31812-fig-0003.jpeg", "/hep/pages/imagegallery.aspx?year=2021&issue=09000&article=00024", "hep_2021_09000_00024_hep31812-fig-0003");
images["hep31812-fig-0004"] = new image("hep31812-fig-0004", "hep31812-fig-0005", "hep31812-fig-0003", "FIG. 4",
"IL‐33 from CD14<sup xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">+</sup> TILs could up‐regulate IL‐6 expression in TILs’ multiple immune cells and enhance HCC proliferation and angiogenesis. (A) Correlation of IL‐33 levels in monocytes and IL‐6 levels in CD4<sup xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">+</sup>, CD14<sup xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">+</sup>, CD19<sup xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">+</sup>, and Lin<sup xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">−</sup> TILs of patients with HCC. (B‐D) Expression of IL‐33 and IL‐6 in hCD4<sup xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">+</sup>, CD8<sup xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">+</sup>, CD19<sup xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">+</sup>, CD14<sup xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">+</sup>, and Lin− cells from blood, spleen, and BM and from among TILs in HCC‐PDX tumor 1# humanized mice models. The statistical results of (C) IL‐33 and (D) IL‐6 are shown. (E) IL‐6 expression in ILCs from spleen and TILs. The statistical result is shown. (F) HCC‐PDX tumor 1# weight after 4 weeks of treatment with saline and anti–IL‐33 Abs. (G) Changes in IL‐6 level in TILs’ multiple human immune cells after anti–human IL‐33 Ab treatment. (H) Western blot analysis of p‐STAT3 and p‐JAK2 from isolated HCC cells from saline and anti‐IL33 Ab treatment groups. (I‐J) Tumor angiogenesis analysis in HCC‐PDX tumor 1# tissues from saline and anti‐IL33 Ab treatment groups. The statistical results of (I) MVD and (J) VCSA are shown (n\u00A0=\u00A05 samples/group, four images were randomly selected for each sample for quantification [total of 20]). (K) Changes in the proportion of multiple human immune cells after anti‐IL33 Ab treatment in TILs. Abbreviations: e‐MDSC, early‐stage MDSC; PMN‐MDSC, polymorphonuclear leukocyte–MDSC; T<sub xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">c</sub>E, effector T<sub xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">c</sub> cell; TcN, naive cytotoxic T cells; T<sub xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">h</sub>E, effector T<sub xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">h</sub> cell; ThN, naive T helper cells; Treg, regulatory T cell. *<em xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">P</em> < 0.05; **<em xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">P</em> < 0.01.",
"https://images.journals.lww.com/hep/Rollover.01515467-202109000-00024.hep31812-fig-0004.jpeg", "https://images.journals.lww.com/hep/Gallery.01515467-202109000-00024.hep31812-fig-0004.jpeg",
"https://journals.lww.com/hep/_layouts/oaks.journals/ImageView.aspx?k=hep:2021:09000:00024&i=hep31812-fig-0004&year=2021&issue=09000&article=00024&type=Fulltext",
"https://images.journals.lww.com/hep/Original.01515467-202109000-00024.hep31812-fig-0004.jpeg", "/hep/pages/imagegallery.aspx?year=2021&issue=09000&article=00024", "hep_2021_09000_00024_hep31812-fig-0004");
images["hep31812-fig-0005"] = new image("hep31812-fig-0005", "hep31812-fig-0006", "hep31812-fig-0004", "FIG. 5",
"CD14 is an essential molecule for IL‐33 generation induced by DAMPs (HMGB1) from HCC through the TLR4/AP‐1 pathway. (A) IL‐33 expression levels in hCD14<sup xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">+</sup> cells after stimulating hCD34<sup xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">−</sup> cells from three healthy donors with different reagents (n\u00A0=\u00A03). (B) The IL‐33 level in U937 cells following stimulation by different reagents with or without VD3 pretreatment (n\u00A0=\u00A03). (C) Network for highly expressed transcription factors in hCD14<sup xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">+</sup> TILs. (D) IL‐33 expression levels in hCD14<sup xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">+</sup> cells combinatorically treated with HepG2 lysates, TAK‐242 (TLR4 inhibitor), and SR‐11302 (AP‐1 transcription factor inhibitor). (E) JUN protein levels, including JUNB, c‐JUN, and JUND, in U937 cells (pretreated with VD3) following combinatorial treatment with HepG2 lysates, TAK‐242 and SR‐11302. (F) ChIP analysis was performed in U937 cells using anti‐JUNB Ab, anti–c‐JUN Ab, and anti‐JUND. ChIP DNA was analyzed using real‐time PCR (n\u00A0=\u00A04). (G) The effect of HMGB1 neutralizing Ab on lysate‐induced IL‐33 expression (n\u00A0=\u00A03). (H) Western blot analysis of HMGB1 levels from the supernatant after IFN‐gamma treatment of LM3 cells for 24\u00A0hours. Abbreviations: ChIP, chromatin immunoprecipitation; MFI, mean fluorescence intensity; n.s, not significant; Q, quadrant. *<em xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">P</em> < 0.05; **<em xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">P</em> < 0.01.",
"https://images.journals.lww.com/hep/Rollover.01515467-202109000-00024.hep31812-fig-0005.jpeg", "https://images.journals.lww.com/hep/Gallery.01515467-202109000-00024.hep31812-fig-0005.jpeg",
"https://journals.lww.com/hep/_layouts/oaks.journals/ImageView.aspx?k=hep:2021:09000:00024&i=hep31812-fig-0005&year=2021&issue=09000&article=00024&type=Fulltext",
"https://images.journals.lww.com/hep/Original.01515467-202109000-00024.hep31812-fig-0005.jpeg", "/hep/pages/imagegallery.aspx?year=2021&issue=09000&article=00024", "hep_2021_09000_00024_hep31812-fig-0005");
images["hep31812-fig-0006"] = new image("hep31812-fig-0006", "hep31812-fig-0007", "hep31812-fig-0005", "FIG. 6",
"hCD14<sup xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">+</sup> myeloid cells from TILs are one of the potential target cells for developing combinatorial HCC immunotherapy. (A) The HCC‐PDX tumor weight after 4 weeks of treatment with C188‐9 (n\u00A0=\u00A06), pembrolizumab (n\u00A0=\u00A06), and combination treatment (n\u00A0=\u00A06). (B) The HCC‐PDX tumor weight after 4 weeks of treatment with bevacizumab (n\u00A0=\u00A04), pembrolizumab (n\u00A0=\u00A04), and combination treatment (n\u00A0=\u00A04). (C) The HCC‐PDX tumor weight after 3.5\u00A0weeks of treatment with saline (n\u00A0=\u00A06), C188‐9\u00A0+\u00A0bevacizumab (n\u00A0=\u00A06), pembrolizumab\u00A0+\u00A0bevacizumab (n\u00A0=\u00A06), pembrolizumab\u00A0+\u00A0C188‐9 (n\u00A0=\u00A06) and combination treatment (n\u00A0=\u00A06). (D‐G) Immunohistochemistry staining of Ki67, CD31, p‐STAT3 and p‐JAK2. The statistical results of (D) Ki67<sup xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">+</sup>, (E) MVD, (F) VCSA, (G) p‐STAT3, and (H) p‐JAK2 are shown (n\u00A0=\u00A05 samples/group, four images were randomly selected for each sample for quantification [total of 20]). (I) Western blot analysis of p‐STAT3 and p‐JAK2 levels from different groups. Abbreviations: APC, allophycocyanin; n.s, not significant. *<em xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">P</em> < 0.05; **<em xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">P</em> < 0.01.",
"https://images.journals.lww.com/hep/Rollover.01515467-202109000-00024.hep31812-fig-0006.jpeg", "https://images.journals.lww.com/hep/Gallery.01515467-202109000-00024.hep31812-fig-0006.jpeg",
"https://journals.lww.com/hep/_layouts/oaks.journals/ImageView.aspx?k=hep:2021:09000:00024&i=hep31812-fig-0006&year=2021&issue=09000&article=00024&type=Fulltext",
"https://images.journals.lww.com/hep/Original.01515467-202109000-00024.hep31812-fig-0006.jpeg", "/hep/pages/imagegallery.aspx?year=2021&issue=09000&article=00024", "hep_2021_09000_00024_hep31812-fig-0006");
images["hep31812-fig-0007"] = new image("hep31812-fig-0007", "", "hep31812-fig-0006", "FIG. 7",
"The DAMP/TLR4/AP‐1/IL‐33/IL‐6 model and combinational anti‐HCC effect of triple‐combination treatment (immune checkpoint blockades, anti‐HCC proliferation therapy, and angiogenesis inhibitors).",
"https://images.journals.lww.com/hep/Rollover.01515467-202109000-00024.hep31812-fig-0007.jpeg", "https://images.journals.lww.com/hep/Gallery.01515467-202109000-00024.hep31812-fig-0007.jpeg",
"https://journals.lww.com/hep/_layouts/oaks.journals/ImageView.aspx?k=hep:2021:09000:00024&i=hep31812-fig-0007&year=2021&issue=09000&article=00024&type=Fulltext",
"https://images.journals.lww.com/hep/Original.01515467-202109000-00024.hep31812-fig-0007.jpeg", "/hep/pages/imagegallery.aspx?year=2021&issue=09000&article=00024", "hep_2021_09000_00024_hep31812-fig-0007");
return images;
}
function getPopupImageId() {
return $get("ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_popupImageId");
}
function getIsExportToPPT() {
return $get("ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_IsExportToPPT");
} //]]>
</script>
<script src="/ScriptResource.axd?d=11ySqNT2t8wJXf-5ynqkHTYVaR0CZPUQDLhFk5-B61-yY4pHK9T4A-OmNoLERHX1OU2F3io32lKHXeNlvH0kpnJP6-ZQm2Ado5OlvNqUwB9TpwuIgMVQBgIz-DSVpHWqDoVFHrt69C9fSrbhF6t9QBuuAcSpa-p9_2de4EnR0aU1&t=2265eaa7" type="text/javascript">
</script>
<script src="/_layouts/15/blank.js?rev=6Epdi%2BEh0XOHrFNRcf4Cwg%3D%3DTAG0" type="text/javascript"></script>
<script type="text/javascript">
//<![CDATA[
window.SPThemeUtils && SPThemeUtils.RegisterCssReferences([]);
(function() {
if (typeof(_spBodyOnLoadFunctions) === 'undefined' || _spBodyOnLoadFunctions === null) {
return;
}
_spBodyOnLoadFunctions.push(function() {
SP.SOD.executeFunc('core.js', 'FollowingDocument', function() {
FollowingDocument();
});
});
})();
(function() {
if (typeof(_spBodyOnLoadFunctions) === 'undefined' || _spBodyOnLoadFunctions === null) {
return;
}
_spBodyOnLoadFunctions.push(function() {
SP.SOD.executeFunc('core.js', 'FollowingCallout', function() {
FollowingCallout();
});
});
})();
if (typeof(DeferWebFormInitCallback) == 'function') DeferWebFormInitCallback(); //]]>
</script>
<script src="/WebResource.axd?d=ujR-dJ4zUHGN6jELxLVetl199sJpE_qZiBmEfUoaRM4DCmEfpBr9GGhTGo9ZJcfF6mQ45yf4Ik1RnQ9yqZG9_5EcA9R0xynU6JEfYiEh3vA1&t=637811513229275428" type="text/javascript"></script>
<script type="text/javascript">
//<![CDATA[
function WebForm_OnSubmit() {
UpdateFormDigest('\u002fhep', 1440000);
if (typeof(ValidatorOnSubmit) == "function" && ValidatorOnSubmit() == false) return false;
if (typeof(_spFormOnSubmitWrapper) != 'undefined') {
return _spFormOnSubmitWrapper();
} else {
return true;
};
return true;
}
//]]>
</script>
<div class="aspNetHidden">
<input type="hidden" name="__VIEWSTATEGENERATOR" id="__VIEWSTATEGENERATOR" value="E50BF36A">
<input type="hidden" name="__EVENTVALIDATION" id="__EVENTVALIDATION"
value="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">
</div>
<script type="text/javascript">
var submitHook = function() {
return false;
};
theForm._spOldSubmit = theForm.submit;
theForm.submit = function() {
if (!submitHook()) {
this._spOldSubmit();
}
};
</script>
<span id="DeltaSPWebPartManager">
</span>
<script type="text/javascript">
$.getJSON("https://login.journals.lww.com/AuthCheck.aspx?Callback=?", null, function(data) {
if (data.IsAuthenticated.toLowerCase() == "true") {
window.location.replace(
"https://login.journals.lww.com/?wa=wsignin1.0&wtrealm=urn%3ajournals&wctx=https%3a%2f%2fjournals.lww.com%2fhep%2f_layouts%2f15%2fAuthenticate.aspx%3fSource%3d%252fhep%252ffulltext%252f2021%252f09000%252fanalysis_and_validation_of_human_targets_and.24.aspx"
);
}
})
</script>
<script type="text/javascript">
//<![CDATA[
Sys.WebForms.PageRequestManager._initialize('ctl00$ScriptManager', 'aspnetForm', ['fctl00$WebPartAdderUpdatePanel', ''], [], ['ctl00$WebPartAdder', '',
'ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$ucArticleTools$exportToCitationManager$btnOpenExportDialog', ''
], 90, 'ctl00');
//]]>
</script>
<span id="DeltaDelegateControls">
</span>
<!-- start ( this can all go into PublishingSiteAction:SiteActionMenu )--->
<!-- end ( this can all go into PublishingSiteAction:SiteActionMenu )--->
<div id="ctl00_MicrobarContainer" class="top-microbar-container">
<script>
;
(function($) {
$.fn.responsiveMenu = function(options) {
var settings = $.extend({
breakWidth: 600,
label: 'Visit our other sites',
position: 'left'
}, options);
var menu = $(this);
var clone = menu.clone().insertBefore(menu).removeAttr('class').removeAttr('id');
var wrapper = $('<div class="responsive-menu rm-' + settings.position + '"></div>');
var button = $('<button onclick="return false;" class="rm-toggle">' + (settings.label ? '<span class="caret"></span><span class="rm-label">' + settings.label + '</span>' : '') + '</button>');
wrapper.insertBefore(menu);
wrapper.prepend(clone);
wrapper.prepend(button);
var switchMenu = function() {
if ($(window).width() <= settings.breakWidth) {
wrapper.show();
menu.hide();
} else {
wrapper.hide();
menu.hide();
}
};
switchMenu();
button.click(function() {
clone.toggle();
});
$(window).resize(switchMenu);
};
})(window.Zepto || window.jQuery);
</script>
<script>
$(function() {
$('#menu').responsiveMenu({
breakWidth: 1000,
// label: false,
position: 'right'
});
});
</script>
<div id="ctl00__fef0fba057c8a3d5_headerLinks">
<script type="text/javascript">
window._mfq = window._mfq || [];
(function() {
var mf = document.createElement("script");
mf.type = "text/javascript";
mf.async = true;
mf.src = "//cdn.mouseflow.com/projects/d007e6ad-c565-44cd-bbf8-fdebe41c0fca.js";
document.getElementsByTagName("head")[0].appendChild(mf);
})();
</script>
<div class="headerNav">
<div class="headerNavContent">
<ul class="headerNavTabs">
<li class="headerNavTab firstNavTab"><a href="/aasldpubs/Pages/default.aspx" target="_blank">AASLD Publications</a></li>
<li class="headerNavTab navTab on"><a href="/hep/Pages/default.aspx" target="_blank">Hepatology</a></li>
<li class="headerNavTab lastTab"><a href="/lt/Pages/default.aspx" target="_blank">Liver Transplantation</a></li>
<li class="headerNavTab navTab"><a href="/cld/Pages/default.aspx" target="_blank">Clinical Liver Disease</a></li>
<li class="headerNavTab lastTab"><a href="/hepcomm/Pages/default.aspx" target="_blank">Hepatology Communications</a></li>
</ul>
</div>
</div>
<div class="responsive-menu rm-right" style="display: none;"><button onclick="return false;" class="rm-toggle"><span class="caret"></span><span class="rm-label">Visit our other sites</span></button>
<ul style="display:none;">
<li><a href="/aasldpubs/Pages/default.aspx" target="_blank">AASLD Publications</a></li>
<li class="on"><a href="/hep/Pages/default.aspx" target="_blank">Hepatology</a></li>
<li><a href="/lt/Pages/default.aspx" target="_blank">Liver Transplantation</a></li>
<li><a href="/cld/Pages/default.aspx" target="_blank">Clinical Liver Disease</a></li>
<li><a href="/hepcomm/Pages/default.aspx" target="_blank">Hepatology Communications</a></li>
</ul>
</div>
<ul id="menu" class="navbar dummyhidden" style="display:none;">
<li><a href="/aasldpubs/Pages/default.aspx" target="_blank">AASLD Publications</a></li>
<li class="on"><a href="/hep/Pages/default.aspx" target="_blank">Hepatology</a></li>
<li><a href="/lt/Pages/default.aspx" target="_blank">Liver Transplantation</a></li>
<li><a href="/cld/Pages/default.aspx" target="_blank">Clinical Liver Disease</a></li>
<li><a href="/hepcomm/Pages/default.aspx" target="_blank">Hepatology Communications</a></li>
</ul>
<style type="text/css">
div.headerNav {
background-color: #EFEFEF;
height: 30px;
width: 100%;
word-spacing: 1.5px;
}
div.headerNavContent {
margin: 0 auto;
min-height: 30px;
padding-right: 2.7%px;
width: 90%;
}
ul.headerNavTabs {
clear: both;
display: block;
left: auto;
margin: 0 auto;
position: relative;
width: 95%;
}
li.navTab {
width: 20%;
}
li.firstNavTab {
width: 20%;
}
li.lastTab {
width: 20%;
}
li.on {
background: none repeat scroll 0 0 #006421 !important;
color: #ffffff;
}
/****** Highlight JBJS Link ******/
li.org {
background: none repeat scroll 0 0 #006421 !important;
}
.org a {
background-color: #003F7B !important;
color: #ffffff !important;
}
.org a:hover {
background-color: #003262 !important;
}
li.headerNavTab {
background: none repeat scroll 0 0 #EFEFEF;
display: inline;
float: left;
height: 30px;
margin: 0;
padding: 0;
}
ul.headerNavTabs li {
display: inline;
float: left;
text-align: center;
}
ul.headerNavTabs li a:link,
ul.headerNavTabs li a:active,
ul.headerNavTabs li a:hover,
ul.headerNavTabs li a:visited {
color: #000;
font-size: 12px;
font-style: normal;
font-weight: bold;
outline: 0 none;
position: relative;
text-decoration: none;
}
li.lastNavTab {
float: left;
width: 123px;
}
li.lastNavTab,
li.lastMainNavTab {
float: right;
}
span.headerNavTab {
color: #FFFFFF;
font-size: 12px;
font-style: normal;
font-weight: bold;
outline: 0 none;
position: relative;
text-decoration: none;
top: 10px;
}
li.on a {
color: #fff !important;
}
@-moz-document url-prefix() {
ul.headerNavTabs li a:link,
ul.headerNavTabs li a:active,
ul.headerNavTabs li a:hover,
ul.headerNavTabs li a:visited {
top: 6px;
}
span.headerNavTab {
top: 6px;
}
}
</style>
<script type="text/javascript" language="javascript">
$(document).ready(function() {
setHeaderLinks();
});
function setHeaderLinks() {
$('li.headerNavTab').click(function(event) {}).mouseenter(function() {
if ($(this).children('ul').length > 0) {
$(this).children('ul').show();
$(this).css('background-color', '#194F3D');
}
}).mouseleave(function() {
if ($(this).children('ul').length > 0) {
$(this).children('ul').hide();
$(this).css('background-color', '#323232');
}
});
}
</script>
</div>
</div>
<!-- Header Banners delegate control -->
<a id="HiddenAnchor" href="javascript:;" style="display: none;"></a>
<!-- Header Advertisements delegate control -->
<div id="ctl00_TopAdvertisementContainer" class="advertisement-content_top top-banner">
<div class="top-banner__content--centered top-banner--low-opacity">
<div id="ctl00_ctl49_adContainer" class="ej-advertisement ej-advertisement-topcombo">
<div class="ej-advertisement-content">
<div>
<div id="ga_d6d6c1fa-31b5-4a89-9d71-73d87bfbfea5" class="ad-slot-container ad-slot-container-ga_d6d6c1fa-31b5-4a89-9d71-73d87bfbfea5" data-sizemap="[[[730, 500], [[728, 90]]], [[0, 0], [[300, 50]]]]"
data-adpath="/15726702761/Desktop/hep/Article/Top" data-autoload="yes" data-outofpage="no" data-sticky="no" data-slottargeting="" data-displayslug="yes" data-sticky-duration="5" data-name="Top"></div>
</div>
</div>
</div>
</div>
</div>
<div class="main-wrapper">
<div id="main-container">
<!-- Header delegate control -->
<header class="header">
<div class="header__holder">
<div class="header__layout-top society wk-grid-page-container">
<script type="text/javascript" src="https://lww.com/_layouts/15/1033/Scripts/wk/UserToolbarDropdown.js?v=05.20.00.150" defer="true">
</script>
<section class="user-action-toolbar">
<ul class="user-menu user-info" role="tablist">
<li id="ctl00_ctl51_Header_UserActionTools_liLogin" class="user-menu__item user-menu__item--popup-container user-menu__item--login-popup-container dib">
<button class="user-menu__link user-menu__link--login js-ejp-login-btn" type="button"
data-config="{"eventName":"login","eventDetail":{"source":"Masthead Dropdown"},"isNull":false}">
<i class="fa fa-sign-in"></i>
<span>Log in</span>
</button>
</li>
<li id="ctl00_ctl51_Header_UserActionTools_liOr" class="dib or-spacing"><span>or</span></li>
<li id="ctl00_ctl51_Header_UserActionTools_liRegister2" class="user-menu__item dib">
<a id="ctl00_ctl51_Header_UserActionTools_RegisterUserPopupLnk" class="user-menu__link js-register-link" data-config="{"eventName":"Register","eventDetail":{"source":"Masthead Dropdown"},"isNull":false}" href="https://journals.lww.com/hep/pages/register.aspx?ContextUrl=%2fhep%2ffulltext%2f2021%2f09000%2fanalysis_and_validation_of_human_targets_and.24.aspx">Register</a>
</li>
<li id="ctl00_ctl51_Header_UserActionTools_liSubscribe" role="presentation" class="user-menu__item dib">
<a id="ctl00_ctl51_Header_UserActionTools_lnkSubscribe" class="user-menu__link" href="https://shop.lww.com/p/0270-9139" target="_blank"><i class="fa fa-bars"></i> <span class="hideOnFixed">Subscribe to journal</span><span class="showOnFixed">Subscribe</span></a>
</li>
<li id="ctl00_ctl51_Header_UserActionTools_liIssueAlerts" class="user-menu__item dib">
<i class="fa fa-envelope"></i>
<a rel="nofollow" title="" href="javascript:javascript: alerts_ShowSubscribeeTOCPopup('Hepatology','hep','eTOC', 'eTOC');;" onclick="javascript: alerts_ShowSubscribeeTOCPopup('Hepatology','hep','eTOC', 'eTOC');" class="user-menu__link"><span id="ctl00_ctl51_Header_UserActionTools_SubscribeToAlertsActionToolLink_defaultText" class="hideOnFixed">Get new issue alerts</span><span id="ctl00_ctl51_Header_UserActionTools_SubscribeToAlertsActionToolLink_stickyText" class="showOnFixed">Get alerts</span></a>
</li>
<li id="ctl00_ctl51_Header_UserActionTools_liDynamicItem" class="user-menu__item dib">
<i class="fa fa-stop user-menu__dynamic-item-icon"></i>
<a id="ctl00_ctl51_Header_UserActionTools_lnkDynamicItem" class="user-menu__link" href="https://login.journals.lww.com/OneID/Login.aspx?PartnerIdpId=https://my.aasld.org&Login_type=SocietySso&returnUrl=https%3a%2f%2fjournals.lww.com%2flt%2fpages%2fdefault.aspx" target="_blank">AASLD Member? Login here</a>
</li>
</ul>
</section>
<span id="ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_dummyTargetControl"></span>
<div id="ej-clear-float">
</div>
<input type="hidden" name="ctl00$ctl51$Header$UserActionTools$ucUnsubscribeToAlertsUserControl$hiddenUnSubscribeAlertType" id="ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenUnSubscribeAlertType">
<input type="hidden" name="ctl00$ctl51$Header$UserActionTools$ucUnsubscribeToAlertsUserControl$hiddenUnsubscribeJournalId" id="ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenUnsubscribeJournalId">
<input type="hidden" name="ctl00$ctl51$Header$UserActionTools$ucUnsubscribeToAlertsUserControl$hiddenUnsubscribeMessage" id="ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenUnsubscribeMessage">
<input type="hidden" name="ctl00$ctl51$Header$UserActionTools$ucUnsubscribeToAlertsUserControl$hiddenTopicalCollectionId" id="ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenTopicalCollectionId">
<input type="hidden" name="ctl00$ctl51$Header$UserActionTools$ucUnsubscribeToAlertsUserControl$hiddenOvidId" id="ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenOvidId">
<input type="hidden" name="ctl00$ctl51$Header$UserActionTools$ucUnsubscribeToAlertsUserControl$hiddenJournalId" id="ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenJournalId">
<script type="text/javascript">
function alerts_ShowUnSubscribeeTOCPopup(title, alertType, journalId) {
var unSubscribeeTocPopup = $find('unSubscribeToAlerts');
var lblUnsubscribeMessage = document.getElementById('ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_lblUnsubscribeMessage');
lblUnsubscribeMessage.innerHTML = title;
document.getElementById('ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenUnSubscribeAlertType').value = alertType;
document.getElementById('ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenUnsubscribeMessage').value = title;
$('#' + 'ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_pUnsubscribeButtons').show();
if (document.getElementById('ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenJournalId').value == null || document.getElementById(
'ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenJournalId').value == '') {
document.getElementById('ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenJournalId').value = journalId;
}
if (unSubscribeeTocPopup != null) {
unSubscribeeTocPopup.show();
}
}
function alerts_ShowUnSubscribeeTOCPopup_Root(title, journalId, alertType) {
var unSubscribeeTocPopup = $find('unSubscribeToAlerts');
var lblUnsubscribeMessage = document.getElementById('ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_lblUnsubscribeMessage');
lblUnsubscribeMessage.innerHTML = title;
document.getElementById('ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenUnsubscribeMessage').value = title;
document.getElementById('ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenUnSubscribeAlertType').value = alertType;
document.getElementById('ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenUnsubscribeJournalId').value = journalId;
$('#' + 'ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_pUnsubscribeButtons').show();
if (unSubscribeeTocPopup != null) {
unSubscribeeTocPopup.show();
}
}
function alerts_ShowUnSubscribeeTOCPopup_Citation(title, journalId, ovidId) {
var unSubscribeeTocPopup = $find('unSubscribeToAlerts');
var lblUnsubscribeMessage = document.getElementById('ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_lblUnsubscribeMessage');
lblUnsubscribeMessage.innerHTML = title;
document.getElementById('ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenUnsubscribeMessage').value = title;
document.getElementById('ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenUnSubscribeAlertType').value = 'Citation';
document.getElementById('ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenUnsubscribeJournalId').value = journalId;
document.getElementById('ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenOvidId').value = ovidId;
$('#' + 'ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_pUnsubscribeButtons').show();
if (unSubscribeeTocPopup != null) {
unSubscribeeTocPopup.show();
}
}
function alerts_ShowUnSubscribeeTOCPopup_Topical(title, journalId, topicalCollectionId) {
var unSubscribeeTocPopup = $find('unSubscribeToAlerts');
var lblUnsubscribeMessage = document.getElementById('ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_lblUnsubscribeMessage');
lblUnsubscribeMessage.innerHTML = title;
document.getElementById('ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenUnsubscribeMessage').value = title;
document.getElementById('ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenUnSubscribeAlertType').value = 'Topical';
document.getElementById('ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenUnsubscribeJournalId').value = journalId;
document.getElementById('ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenTopicalCollectionId').value = topicalCollectionId;
$('#' + 'ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_pUnsubscribeButtons').show();
if (document.getElementById('ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenJournalId').value == null || document.getElementById(
'ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenJournalId').value == '') {
document.getElementById('ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_hiddenJournalId').value = journalId;
}
if (unSubscribeeTocPopup != null) {
unSubscribeeTocPopup.show();
}
}
function alerts_ShowUnSubscribeeTOCSuccessPopup() {
var unSubscribeeTocPopup = $find('unSubscribeToAlerts');
if (unSubscribeeTocPopup != null) {
unSubscribeeTocPopup.show();
}
}
$('.js-close').on('click', function() {
var unSubscribeeTocPopup = $find('unSubscribeToAlerts');
if (unSubscribeeTocPopup != null) {
unSubscribeeTocPopup.hide();
}
return false;
});
</script>
<span id="ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_dummyTargetControl"></span>
<input type="hidden" name="ctl00$ctl51$Header$UserActionTools$SubscribeToEtocPopupControl$hiddenSubscribeToEtocPopupState" id="ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_hiddenSubscribeToEtocPopupState"
value="showemail">
<input type="hidden" name="ctl00$ctl51$Header$UserActionTools$SubscribeToEtocPopupControl$hiddenConfirmSubscriptionPageUrl" id="ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_hiddenConfirmSubscriptionPageUrl">
<input type="hidden" name="ctl00$ctl51$Header$UserActionTools$SubscribeToEtocPopupControl$hiddenJournalId" id="ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_hiddenJournalId">
<input type="hidden" name="ctl00$ctl51$Header$UserActionTools$SubscribeToEtocPopupControl$hiddenSubscriptionType" id="ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_hiddenSubscriptionType">
<div id="divPopupOverLay" class="Popup-Overlay" style="display: none; position: fixed; left: 0; top: 0; z-index: 3800; width: 1920px; height: 4517px;"></div>
<div id="ej-clear-float">
</div>
<script type="text/javascript">
function alerts_SaveSubscriptionTypeInHiddenField(url, subscriptionType, journalId, yearId, issueId, articleId) {
if (journalId && yearId && issueId && articleId) {
logCounterDataAlertWhenCitedSynchronously(journalId, yearId, issueId, articleId);
}
$('#' + 'ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_hiddenSubscriptionType').val(subscriptionType);
$('#' + 'ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_hiddenJournalId').val(journalId);
if (url) window.location = url;
else __doPostBack('hypSubscribeToAlerts');
return false;
}
function alerts_ShowSubscribeeTOCPopup(journalTitle, journalId, subscriptionType, displaySubscriptionType) {
$('#' + 'ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_hiddenSubscriptionType').val(subscriptionType);
var subscribeToEtocPopup = $find('subscribeToEtoc');
subscribeToEtocPopup.show();
document.getElementsByTagName('html')[0].classList.add('no-scroll');
var modelPopupState = document.getElementById('ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_hiddenSubscribeToEtocPopupState');
var emailTextBox = document.getElementById('ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_txtEmailAddress');
var thanksPanel = document.getElementById('ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_pnlAuthenticatedUser');
var mainPanel = document.getElementById('ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_pnlMain');
var thankYouMessageUnAuthenticated = document.getElementById('ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_lblThankYouMessage');
var thankYouMessageAuthenticated = document.getElementById('ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_lblAuthenticatedUserTitle');
if (!displaySubscriptionType) {
displaySubscriptionType = subscriptionType;
}
if (modelPopupState.value == 'showthanksmessage') {
thanksPanel.style.display = "block";
mainPanel.style.display = "none";
thankYouMessageAuthenticated.innerHTML = "Thank you for subscribing to the " + displaySubscriptionType + " for " + journalTitle + ".";
}
if (modelPopupState.value == 'showemail') {
thanksPanel.style.display = "none";
mainPanel.style.display = "block";
thankYouMessageUnAuthenticated.innerHTML = "Thank you for choosing to subscribe to the " + displaySubscriptionType + " for " + journalTitle + ".";
}
if ($('.etoc-popup') != null) {
document.getElementById('ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_hiddenJournalId').value = journalId;
if (modelPopupState.value == 'showemail') emailTextBox.focus();
}
}
$('.js-close').on('click', function() {
document.getElementById('ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_txtEmailAddress').value = "";
document.getElementById('ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_cvEmailError').style.display = "none";
var pageUrl = document.getElementById('ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_hiddenConfirmSubscriptionPageUrl');
var subscribeeTocPopup = $find('subscribeToEtoc');
if (subscribeeTocPopup != null) {
subscribeeTocPopup.hide();
document.getElementsByTagName('html')[0].classList.remove('no-scroll');
if (pageUrl.value !== '' && pageUrl.value !== window.location.pathname) window.location = pageUrl.value;
}
return false;
});
</script>
<div id="ctl00_ctl51_Header_UserActionTools_eTocTopContainer">
<div id="eTocTop" style="display: none;">
<a rel="nofollow" title="" href="javascript:javascript: alerts_ShowSubscribeeTOCPopup('Hepatology','hep','eTOC', 'eTOC');;" onclick="javascript: alerts_ShowSubscribeeTOCPopup('Hepatology','hep','eTOC', 'eTOC');"><span id="ctl00_ctl51_Header_UserActionTools_alertLinkControlTop_defaultText" class="hideOnFixed">Subscribe to eTOC</span></a>
</div>
</div>
<script>
$(function() {
//find recent searches link and move container
var recentSearchesControl = $("a[id$='RecentSearches']");
if (recentSearchesControl.length) {
recentSearchesControl.click(function(e) {
e.stopPropagation();
if ($("#ResentSearchContainer").is(":hidden")) {
$("#ResentSearchContainer").slideDown("slow");
recentSearchesControl.addClass('open');
} else {
$("#ResentSearchContainer").hide();
recentSearchesControl.removeClass('open');
}
});
}
var eTocAccountLink = $("ul.js-user-action-toolbar__dropdown>li>a[id='SubscribeToEToc']");
if (eTocAccountLink.length) {
eTocAccountLink.parent().html($("#eTocTop>a"));
}
});
</script>
<a class="logo-secondary black" href="https://www.aasld.org/" target="_blank">
<h3 class="logo-secondary-text">Secondary Logo</h3>
</a>
<a href="#" class="sticky-search"><i class="fa fa-search"></i></a>
<div id="unSubscribeToAlerts_foregroundElement" style="display: none; position: fixed; z-index: 38001;">
<div id="ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_pnlunSubscribeToAlerts" style="display: none;">
<div tabindex="-1" role="dialog" class="wk-modal horizontally-centered small wk-modal-with-overlay wk-modal-small ejp-modal">
<div id="ej-box-modal-style-1">
<div id="ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_pnlMain">
<div id="tocUnsubscribeModal">
<section class="wk-modal-content">
<header class="wk-modal-header ejp-modal-header">
<div class="wk-modal-title ejp-modal-title"></div>
<button aria-label="close dialog" class="js-close primary-button wk-button-icon wk-modal-close ejp-modal-close "><i class="fa fa-times"></i></button>
</header>
<div class="wk-modal-body">
<div class="wk-field-item">
<p>
<span id="ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_lblUnsubscribeMessage"></span>
</p>
<div class="wk-button-bar">
<div class="wk-button-group-left">
<p id="ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_pUnsubscribeButtons" style="display: none;">
<input type="submit" name="ctl00$ctl51$Header$UserActionTools$ucUnsubscribeToAlertsUserControl$btnContinue" value="Yes"
onclick="javascript:WebForm_DoPostBackWithOptions(new WebForm_PostBackOptions("ctl00$ctl51$Header$UserActionTools$ucUnsubscribeToAlertsUserControl$btnContinue", "", true, "", "", false, false))"
id="ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_btnContinue" class="primary-button">
<input type="button" value="No" id="btnCancel" aria-label="close dialog" class="js-close secondary-button">
</p>
</div>
</div>
</div>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
</div>
<div id="unSubscribeToAlerts_backgroundElement" class="Popup-Overlay" style="display: none; position: fixed; left: 0px; top: 0px; z-index: 10000;"></div>
<div id="subscribeToEtoc_foregroundElement" style="display: none; position: fixed; z-index: 38001;">
<div id="ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_pnlSubscribeToEtoc" class="etoc-popup ej-box-modal-drop-shadow" style="display: none;">
<div tabindex="-1" role="dialog" class="wk-modal horizontally-centered small wk-modal-with-overlay wk-modal-small ejp-modal">
<div id="ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_pnlMain" onkeypress="javascript:return WebForm_FireDefaultButton(event, 'ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_btnContinue')">
<section class="wk-modal-content">
<header class="wk-modal-header ejp-modal-header">
<div class="wk-modal-title ejp-modal-title">
<span id="ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_lblTitle"></span>
</div>
<button aria-label="close dialog" class="js-close primary-button wk-button-icon wk-modal-close ejp-modal-close ">
<i class="fa fa-times"></i>
</button>
</header>
<div class="wk-modal-body">
<div class="wk-field-item">
<div class="wk-field-body">
<strong>
<span id="ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_lblThankYouMessage"></span></strong>
</div>
<div class="wk-field-body">
<span id="ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_cvEmailError" style="color:Black;display:none;">
<div class="ej-error-message">
</div>
</span>
<label for="Email input">Enter your Email address:</label>
<div class="wk-field-body">
<input name="ctl00$ctl51$Header$UserActionTools$SubscribeToEtocPopupControl$txtEmailAddress" type="text" id="ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_txtEmailAddress"
class="ej-box-modal-style-1-input">
</div>
</div>
<div class="wk-button-bar">
<div class="wk-button-group-left">
<input type="submit" name="ctl00$ctl51$Header$UserActionTools$SubscribeToEtocPopupControl$btnContinue" value="Continue"
onclick="javascript:WebForm_DoPostBackWithOptions(new WebForm_PostBackOptions("ctl00$ctl51$Header$UserActionTools$SubscribeToEtocPopupControl$btnContinue", "", true, "", "", false, false))"
id="ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_btnContinue" class="primary-button">
<input type="button" value="Cancel" id="btnCancel" class="js-close secondary-button">
</div>
</div>
</div>
<div class="wk-field-item">
<div class="wk-field-body"> Wolters Kluwer Health may email you for journal alerts and information, but is committed to maintaining your privacy and will not share your personal information without your express consent. For
more information, please refer to our Privacy Policy. </div>
</div>
</div>
</section>
</div>
<div id="ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_pnlAuthenticatedUser" style="display: none;">
<section class="wk-modal-content">
<header class="wk-modal-header ejp-modal-header">
<div class="wk-modal-title ejp-modal-title"></div>
<button aria-label="close dialog" class="js-close primary-button wk-button-icon wk-modal-close ejp-modal-close "><i class="fa fa-times"></i></button>
</header>
<div class="wk-modal-body">
<div class="wk-field-item">
<p>
<strong>
<span id="ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_lblAuthenticatedUserTitle"></span>
</strong>
</p>
</div>
</div>
</section>
</div>
</div>
</div>
</div>
<div id="subscribeToEtoc_backgroundElement" class="Popup-Overlay" style="display: none; position: fixed; left: 0px; top: 0px; z-index: 10000;"></div>
</div>
<div class="header__layout-bottom wk-grid-page-container">
<a id="hypJournals" class="logo-main" href="https://journals.lww.com/hep/pages/default.aspx">
<h3 class="logo-main-text">Journal Logo
</h3>
</a>
<div class="search-v2">
<div class="search-wrapper">
<select name="ctl00$ctl51$Header$SearchTopBoxControl$ddlContentScope" id="ctl00_ctl51_Header_SearchTopBoxControl_ddlContentScope" tabindex="-1" style="display: none;" class="selectized">
<option value="Articles" selected="selected">Articles</option>
</select>
<div class="selectize-control single">
<div class="selectize-input items full has-options has-items">
<div class="item" data-value="Articles">Articles</div><input type="text" autocomplete="off" tabindex="" id="ctl00_ctl51_Header_SearchTopBoxControl_ddlContentScope-selectized" style="width: 4px;">
</div>
<div class="selectize-dropdown single" style="display: none;">
<div class="selectize-dropdown-content"></div>
</div>
</div>
<div class="input-group" id="globalSearch">
<input name="ctl00$ctl51$Header$SearchTopBoxControl$txtKeywords" type="text" value="Search" id="ctl00_ctl51_Header_SearchTopBoxControl_txtKeywords" class="form-control searchText">
<span class="input-group-btn">
<button id="ctl00_ctl51_Header_SearchTopBoxControl_btnGlobalSearchMagnifier" type="submit" class="btn btn-default"><i class="fa fa-search"></i></button>
</span>
<input type="hidden" name="ctl00$ctl51$Header$SearchTopBoxControl$IsAutoCompleteEnabled" id="ctl00_ctl51_Header_SearchTopBoxControl_IsAutoCompleteEnabled" value="false">
<input type="hidden" name="ctl00$ctl51$Header$SearchTopBoxControl$AutocompleteApiUrl" id="ctl00_ctl51_Header_SearchTopBoxControl_AutocompleteApiUrl"
value="https://platformservices.wolterskluwerhealth.com/autocomplete/HEPA/shingle/">
</div>
</div>
<div class="advance-search" style="">
<a id="ctl00_ctl51_Header_SearchTopBoxControl_lnkAdvanceSearch" href="https://journals.lww.com/hep/pages/advancedsearch.aspx">Advanced Search</a>
<input type="submit" name="ctl00$ctl51$Header$SearchTopBoxControl$btnGlobalSearch" value="" id="ctl00_ctl51_Header_SearchTopBoxControl_btnGlobalSearch" disabled="disabled" class="aspNetDisabled btnGlobalSearch" style="display: none;">
<input name="ctl00$ctl51$Header$SearchTopBoxControl$hfldKeywords" type="hidden" id="ctl00_ctl51_Header_SearchTopBoxControl_hfldKeywords" class="hfldKeywords" value="disableButton">
</div>
</div>
<script>
$(function() {
try {
var objSearchBox = {
btnGlobalSearchMagnifierId: 'ctl00_ctl51_Header_SearchTopBoxControl_btnGlobalSearchMagnifier',
searchButtonId: 'ctl00_ctl51_Header_SearchTopBoxControl_btnGlobalSearch',
txtKeywordsId: 'ctl00_ctl51_Header_SearchTopBoxControl_txtKeywords',
hfldKeywordsHiddenId: 'ctl00_ctl51_Header_SearchTopBoxControl_hfldKeywords',
defaultSearchText: 'Search'
};
new Searchbox(objSearchBox).Init();
} catch (e) {
console.error(e);
}
});
//autocomplete functionality for basic search
//this functionality will call the SBA url and start suggesting after typing 3rd character
var textKeywords = null;
var hiddenAutocompleteApiUrl = null;
var buttonGlobalSearch = null;
$(function() {
try {
var objAutocomplete = {
hiddenIsAutoCompleteEnabled: $('#ctl00_ctl51_Header_SearchTopBoxControl_IsAutoCompleteEnabled'),
textKeywords: $('#ctl00_ctl51_Header_SearchTopBoxControl_txtKeywords'),
hiddenAutocompleteApiUrl: $('#ctl00_ctl51_Header_SearchTopBoxControl_AutocompleteApiUrl'),
buttonGlobalSearch: $('#ctl00_ctl51_Header_SearchTopBoxControl_btnGlobalSearch')
};
autoComplete(objAutocomplete);
} catch (e) {
console.error(e);
}
});
$(function() {
let searchSelect = $('select[id$="ddlContentScope"]');;
if (searchSelect.length) {
searchSelect.selectize();
}
});
</script>
</div>
<div id="main-nav-container-v2">
<nav id="main-nav" class="navbar navbar-default yamm wk-grid-page-container">
<div class="navbar-header">
<button id="fatJuicy" type="button" class="navbar-hamburger-button navbar-toggle collapsed pull-left" data-bs-toggle="collapse" data-bs-target="#zz1_TopNavigationMenu" aria-expanded="false" aria-controls="navbar">
<span class="visually-hidden">Toggle navigation</span>
<span class="icon-bar"></span>
<span class="icon-bar"></span>
<span class="icon-bar"></span>
<span class="navbar-hamburger-button__text"></span>
</button>
</div>
<div id="navActionButtons" class="btn-group navbar-hover-color" role="group" aria-label="...">
<a id="ctl00_ctl51_lnkSubscribe" class="btn btn-default navbar-button" href="https://shop.lww.com/p/0270-9139" target="_blank">Subscribe</a>
<a id="ctl00_ctl51_lnkRegister" class="btn btn-default navbar-button" href="https://journals.lww.com/hep/pages/register.aspx?ContextUrl=%2fhep%2ffulltext%2f2021%2f09000%2fanalysis_and_validation_of_human_targets_and.24.aspx">Register</a>
<button class="user-menu__link user-menu__link--login js-ejp-login-btn btn btn-default navbar-button" type="button" data-config="{"eventName":"login","eventDetail":{},"isNull":false}">
<span>Login</span>
</button>
</div>
<div id="ctl00_ctl51_TopNavigationMenuConfiguration" style="display:none" class="js-top-navigation-menu-configuration"
data-config="{"browsingHistory":{"isEnabled":true,"serviceUrl":"https://apim-hlrp-ejp-prod.azure-api.net/ee","pdfDownloadUrl":"/_layouts/15/oaks.journals/downloadpdf.aspx?trckng_src_pg=HistoryTab"}}">
</div>
<div id="zz1_TopNavigationMenu" class="navbar-collapse collapse js-top-navigation-menu">
<ul id="zz2_RootAspMenu" class="nav navbar-nav">
<li class="js-navbar-nav__history navbar-nav__history">
<a href="#" class="ejp-browsing-history-link"><span class="ejp-browsing-history-link__text"><span class="ejp-browsing-history-link__text-mobile">Browsing </span>History</span><i class="fa fa-history ejp-browsing-history-link__icon"></i></a>
</li>
<li class="">
<a class="static menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" tabindex="0" href="https://journals.lww.com/hep/pages/default.aspx">
<span class="additional-background ms-navedit-flyoutArrow">
<span class="menu-item-text">Home</span>
</span>
</a>
</li>
<li class=" dropdown">
<a href="#" class="dropdown-toggle js-dropdown-toggle" data-bs-toggle="dropdown" role="button" aria-haspopup="true" aria-expanded="false">Browse<i class="fa"></i></a>
<ul class="dropdown-menu">
<li class=" dynamic">
<a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" tabindex="0" href=" https://journals.lww.com/hep/toc/publishahead">
<span class="additional-background ms-navedit-flyoutArrow">
<span class="menu-item-text">Articles in Press</span>
</span>
</a>
</li>
<li class=" dynamic">
<a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" tabindex="0" href=" https://journals.lww.com/hep/pages/currenttoc.aspx">
<span class="additional-background ms-navedit-flyoutArrow">
<span class="menu-item-text">Current Issue</span>
</span>
</a>
</li>
<li class=" dynamic">
<a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" tabindex="0" href=" https://journals.lww.com/hep/pages/issuelist.aspx">
<span class="additional-background ms-navedit-flyoutArrow">
<span class="menu-item-text">All Issues</span>
</span>
</a>
</li>
</ul>
</li>
<li class=" dropdown">
<a href="#" class="dropdown-toggle " data-bs-toggle="dropdown" role="button" aria-haspopup="true" aria-expanded="false">Collections<i class="fa"></i></a>
<ul class="dropdown-menu">
<li class=" dynamic">
<a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" tabindex="0" href=" https://journals.lww.com/hep/pages/collectiondetails.aspx?TopicalCollectionId=5">
<span class="additional-background ms-navedit-flyoutArrow">
<span class="menu-item-text">Review Articles</span>
</span>
</a>
</li>
<li class=" dynamic">
<a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" tabindex="0" href=" https://journals.lww.com/hep/pages/collectiondetails.aspx?TopicalCollectionId=6">
<span class="additional-background ms-navedit-flyoutArrow">
<span class="menu-item-text">Graphical Abstracts</span>
</span>
</a>
</li>
<li class=" dynamic">
<a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" tabindex="0" href=" https://journals.lww.com/hep/pages/collectiondetails.aspx?TopicalCollectionId=9">
<span class="additional-background ms-navedit-flyoutArrow">
<span class="menu-item-text">Top Cited Articles</span>
</span>
</a>
</li>
<li class=" dynamic">
<a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" tabindex="0" href=" https://journals.lww.com/hep/pages/collectiondetails.aspx?TopicalCollectionId=10">
<span class="additional-background ms-navedit-flyoutArrow">
<span class="menu-item-text">Top Altmetric Articles</span>
</span>
</a>
</li>
<li class=" dynamic">
<a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" tabindex="0" href=" https://journals.lww.com/aasldpubs/pages/collections.aspx?Collection=Topical" target="_blank">
<span class="additional-background ms-navedit-flyoutArrow">
<span class="menu-item-text">Multi-journal Article Collections</span>
</span>
</a>
</li>
</ul>
</li>
<li class=" dropdown">
<a href="#" class="dropdown-toggle " data-bs-toggle="dropdown" role="button" aria-haspopup="true" aria-expanded="false">About<i class="fa"></i></a>
<ul class="dropdown-menu">
<li class=" dynamic">
<a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" tabindex="0" href=" https://journals.lww.com/hep/pages/aboutthejournal.aspx">
<span class="additional-background ms-navedit-flyoutArrow">
<span class="menu-item-text">About the Journal</span>
</span>
</a>
</li>
<li class=" dynamic">
<a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" tabindex="0" href=" https://journals.lww.com/hep/Pages/About-the-Association.aspx">
<span class="additional-background ms-navedit-flyoutArrow">
<span class="menu-item-text">About AASLD</span>
</span>
</a>
</li>
<li class=" dynamic">
<a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" tabindex="0" href=" https://journals.lww.com/hep/pages/editorialboard.aspx">
<span class="additional-background ms-navedit-flyoutArrow">
<span class="menu-item-text">Editorial Board</span>
</span>
</a>
</li>
<li class=" dynamic">
<a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" tabindex="0" href=" https://edmgr.ovid.com/hep/accounts/ifauth.htm" target="_blank">
<span class="additional-background ms-navedit-flyoutArrow">
<span class="menu-item-text">Instructions for Authors</span>
</span>
</a>
</li>
<li class=" dynamic">
<a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" tabindex="0" href=" https://journals.lww.com/hep/Pages/Advertising.aspx">
<span class="additional-background ms-navedit-flyoutArrow">
<span class="menu-item-text">Advertising</span>
</span>
</a>
</li>
<li class=" dynamic">
<a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" tabindex="0" href=" https://journals.lww.com/hep/Pages/Permissions.aspx">
<span class="additional-background ms-navedit-flyoutArrow">
<span class="menu-item-text">Permissions</span>
</span>
</a>
</li>
<li class=" dynamic">
<a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" tabindex="0" href=" https://www.wolterskluwer.com/en/solutions/lippincott-journals/lippincott-open-access" target="_blank">
<span class="additional-background ms-navedit-flyoutArrow">
<span class="menu-item-text">Open Access</span>
</span>
</a>
</li>
<li class=" dynamic">
<a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" tabindex="0" href=" https://journals.lww.com/hep/Pages/Reprints.aspx">
<span class="additional-background ms-navedit-flyoutArrow">
<span class="menu-item-text">Reprints</span>
</span>
</a>
</li>
</ul>
</li>
<li class=" dropdown">
<a href="#" class="dropdown-toggle " data-bs-toggle="dropdown" role="button" aria-haspopup="true" aria-expanded="false">For Authors<i class="fa"></i></a>
<ul class="dropdown-menu">
<li class=" dynamic">
<a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" tabindex="0" href=" https://edmgr.ovid.com/hep/accounts/ifauth.htm" target="_blank">
<span class="additional-background ms-navedit-flyoutArrow">
<span class="menu-item-text">Instructions for Authors</span>
</span>
</a>
</li>
<li class=" dynamic">
<a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" tabindex="0" href=" https://preflight.paperpal.com/partner/lww/hepatol/submit" target="_blank">
<span class="additional-background ms-navedit-flyoutArrow">
<span class="menu-item-text">Submit an Article</span>
</span>
</a>
</li>
<li class=" dynamic">
<a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" tabindex="0" href=" https://journals.lww.com/hep/_layouts/1033/oaks.journals/editservices.aspx">
<span class="additional-background ms-navedit-flyoutArrow">
<span class="menu-item-text">Language Editing Services</span>
</span>
</a>
</li>
<li class=" dynamic">
<a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" tabindex="0" href=" https://view.officeapps.live.com/op/view.aspx?src=https%3A%2F%2Fedmgr.ovid.com%2Fhep%2Faccounts%2FAASLD_Visual_Abstract_Template_Hepatology.pptx&wdOrigin=BROWSELINK" target="_blank">
<span class="additional-background ms-navedit-flyoutArrow">
<span class="menu-item-text">Graphical Abstract Guidelines</span>
</span>
</a>
</li>
</ul>
</li>
<li class=" dropdown">
<a href="#" class="dropdown-toggle " data-bs-toggle="dropdown" role="button" aria-haspopup="true" aria-expanded="false">Resources<i class="fa"></i></a>
<ul class="dropdown-menu">
<li class=" dynamic">
<a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" tabindex="0" href=" https://journals.lww.com/aasldpubs/Pages/Publish-with-Us.aspx" target="_blank">
<span class="additional-background ms-navedit-flyoutArrow">
<span class="menu-item-text">Publish with Us</span>
</span>
</a>
</li>
<li class=" dynamic">
<a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" tabindex="0" href=" https://careercenter.aasld.org/" target="_blank">
<span class="additional-background ms-navedit-flyoutArrow">
<span class="menu-item-text">AASLD Career Center</span>
</span>
</a>
</li>
<li class=" dynamic">
<a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" tabindex="0" href=" https://journals.lww.com/aasldpubs/Documents/GISociety-JointStatement-Racism-FINAL.pdf" target="_blank">
<span class="additional-background ms-navedit-flyoutArrow">
<span class="menu-item-text">Joint GI Society Statement on Racism</span>
</span>
</a>
</li>
<li class=" dynamic">
<a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" tabindex="0" href=" https://journals.lww.com/hep/Citation/9900/What_is_Hepatology_looking_for_version_2_0_.90.aspx">
<span class="additional-background ms-navedit-flyoutArrow">
<span class="menu-item-text">What is Hepatology looking for 2.0?</span>
</span>
</a>
</li>
<li class=" dynamic">
<a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" tabindex="0" href=" https://www.aasld.org/covid-19-and-liver" target="_blank">
<span class="additional-background ms-navedit-flyoutArrow">
<span class="menu-item-text">COVID-19 Resources</span>
</span>
</a>
</li>
<li class=" dynamic">
<a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" tabindex="0" href=" https://liverlearning.aasld.org/" target="_blank">
<span class="additional-background ms-navedit-flyoutArrow">
<span class="menu-item-text">LiverLearning</span>
</span>
</a>
</li>
<li class=" dynamic">
<a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" tabindex="0" href=" https://www.aasld.org/forums" target="_blank">
<span class="additional-background ms-navedit-flyoutArrow">
<span class="menu-item-text">Liver Connect Forums</span>
</span>
</a>
</li>
<li class=" dynamic">
<a class="dynamic menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" tabindex="0" href=" https://www.aasld.org/become-member" target="_blank">
<span class="additional-background ms-navedit-flyoutArrow">
<span class="menu-item-text">Become a Member</span>
</span>
</a>
</li>
</ul>
</li>
<li class="">
<a class="static menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" tabindex="0" href="https://journals.lww.com/aasldpubs/Pages/AASLD-Practice-Guidelines-new.aspx" target="_blank">
<span class="additional-background ms-navedit-flyoutArrow">
<span class="menu-item-text">AASLD Guidelines</span>
</span>
</a>
</li>
<li class="">
<a class="static menu-item ms-core-listMenu-item ms-displayInline ms-navedit-linkNode" tabindex="0" href="https://preflight.paperpal.com/partner/lww/hepatol/submit" target="_blank">
<span class="additional-background ms-navedit-flyoutArrow">
<span class="menu-item-text">Submit an Article</span>
</span>
</a>
</li>
</ul>
</div>
<div class="search-v2">
<div class="search-wrapper">
<select name="ctl00$ctl51$SearchBox$ddlContentScope" id="ctl00_ctl51_SearchBox_ddlContentScope" tabindex="-1" style="display: none;" class="selectized">
<option value="Articles" selected="selected">Articles</option>
</select>
<div class="selectize-control single">
<div class="selectize-input items full has-options has-items">
<div class="item" data-value="Articles">Articles</div><input type="text" autocomplete="off" tabindex="" id="ctl00_ctl51_SearchBox_ddlContentScope-selectized" style="width: 4px;">
</div>
<div class="selectize-dropdown single" style="display: none;">
<div class="selectize-dropdown-content"></div>
</div>
</div>
<div class="input-group" id="globalSearch">
<input name="ctl00$ctl51$SearchBox$txtKeywords" type="text" value="Search" id="ctl00_ctl51_SearchBox_txtKeywords" class="form-control searchText">
<span class="input-group-btn">
<button id="ctl00_ctl51_SearchBox_btnGlobalSearchMagnifier" type="submit" class="btn btn-default"><i class="fa fa-search"></i></button>
</span>
<input type="hidden" name="ctl00$ctl51$SearchBox$IsAutoCompleteEnabled" id="ctl00_ctl51_SearchBox_IsAutoCompleteEnabled" value="false">
<input type="hidden" name="ctl00$ctl51$SearchBox$AutocompleteApiUrl" id="ctl00_ctl51_SearchBox_AutocompleteApiUrl" value="https://platformservices.wolterskluwerhealth.com/autocomplete/HEPA/shingle/">
</div>
</div>
<div class="advance-search" style="">
<a id="ctl00_ctl51_SearchBox_lnkAdvanceSearch" href="https://journals.lww.com/hep/pages/advancedsearch.aspx">Advanced Search</a>
<input type="submit" name="ctl00$ctl51$SearchBox$btnGlobalSearch" value="" id="ctl00_ctl51_SearchBox_btnGlobalSearch" disabled="disabled" class="aspNetDisabled btnGlobalSearch" style="display: none;">
<input name="ctl00$ctl51$SearchBox$hfldKeywords" type="hidden" id="ctl00_ctl51_SearchBox_hfldKeywords" class="hfldKeywords" value="disableButton">
</div>
</div>
<script>
$(function() {
try {
var objSearchBox = {
btnGlobalSearchMagnifierId: 'ctl00_ctl51_SearchBox_btnGlobalSearchMagnifier',
searchButtonId: 'ctl00_ctl51_SearchBox_btnGlobalSearch',
txtKeywordsId: 'ctl00_ctl51_SearchBox_txtKeywords',
hfldKeywordsHiddenId: 'ctl00_ctl51_SearchBox_hfldKeywords',
defaultSearchText: 'Search'
};
new Searchbox(objSearchBox).Init();
} catch (e) {
console.error(e);
}
});
//autocomplete functionality for basic search
//this functionality will call the SBA url and start suggesting after typing 3rd character
var textKeywords = null;
var hiddenAutocompleteApiUrl = null;
var buttonGlobalSearch = null;
$(function() {
try {
var objAutocomplete = {
hiddenIsAutoCompleteEnabled: $('#ctl00_ctl51_SearchBox_IsAutoCompleteEnabled'),
textKeywords: $('#ctl00_ctl51_SearchBox_txtKeywords'),
hiddenAutocompleteApiUrl: $('#ctl00_ctl51_SearchBox_AutocompleteApiUrl'),
buttonGlobalSearch: $('#ctl00_ctl51_SearchBox_btnGlobalSearch')
};
autoComplete(objAutocomplete);
} catch (e) {
console.error(e);
}
});
$(function() {
let searchSelect = $('select[id$="ddlContentScope"]');;
if (searchSelect.length) {
searchSelect.selectize();
}
});
</script>
</nav>
</div>
</div>
</header>
<!-- topbanner start -->
<!-- topbanner start -->
<!-- topbanner end -->
<!-- topbanner end -->
<div id="main-container-content" class="wk-grid-page-container">
<div id="DeltaWebPartAdderUpdatePanelContainer" class="ms-core-webpartadder">
<div id="WebPartAdderUpdatePanelContainer">
<div id="ctl00_WebPartAdderUpdatePanel">
<span id="ctl00_WebPartAdder"></span>
</div>
</div>
</div>
<div id="notificationArea" class="ms-notif-box"></div>
<div id="DeltaPageStatusBar">
<div id="pageStatusBar" class="ms-status-blue" style="display: none;"></div>
</div>
<div id="DeltaPlaceHolderMain" class="delta-place-holder-main">
<a id="mainContent" name="mainContent" tabindex="-1"></a>
<div id="ctl00_PlaceHolderMain_ResponsivePageLayoutRenderer_responsivePageLayoutContainer" class="main-content ejp-page-container">
<div class="wk-grid-container-no-margin" id="AddRowTopContainer">
</div>
<div id="ctl00_PlaceHolderMain_ResponsivePageLayoutRenderer_ResponsiveLayoutRowRepeater_ctl00_ResponsiveLayoutRowContainer" class="wk-grid-container-no-margin">
<div id="ctl00_PlaceHolderMain_ResponsivePageLayoutRenderer_ResponsiveLayoutRowRepeater_ctl00_ResponsiveLayoutRow" class="wk-grid">
<div id="ctl00_PlaceHolderMain_ResponsivePageLayoutRenderer_ResponsiveLayoutRowRepeater_ctl00_ResponsiveLayoutColumnRepeater_ctl00_ResponsiveLayoutColumn"
class=" wk-column-12 wk-column-12-m wk-column-12-l wk-column-12-xl wk-column-12-xxl">
<div class="ms-webpart-zone ms-fullWidth">
<div id="MSOZoneCell_WebPartctl00_ctl29_g_e49ed9af_7fd4_441c_b621_1aa76f20fffa" class="s4-wpcell-plain ms-webpartzone-cell ms-webpart-cell-vertical-inline-table ms-webpart-cell-vertical ms-fullWidth ">
<div class="ms-webpart-chrome ms-webpart-chrome-vertical ms-webpart-chrome-fullWidth ">
<div webpartid="e49ed9af-7fd4-441c-b621-1aa76f20fffa" haspers="false" id="WebPartctl00_ctl29_g_e49ed9af_7fd4_441c_b621_1aa76f20fffa" width="100%" class="ms-WPBody noindex " allowdelete="false" style="">
<div id="ctl00_ctl29_g_e49ed9af_7fd4_441c_b621_1aa76f20fffa">
<!-- ===== ASP._controltemplates_oaks_journals_articlenavigationcontrol_ascx generated at 6/19/2024 10:11:54 PM ===== -->
<div class="ejp-article-breadcrumb">
<div class="ejp-article-breadcrumb__left">
<a title="" href="/hep/toc/2021/09000" class="ejp-article-nav__list-link-back">September 2021 - Volume 74 - Issue 3
</a>
</div>
<div class="ejp-article-breadcrumb__right">
<nav id="ctl00_ctl29_g_e49ed9af_7fd4_441c_b621_1aa76f20fffa__ff8d793d98b8a986_ArticleNavigator">
<ul class="ejp-article-nav__list">
<li id="ctl00_ctl29_g_e49ed9af_7fd4_441c_b621_1aa76f20fffa__ff8d793d98b8a986_liArticleNavigatorPrev">
<a title="" href="/hep/fulltext/2021/09000/state_level_hcc_incidence_and_association_with.23.aspx" onmouseover="javascript:Tooltip_Article('State‐Level HCC Incidence and Association With Obesity and Physical Activity in the United States', 'Lee Yi‐Te; Wang, Jasmine J.; Luu, Michael; Tseng, Hsian‐Rong; Rich, Nicole E.; Lu, Shelly C.; Nissen, Nicholas N.; Noureddin, Mazen; Singal, Amit G.; Yang, Ju Dong', 'Hepatology', 'September 2021', '74', '3' , 'p 1384-1394')" onmouseout="javascript:Tooltip_MouseOut()" class="ejp-article-nav__list-link-prev">
<span>Previous</span>
<span class="ejp-article-nav__list-link-mobile-hide">Article</span>
</a>
</li>
<li id="ctl00_ctl29_g_e49ed9af_7fd4_441c_b621_1aa76f20fffa__ff8d793d98b8a986_liArticleNavigatorNext">
<a title="" href="/hep/fulltext/2021/09000/sulfatase_2__sulf2__monoclonal_antibody_5d5.25.aspx" onmouseover="javascript:Tooltip_Article('Sulfatase 2 (SULF2) Monoclonal Antibody 5D5 Suppresses Human Cholangiocarcinoma Xenograft Growth Through Regulation of a SULF2–Platelet‐Derived Growth Factor Receptor Beta–Yes‐Associated Protein Signaling Axis', 'Luo Xin; Campbell, Nellie A.; He, Li; O\'Brien, Daniel R.; Singer, Mark S.; Lemjabbar‐Alaoui, Hassan; Ahn, Keun Soo; Smoot, Rory; Torbenson, Michael S.; Rosen, Steven D.; Roberts, Lewis R.', 'Hepatology', 'September 2021', '74', '3' , 'p 1411-1428')" onmouseout="javascript:Tooltip_MouseOut()" class="ejp-article-nav__list-link-next">
<span>Next</span>
<span class="ejp-article-nav__list-link-mobile-hide">Article</span>
</a>
</li>
</ul>
</nav>
</div>
</div>
</div>
<div class="ms-clear"></div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
<div id="ctl00_PlaceHolderMain_ResponsivePageLayoutRenderer_ResponsiveLayoutRowRepeater_ctl01_ResponsiveLayoutRowContainer" class="wk-grid-container-no-margin">
<div id="ctl00_PlaceHolderMain_ResponsivePageLayoutRenderer_ResponsiveLayoutRowRepeater_ctl01_ResponsiveLayoutRow" class="wk-grid">
<div id="ctl00_PlaceHolderMain_ResponsivePageLayoutRenderer_ResponsiveLayoutRowRepeater_ctl01_ResponsiveLayoutColumnRepeater_ctl00_ResponsiveLayoutColumn"
class=" wk-column-12 wk-column-8-m wk-column-8-l wk-column-8-xl wk-column-8-xxl">
<div class="ms-webpart-zone ms-fullWidth">
<div id="MSOZoneCell_WebPartctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d" class="s4-wpcell-plain ms-webpartzone-cell ms-webpart-cell-vertical-inline-table ms-webpart-cell-vertical ms-fullWidth ">
<div class="ms-webpart-chrome ms-webpart-chrome-vertical ms-webpart-chrome-fullWidth ">
<div webpartid="66d092b4-9819-4479-a267-faf7b1636d3d" haspers="false" id="WebPartctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d" width="100%" class="ms-WPBody noindex " allowdelete="false" style="">
<div id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d">
<!-- ===== ASP._controltemplates_oaks_journals_articleviewerusercontrol_ascx generated at 6/19/2024 10:11:54 PM ===== -->
<script type="text/javascript" src="https://lww.com/_layouts/15/1033/Scripts/wk/article.min.js?v=05.20.00.150">
</script>
<link rel="stylesheet" type="text/css" href="https://lww.com/_layouts/1033/OAKS.Journals/MediaElement/mediaelementplayer.css?v=05.20.00.150" media="print">
<span class="js-custom-event"
data-config="{"name":"articleView","detail":{"articleDetails":{"journalName":"Hepatology","articleTopicName":"","articleName":"Analysis and Validation of Human Targets and Treatments Using a Hepatocellular Carcinoma–Immune Humanized Mouse Model","publicationDate":"09/01/2021","accessionNumber":"01515467-202109000-00000","doi":"10.1002/hep.31812","authors":"Yue Zhao; Jiaxu Wang; Wai Nam Liu; Shin Yie Fong; Timothy Wai Ho Shuen; Min Liu; Sarah Harden; Sue Yee Tan; Jia Ying Cheng; Wilson Wei Sheng Tan; Jerry Kok Yen Chan; Cheng Ean Chee; Guan Huei Lee; Han Chong Toh; Seng Gee Lim; Yue Wan; Qingfeng Chen","societyName":"American Association for the Study of Liver Diseases","collectionName":"","abstractValues":"Background and Aims Recent development of multi","sku":"0270-9139","format":"HTML","articleKeywords":"","articleMetadata":"OPENACCESS=TRUE","systemIndicators":["Open"],"meshTerms":["Neoplasms","Cells","Tumor Microenvironment","Flow Cytometry","Antibodies, Neoplasm","Immunohistochemistry","Cell Proliferation","Transplantation, Heterologous","Neoplasm Proteins","Injections, Subcutaneous"],"pageSource":"ArticleViewer"},"articleDisplayType":"Fulltext"},"order":2147483647,"config":{"bubbles":true,"cancelable":true,"composed":false}}"></span>
<!--link tag emitted to support printing-->
<link rel="stylesheet" type="text/css" href="https://lww.com/_layouts/1033/styles/oaks.journals/print-article.css?v=05.20.00.150" media="print">
<script type="text/javascript">
var articleContainer = document.getElementById('ArticleContainer');
function getElementReferences() {
textDiv = articleContainer;
// textDiv = document.getElementById('ArticleContainer');
}
function getArticleContainer() {
return articleContainer;
}
$(function() {
// Change the '+', '-' icon when panels are collapsed.
$('a.toggle-content').click(function() {
var isExpanded = $(this).attr('aria-expanded');
var i = $(this).children('i');
if (isExpanded === 'true') {
i.removeClass('fa fa-minus-square-o').addClass('fa fa-plus-square-o');
} else {
i.removeClass('fa fa-plus-square-o').addClass('fa fa-minus-square-o');
}
});
var articleAbstractLink = $('#article-abstract-content4>ul>li>a')[0];
if ($(articleAbstractLink).html() === 'Abstract') {
$(articleAbstractLink).click($.proxy(clickAbstractLink, this));
}
});
function ArticleTabClickLogToCounterService() {
var dualAccessHelper = new DualAccess();
dualAccessHelper.SendCounterDataRequestByAn(dualAccessHelper.EventTypes.Investigation, dualAccessHelper.ContentTypes.ArticleTab, '01515467-202109000-00024');
};
window.addEventListener("load", () => {
HighlightSearchTerms();
});
</script>
<script>
function closeArticleViewerModalDialog() {
$('#articleViewerDialog').hide();
return false;
}
</script>
<div class="ejp-article-wrapper">
<div id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_container"
data-article-config="{"title":"ReadAloud: Analysis and Validation of Human Targets and Treatments Using a Hepatocellular Carcinoma–Immune Humanized Mouse Model","doi":"10.1002/hep.31812"}"
data-read-along="false"
data-ppt-event-detail="{"eventName":"PPTDownload","eventDetail":{"url":"https://journals.lww.com:443/hep/fulltext/2021/09000/analysis_and_validation_of_human_targets_and.24.aspx?Ppt=Article|hep:2021:09000:00024|10.1002/hep.31812|","gating":false},"eventOptions":{"bubbles":true,"cancelable":true,"composed":false},"loginDetail":{"isLoginOptional":true,"promptLogin":false},"isNull":false}"
data-has-ce="false" data-is-social-sharing-enabled="false" data-ce-cme-redirect="false" data-ppt-visible="true"
data-email-to-colleague-control-id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl" data-images-slideshow-visible="true"
data-social-sharing-title="Analysis and Validation of Human Targets and Treatments... : Hepatology" data-pdf-visible="true" class="js-ejp-article-tools lww-ejp-article-tools" data-ce-cme-url=""
data-has-permissions="true" data-epub-enabled="true" data-article-accession-number="01515467-202109000-00024" data-epub-visible="true"
data-image-gallery-url="/hep/pages/imagegallery.aspx?year=2021&issue=09000&article=00024"
data-social-sharing-source="https://journals.lww.com/hep/fulltext/2021/09000/analysis_and_validation_of_human_targets_and.24.aspx"
data-favorites-event-detail="{"eventName":"AddToFavorites","eventDetail":{"items":["Article|hep:2021:09000:00024|10.1002/hep.31812|"],"an":"01515467-202109000-00024"},"eventOptions":{"bubbles":true,"cancelable":true,"composed":false},"loginDetail":{"isLoginOptional":false,"promptLogin":true,"loginPromptText":"To save this item, login or register"},"isNull":false}"
data-ce-cme-title="" data-is-fulltext="true" data-has-cme="false" data-pdf-enabled="true" data-images-gallery-visible="true"
data-pdf-event-detail="{"eventName":"PDFDownloadInit","eventDetail":{"url":"https://journals.lww.com/hep/_layouts/15/oaks.journals/downloadpdf.aspx?trckng_src_pg=ArticleViewer&an=01515467-202109000-00024","gating":false},"eventOptions":{"bubbles":true,"cancelable":true,"composed":false},"loginDetail":{"isLoginOptional":true,"promptLogin":false},"isNull":false}"
data-epub-event-detail="{"eventName":"EPUBDownload","eventDetail":{"url":"https://journals.lww.com:443/hep/fulltext/2021/09000/analysis_and_validation_of_human_targets_and.24.aspx?generateEpub=Article|hep:2021:09000:00024|10.1002/hep.31812|","gating":false},"eventOptions":{"bubbles":true,"cancelable":true,"composed":false},"loginDetail":{"isLoginOptional":true,"promptLogin":false},"isNull":false}"
data-pdf-url="https://journals.lww.com/hep/_layouts/15/oaks.journals/downloadpdf.aspx?trckng_src_pg=ArticleViewer&an=01515467-202109000-00024">
<aside class="ejp-sticky-bar">
<nav class="ejp-article-tools">
<ul class="ejp-article-tools__list">
<li class="ejp-article-tools__list-item "><button type="button" class="ejp-article-tools__list-button " data-config=""><span class="ejp-article-tools__list-icon-holder"><i class="icon-contributors"></i><strong
class="ejp-article-tools__list-icon-title">Outline</strong></span></button>
<ul class="ejp-article-tools__dropdown-list ejp-article-tools__dropdown-list--dots ">
<li class="ejp-article-tools__dropdown-list-item ejp-article-tools__dropdown-list-item--level1"><button type="button" class="ejp-article-tools__dropdown-list-button ">Materials and Methods</button></li>
<li class="ejp-article-tools__dropdown-list-item ejp-article-tools__dropdown-list-item--level2"><button type="button" class="ejp-article-tools__dropdown-list-button ">MICE</button></li>
<li class="ejp-article-tools__dropdown-list-item ejp-article-tools__dropdown-list-item--level1"><button type="button" class="ejp-article-tools__dropdown-list-button ">Results</button></li>
<li class="ejp-article-tools__dropdown-list-item ejp-article-tools__dropdown-list-item--level2"><button type="button" class="ejp-article-tools__dropdown-list-button ">The Human Immune System Promotes HCC
Proliferation and Angiogenesis</button></li>
<li class="ejp-article-tools__dropdown-list-item ejp-article-tools__dropdown-list-item--level2"><button type="button" class="ejp-article-tools__dropdown-list-button ">Intratumor hCD14 Cells Contribute to
Promoting HCC Proliferation and Angiogenesis</button></li>
<li class="ejp-article-tools__dropdown-list-item ejp-article-tools__dropdown-list-item--level2"><button type="button" class="ejp-article-tools__dropdown-list-button ">Intratumor Human Immune Cells are
Strongly Modulated by HCC Tumors</button></li>
<li class="ejp-article-tools__dropdown-list-item ejp-article-tools__dropdown-list-item--level2"><button type="button" class="ejp-article-tools__dropdown-list-button ">IL‐33 Secreted From Intratumor
hCD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> Cells Up‐Regulates IL‐6 Expression in Multiple Intratumor Immune Cells and Enhances HCC Proliferation</button></li>
<li class="ejp-article-tools__dropdown-list-item ejp-article-tools__dropdown-list-item--level2"><button type="button" class="ejp-article-tools__dropdown-list-button ">Co‐receptor CD14 Is Essential for
IL‐33 Production Through Damp (HMGB1)/TLR4/Activator Protein 1 Pathway</button></li>
<li class="ejp-article-tools__dropdown-list-item ejp-article-tools__dropdown-list-item--level2"><button type="button"
class="ejp-article-tools__dropdown-list-button ">hCD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> Monocytes Among TILs are Crucial for Combinatorial Immunotherapy on HCC</button></li>
<li class="ejp-article-tools__dropdown-list-item ejp-article-tools__dropdown-list-item--level1"><button type="button" class="ejp-article-tools__dropdown-list-button ">Discussion</button></li>
<li class="ejp-article-tools__dropdown-list-item ejp-article-tools__dropdown-list-item--level1"><button type="button" class="ejp-article-tools__dropdown-list-button ">Authors Contributions</button></li>
<li class="ejp-article-tools__dropdown-list-item ejp-article-tools__dropdown-list-item--level1"><button type="button" class="ejp-article-tools__dropdown-list-button ">Acknowledgment</button></li>
<li class="ejp-article-tools__dropdown-list-item ejp-article-tools__dropdown-list-item--level1"><button type="button" class="ejp-article-tools__dropdown-list-button ">References</button></li>
</ul>
</li>
<li class="ejp-article-tools__list-item ejp-article-tools__list-item--images ejp-hide-on-mobile "><button type="button" class="ejp-article-tools__list-button " data-config=""><span
class="ejp-article-tools__list-icon-holder"><i class="icon-images"></i><strong class="ejp-article-tools__list-icon-title">Images</strong></span></button>
<ul class="ejp-article-tools__dropdown-list ">
<li class="ejp-article-tools__dropdown-list-item "><button type="button" class="ejp-article-tools__dropdown-list-button "><i class="icon-slideshow"></i>Slideshow</button></li>
<li class="ejp-article-tools__dropdown-list-item "><button type="button" class="ejp-article-tools__dropdown-list-button "><i class="icon-gallery"></i>Gallery</button></li>
<li class="ejp-article-tools__dropdown-list-item "><button type="button" class="ejp-article-tools__dropdown-list-button js-ejp-login-btn"
data-config="{"eventName":"PPTDownload","eventDetail":{"url":"https://journals.lww.com:443/hep/fulltext/2021/09000/analysis_and_validation_of_human_targets_and.24.aspx?Ppt=Article|hep:2021:09000:00024|10.1002/hep.31812|","gating":false,"isArticleTools":true},"eventOptions":{"bubbles":true,"cancelable":true,"composed":false},"loginDetail":{"isLoginOptional":true,"promptLogin":false},"isNull":false}"><i class="icon-powerpoint"></i>Export
PowerPoint file</button></li>
</ul>
</li>
<li class="ejp-article-tools__list-item "><button type="button" class="ejp-article-tools__list-button " data-config=""><span class="ejp-article-tools__list-icon-holder"><i class="icon-pdf"></i><strong
class="ejp-article-tools__list-icon-title">Download</strong></span></button>
<ul class="ejp-article-tools__dropdown-list ">
<li class="ejp-article-tools__dropdown-list-item "><button type="button" class="ejp-article-tools__dropdown-list-button js-ejp-login-btn"
data-config="{"eventName":"PDFDownloadInit","eventDetail":{"url":"https://journals.lww.com/hep/_layouts/15/oaks.journals/downloadpdf.aspx?trckng_src_pg=ArticleViewer&an=01515467-202109000-00024","gating":false,"isArticleTools":true},"eventOptions":{"bubbles":true,"cancelable":true,"composed":false},"loginDetail":{"isLoginOptional":true,"promptLogin":false},"isNull":false}"><i class="icon-pdf"></i>PDF</button>
</li>
<li class="ejp-article-tools__dropdown-list-item "><button type="button" class="ejp-article-tools__dropdown-list-button js-ejp-login-btn"
data-config="{"eventName":"EPUBDownload","eventDetail":{"url":"https://journals.lww.com:443/hep/fulltext/2021/09000/analysis_and_validation_of_human_targets_and.24.aspx?generateEpub=Article|hep:2021:09000:00024|10.1002/hep.31812|","gating":false,"isArticleTools":true},"eventOptions":{"bubbles":true,"cancelable":true,"composed":false},"loginDetail":{"isLoginOptional":true,"promptLogin":false},"isNull":false}"><i class="icon-epub"></i>EPUB</button>
</li>
</ul>
</li>
<li class="ejp-article-tools__list-item ejp-hide-on-mobile "><button type="button" class="ejp-article-tools__list-button " data-config=""><span
class="ejp-article-tools__list-icon-holder"><i class="icon-cite"></i><strong class="ejp-article-tools__list-icon-title">Cite</strong></span></button>
<ul class="ejp-article-tools__dropdown-list ejp-cite">
<li class="ejp-article-tools__dropdown-list-item ejp-cite-text"></li>
<li class="ejp-article-tools__dropdown-list-item "><button type="button" class="ejp-article-tools__dropdown-list-button "><i class="icon-copy"></i>Copy</button></li>
<li class="ejp-article-tools__dropdown-list-item "><button type="button" class="ejp-article-tools__dropdown-list-button "><i class="icon-export"></i>Export to RIS</button></li>
<li class="ejp-article-tools__dropdown-list-item "><button type="button" class="ejp-article-tools__dropdown-list-button "><i class="icon-export"></i>Export to EndNote</button></li>
</ul>
</li>
<li class="ejp-article-tools__list-item "><button type="button" class="ejp-article-tools__list-button " data-config=""><span class="ejp-article-tools__list-icon-holder"><i class="icon-share"></i><strong
class="ejp-article-tools__list-icon-title">Share</strong></span></button>
<ul class="ejp-article-tools__dropdown-list ">
<li class="ejp-article-tools__dropdown-list-item "><button type="button" class="ejp-article-tools__dropdown-list-button "><i class="icon-mail"></i>Email</button></li>
<li class="ejp-article-tools__dropdown-list-item "><button type="button" class="ejp-article-tools__dropdown-list-button "><i class="icon-facebook2"></i>Facebook</button></li>
<li class="ejp-article-tools__dropdown-list-item "><button type="button" class="ejp-article-tools__dropdown-list-button twitter-share-button-with-link "><i class="icon-twitter"></i>Twitter</button></li>
<li class="ejp-article-tools__dropdown-list-item "><button type="button" class="ejp-article-tools__dropdown-list-button "><i class="icon-linkedIn"></i>LinkedIn</button></li>
</ul>
</li>
<li class="ejp-article-tools__list-item "><button type="button" class="ejp-article-tools__list-button js-ejp-login-btn"
data-config="{"eventName":"AddToFavorites","eventDetail":{"items":["Article|hep:2021:09000:00024|10.1002/hep.31812|"],"an":"01515467-202109000-00024"},"eventOptions":{"bubbles":true,"cancelable":true,"composed":false},"loginDetail":{"isLoginOptional":false,"promptLogin":true,"loginPromptText":"To save this item, login or register"},"isNull":false}"><span
class="ejp-article-tools__list-icon-holder"><i class="icon-fav"></i><strong class="ejp-article-tools__list-icon-title">Favorites</strong></span></button></li>
<li class="ejp-article-tools__list-item ejp-hide-on-mobile "><button type="button" class="ejp-article-tools__list-button " data-config=""><span
class="ejp-article-tools__list-icon-holder"><i class="icon-permissions"></i><strong class="ejp-article-tools__list-icon-title">Permissions</strong></span></button></li>
<li class="ejp-article-tools__list-item ejp-hide-on-desktop"><button type="button" class="ejp-article-tools__list-button " data-config=""><span
class="ejp-article-tools__list-icon-holder"><i class="icon-more"></i><strong class="ejp-article-tools__list-icon-title">More</strong></span></button>
<ul class="ejp-article-tools__dropdown-list ">
<li class="ejp-article-tools__dropdown-list-item "><button type="button" class="ejp-article-tools__dropdown-list-button "><i class="icon-cite"></i>Cite</button></li>
<li class="ejp-article-tools__dropdown-list-item "><button type="button" class="ejp-article-tools__dropdown-list-button "><i class="icon-permissions"></i>Permissions</button></li>
<li class="ejp-article-tools__dropdown-list-item "><button type="button" class="ejp-article-tools__dropdown-list-button "><i class="icon-gallery"></i>Image Gallery</button></li>
</ul>
</li>
</ul>
</nav>
</aside>
</div>
<div style="display: none;">
<div id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_epubContainer">
<a an="01515467-202109000-00024" rel="opener" title="" href="#epub-link" class="ej-art-as-epub">Article as EPUB</a>
</div>
<a href="/hep/fulltext/2021/09000/analysis_and_validation_of_human_targets_and.24.aspx?Ppt=Article|hep:2021:09000:00024|10.1002/hep.31812|" id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_lnkExportImagesToPPT_fileLink" rel="nofollow">Export All Images to PowerPoint File</a>
<button class="user-menu__link user-menu__link--add-to-favorites js-ejp-login-btn addToMyFavoriteLink" type="button"
data-config="{"eventName":"AddToFavorites","eventDetail":{"items":["Article|hep:2021:09000:00024|10.1002/hep.31812|"],"an":"01515467-202109000-00024"},"eventOptions":{"bubbles":true,"cancelable":true,"composed":false},"loginDetail":{"isLoginOptional":false,"promptLogin":true,"loginPromptText":"To save this item, login or register"},"isNull":false}">
<span>Add to My Favorites</span>
</button>
</div>
<script type="text/javascript" src="https://lww.com/_layouts/15/1033/Scripts/wk/EmailToColleague.js?v=05.20.00.150" defer="true">
</script>
<a id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_hypEmailToColleague" href="javascript:" style="display:none;"></a>
<div id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_pnlEmailToColleague" class="wk-modal-table" style="display: none; position: fixed; z-index: 100001;">
<div class="wk-modal-cell">
<div id="ej-box-modal-drop-shadow" class="wk-modal horizontally-centered small wk-modal-with-overlay wk-modal-small ejp-modal email-to-colleague" tabindex="-1" role="dialog" style="position: static;">
<div id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_pnlMain" class="js-main-panel"
onkeypress="javascript:return WebForm_FireDefaultButton(event, 'ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_btnSend')">
<section class="wk-modal-content">
<header class="wk-modal-header ejp-modal-header">
<div class="wk-modal-title ejp-modal-title">
<strong>
<span id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_lblEmailToColleague">Email to Colleague</span></strong>
</div>
<button aria-label="close dialog" class="primary-button wk-button-icon wk-modal-close ejp-modal-close js-close ">
<i class="fa fa-times"></i>
</button>
</header>
<div class="wk-modal-body">
<div class="wk-field-item">
<div class="wk-field-header">
<div id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_divErrorMessage" class="js-error-message-div ej-error-message-panel"
style="display: none; color: red; font-style: italic">
<p class="ej-error-message-icon">
<span id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_lblErrorMessage" class="js-error-message-label">Colleague's E-mail is Invalid</span>
</p>
</div>
</div>
</div>
<div class="wk-field-item">
<div class="wk-field-header"> Your Name: </div>
<div class="wk-field-body">
<input name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$ucArticleTools$emailToColleagueControl$txtYourName" type="text"
id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_txtYourName" class="js-name">
</div>
</div>
<div class="wk-field-item">
<div class="wk-field-header">
<span id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_lblColleaguesEmail" class="js-collegaues-email-lbl">Colleague's Email:</span>
</div>
<div class="wk-field-body no-bottom-margin">
<input name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$ucArticleTools$emailToColleagueControl$txtColleaguesEmail" type="text"
id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_txtColleaguesEmail" class="js-collegaues-email">
</div>
<div class="wk-field-header"><span class="ej-form-comments">Separate multiple e-mails with a (;).</span></div>
</div>
<div class="wk-field-item">
<div class="wk-field-header"> Message: </div>
<div class="wk-field-body">
<textarea name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$ucArticleTools$emailToColleagueControl$txtMessage" rows="2" cols="20"
id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_txtMessage"
class="js-message">Thought you might appreciate this item(s) I saw in Hepatology.</textarea>
</div>
</div>
<div class="wk-button-bar">
<div class="wk-button-group-left">
<input type="submit" name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$ucArticleTools$emailToColleagueControl$btnSend" value="Send"
id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_btnSend"
class="js-send-button primary-button grecaptcha-email-colleague-ec586332cb8544eebc427caa460ebe0b">
<input type="button" value="Cancel" id="btnCancel" class="secondary-button js-close">
</div>
</div>
<div class="wk-field-item wk-email-colleague-captcha-bar">
<div class="wk-field-body">
<div id="div-recaptcha-ec586332cb8544eebc427caa460ebe0b" class="div-recaptcha-container" data-uniqueclassidentifier="grecaptcha-email-colleague-ec586332cb8544eebc427caa460ebe0b"
data-sitekey="6LeeoSAUAAAAACFv8yNuINPv8IWyXHJ6uN447qEK" data-callback="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_captchaCallBack"
data-badge="inline" data-size="invisible" data-type="image">
</div>
</div>
</div>
</div>
</section>
</div>
<div id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_pnlSuccessMessage" class="js-success-message-panel" style="display: none;">
<section class="wk-modal-content">
<header class="wk-modal-header ejp-modal-header">
<div class="wk-modal-title ejp-modal-title"></div>
<button aria-label="close dialog" class="primary-button wk-button-icon wk-modal-close ejp-modal-close js-close "><i class="fa fa-times"></i></button>
</header>
<div class="wk-modal-body">
<div class="wk-field-item">
<br>
<p>
<span id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_lblMessageSent">Your message has been successfully sent to your colleague.</span>
</p>
<br>
</div>
<div class="wk-button-bar">
<div class="wk-button-group-left">
<input type="button" value="Close Window" id="btnClose" class="primary-button js-close">
</div>
</div>
</div>
</section>
</div>
<div id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_pnlErrorMessage" class="js-error-message-panel" style="display: none;">
<section class="wk-modal-content">
<header class="wk-modal-header ejp-modal-header">
<div class="wk-modal-title ejp-modal-title"></div>
<button aria-label="close dialog" class="primary-button wk-button-icon wk-modal-close ejp-modal-close js-close "><i class="fa fa-times"></i></button>
</header>
<div class="wk-modal-body">
<br>
<div class="wk-field-item">
<span id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_lblInvalidEmail" style="color:Red;">Some error has occurred while processing your request. Please
try after some time.</span>
</div>
<br>
<div class="wk-button-bar">
<div class="wk-button-group-left">
<input type="button" value="Close Window" id="btnEClose" class="primary-button js-close">
</div>
</div>
</div>
</section>
</div>
</div>
<input type="hidden" name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$ucArticleTools$emailToColleagueControl$hiddenEmailToColleague"
id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_hiddenEmailToColleague">
<input type="hidden" name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$ucArticleTools$emailToColleagueControl$hiddenIsUser"
id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_hiddenIsUser">
</div>
</div>
<script type="text/javascript">
window.emailToColleaguePopups = window.emailToColleaguePopups || [];
var ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_captchaCallBack = function() {
ejpAnalytics.track('emailColleaguereCAPTCHA');
ejpAnalytics.track('emailColleagueComplete');
__doPostBack('ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$ucArticleTools$emailToColleagueControl$btnSend', '')
};
var initEmailToColleaguectl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl = function() {
window.emailToColleaguePopups['ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl'] = new
EmailToColleagueComponent('ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_pnlEmailToColleague', 'div-recaptcha-ec586332cb8544eebc427caa460ebe0b',
'grecaptcha-email-colleague-ec586332cb8544eebc427caa460ebe0b', 'emailToColleaguePopupExtender__1604761164',
'ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_hiddenEmailToColleague',
'ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_hiddenIsUser', '01515467-202109000-00024');
}
Sys.WebForms.PageRequestManager.getInstance().add_pageLoaded(initEmailToColleaguectl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl);
</script>
<script type="text/javascript" src="https://lww.com/_layouts/15/1033/Scripts/wk/ExportToCitationManager.js?v=05.20.00.150" defer="true">
</script>
<a id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_exportToCitationManager_hypExportToCitationManager" href="javascript:" style="display:none;"></a>
<div id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_exportToCitationManager_pnlExportTo" style="display: none; position: fixed; z-index: 100001;">
<div id="ej-box-modal-drop-shadow">
<div id="ej-box-modal-style-1" tabindex="-1" role="dialog" class="wk-modal wk-modal-with-overlay wk-modal-small ejp-modal horizontally-centered" data-behaviorid="OpenExportToPopupExtender_1745200279">
<div id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_exportToCitationManager_pnlMainExport" style="display: block;">
<section class="wk-modal-content">
<header class="wk-modal-header ejp-modal-header">
<div class="wk-modal-title ejp-modal-title"><strong>Export to</strong></div>
<button onclick="return closeExportToModalPopUp();" aria-label="close dialog" class="primary-button wk-button-icon wk-modal-close ejp-modal-close "><i class="fa fa-times"></i></button>
</header>
<div class="wk-modal-body">
<div class="wk-field-item">
<fieldset>
<table id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_exportToCitationManager_radioBtnExportTypes">
<tbody>
<tr>
<td><input id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_exportToCitationManager_radioBtnExportTypes_0" type="radio"
name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$ucArticleTools$exportToCitationManager$radioBtnExportTypes" value="EndNote" checked="checked"><label
for="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_exportToCitationManager_radioBtnExportTypes_0">End Note</label></td>
</tr>
<tr>
<td><input id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_exportToCitationManager_radioBtnExportTypes_1" type="radio"
name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$ucArticleTools$exportToCitationManager$radioBtnExportTypes" value="Procite"><label
for="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_exportToCitationManager_radioBtnExportTypes_1">Procite</label></td>
</tr>
<tr>
<td><input id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_exportToCitationManager_radioBtnExportTypes_2" type="radio"
name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$ucArticleTools$exportToCitationManager$radioBtnExportTypes" value="ReferenceManager"><label
for="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_exportToCitationManager_radioBtnExportTypes_2">Reference Manager</label></td>
</tr>
</tbody>
</table>
</fieldset>
<p>
<label for="default">
<input id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_exportToCitationManager_checkBoxSaveMySelection" type="checkbox"
name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$ucArticleTools$exportToCitationManager$checkBoxSaveMySelection"><label
for="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_exportToCitationManager_checkBoxSaveMySelection">Save my selection</label>
</label>
</p>
<div class="wk-button-bar">
<div class="wk-button-group-left">
<input type="submit" name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$ucArticleTools$exportToCitationManager$btnOpenExportDialog" value="Export"
onclick="return validateExportType();WebForm_DoPostBackWithOptions(new WebForm_PostBackOptions("ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$ucArticleTools$exportToCitationManager$btnOpenExportDialog", "", true, "", "", false, false))"
id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_exportToCitationManager_btnOpenExportDialog" class="primary-button">
<input type="submit" name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$ucArticleTools$exportToCitationManager$btnCancelOpenExportDialog" value="Cancel"
onclick="return closeExportToModalPopUp();WebForm_DoPostBackWithOptions(new WebForm_PostBackOptions("ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$ucArticleTools$exportToCitationManager$btnCancelOpenExportDialog", "", true, "", "", false, false))"
id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_exportToCitationManager_btnCancelOpenExportDialog" class="secondary-button">
</div>
</div>
</div>
</div>
</section>
</div>
</div>
</div>
<div id="ej-clear-float"></div>
<input type="hidden" name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$ucArticleTools$exportToCitationManager$hiddenExportType"
id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_exportToCitationManager_hiddenExportType">
</div>
<script type="text/javascript">
var hiddenExportType = $get('ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_exportToCitationManager_hiddenExportType');
function getExportPopup() {
return $find('OpenExportToPopupExtender_1745200279');
}
var pnlMainExport = $get('ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_exportToCitationManager_pnlMainExport');
</script>
<script type="text/javascript">
$(document).ready(function() {
$('p').filter(function() {
return this.innerHTML.trim() === ""
}).remove();
});
function showPrinterFriendlyView() {
open("https://journals.lww.com/hep/pages/printerfriendly.aspx?year=2021&issue=09000&article=00024&type=Fulltext", "");
}
function showExportToCitationPopUp() {
return "OpenExportToPopupExtender_1745200279";
}
function getPermissionsClick() {
showRightsLinkPopUp('https://s100.copyright.com/AppDispatchServlet', 'WoltersKluwer', 'HEP', 'Analysis and Validation of Human Targets and Treatments Using a Hepatocellular Carcinoma–Immune Humanized Mouse Model',
'09152021', 'Yue Zhao, Jiaxu Wang, Wai Nam Liu, et al', '74', '3', '\u00A9 2021 The Authors. Hepatology published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.',
'01515467-202109000-00024', '', true, '');
}
</script>
<div id="ArticleContainer">
<article id="ej-article-view" class="js-article-view ej-article-view" xmlns:ssr="http://ssr-eus-go-csi.cloudapp.net/v1/assets" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"
xmlns:xhtml="http://www.w3.org/1999/xhtml">
<section class="ejp-r-article-subsection">
<div class="ejp-r-article-subsection__text">Original Articles: Hepatobiliary Malignancies</div>
</section>
<header class="ejp-article-header">
<h1 class="ejp-article-title">Analysis and Validation of Human Targets and Treatments Using a Hepatocellular Carcinoma–Immune Humanized Mouse Model</h1>
</header>
<section id="ejp-article-authors">
<p id="P7">
<i class="wki icon-orcid" onclick="javascript:ToolTip_Orcid('Zhao, Yue', 'https://orcid.org/0000-0003-2869-5257');" onmouseover="javascript:ToolTip_Orcid('Zhao, Yue', 'https://orcid.org/0000-0003-2869-5257');"></i>Zhao,
Yue<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">1,*</sup>;
<i class="wki icon-orcid" onclick="javascript:ToolTip_Orcid('Wang, Jiaxu', 'https://orcid.org/0000-0001-7101-8230');" onmouseover="javascript:ToolTip_Orcid('Wang, Jiaxu', 'https://orcid.org/0000-0001-7101-8230');"></i>Wang,
Jiaxu<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">2,*</sup>; Liu, Wai Nam<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">1</sup>; Fong, Shin
Yie<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">1</sup>; Shuen, Timothy Wai Ho<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">3</sup>; Liu,
Min<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">1</sup>; Harden, Sarah<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">1</sup>; Tan, Sue
Yee<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">1</sup>; Cheng, Jia Ying<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">1</sup>; Tan, Wilson Wei
Sheng<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">1</sup>; Chan, Jerry Kok Yen<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">4,5</sup>; Chee, Cheng
Ean<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">6</sup>; Lee, Guan Huei<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">7</sup>; Toh, Han
Chong<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">3</sup>;
<i class="wki icon-orcid" onclick="javascript:ToolTip_Orcid('Lim, Seng Gee', 'https://orcid.org/0000-0003-0994-4932');" onmouseover="javascript:ToolTip_Orcid('Lim, Seng Gee', 'https://orcid.org/0000-0003-0994-4932');"></i>Lim,
Seng Gee<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">7</sup>;
<i class="wki icon-orcid" onclick="javascript:ToolTip_Orcid('Wan, Yue', 'https://orcid.org/0000-0002-2433-9637');" onmouseover="javascript:ToolTip_Orcid('Wan, Yue', 'https://orcid.org/0000-0002-2433-9637');"></i>Wan,
Yue<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">2</sup>; Chen, Qingfeng<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">*,1,8</sup></p>
<section><a href="#" id="ejp-article-authors-link">
Author Information <i class="wk-icon-arrow-down-r"></i></a></section>
</section>
<section id="ejp-article-authors-info" class="ejp-article-authors-info ejp-article-authors-info--hidden">
<div class="ejp-article-authors-info-holder">
<p id=""><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">1</sup>Institute of Molecular and Cell BiologyAgency for Science, Technology and ResearchSingapore</p>
<p id=""><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">2</sup>Genome Institute of SingaporeAgency for Science, Technology and ResearchSingapore</p>
<p id=""><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">3</sup>Division of Medical OncologyNational Cancer Centre SingaporeSingapore</p>
<p id=""><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">4</sup>Department of Reproductive MedicineKandang Kerbau Women’s and Children's HospitalSingapore</p>
<p id=""><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">5</sup>Experimental Fetal Medicine GroupYong Loo Lin School of MedicineNational University of SingaporeSingapore</p>
<p id=""><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">6</sup>Department of Hematology‐OncologyNational University Cancer InstituteSingapore</p>
<p id=""><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">7</sup>Division of Gastroenterology and HepatologyNational University Health SystemSingapore</p>
<p id=""><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">8</sup>Department of Microbiology and ImmunologyYong Loo Lin School of MedicineNational University of SingaporeSingapore</p>
<p id="correspondenceTo"><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">*</sup><strong xmlns:mrws="http://webservices.ovid.com/mrws/1.0">ADDRESS CORRESPONDENCE AND REPRINT REQUESTS TO:</strong><br>
Qingfeng Chen, Ph.D.<br> Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR)<br> Proteos, 61 Biopolis Drive<br> Singapore 138673, Singapore<br> E.mail:
<span><a href="mailto:mailto:qchen@imcb.a-star.edu.sg" onclick="javascript:window.open('mailto:mailto:qchen@imcb.a-star.edu.sg');return false">qchen@imcb.a-star.edu.sg</a></span><br> Tel: +65‐65869873<br></p>
<p id="hep31812-note-0003"><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">*</sup>These authors contributed equally to this work.</p>
<p id="">This is an open access article under the terms of the
<span><a href="http://creativecommons.org/licenses/by-nc-nd/4.0/" onclick="javascript:window.open('http://creativecommons.org/licenses/by-nc-nd/4.0/');return false" target="_blank">Creative Commons Attribution‐NonCommercial‐NoDerivs</a></span>
License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</p>
</div>
</section>
<section id="article-journal-info">
<div class="ej-journal-info"><span class="ej-journal-name">Hepatology </span><span id="ej-journal-date-volume-issue-pg"><a href="/hep/toc/2021/09000">74(3):p 1395-1410, September 2021.</a></span><span> |
</span><span class="ej-journal-doi">DOI: </span>10.1002/hep.31812</div>
</section>
<section id="ejp-article-indicators" class="ejp-article-indicators">
<ul class="ejp-article-indicators__list">
<li id="ej-article-indicators-open" class="ejp-article-indicators__list-item" onmouseover="javascript:Tooltip_Open()" onmouseout="javascript:Tooltip_MouseOut()"><span class="ejp-indicator">Open</span></li>
</ul><button id="openArticleMetricsPopupButton" type="button" class="wk-button wk-button-ghost wk-button-icon-left ejp-article-metrics-btn"
data-articlemetricsendpoint="//services.journals.lww.com/IntegrationServices/ArticleMetricsService.svc" data-articlemetricsdetailsurl="https://wolterskluwer.altmetric.com/details/" data-doi="10.1002/hep.31812"
data-suiteid="vrs_woltere_journalsglobalvrs" data-articlepublicationdate="2021-09-15" data-articlepublicationdatestring="September 15, 2021" data-receiveddate="2020-06-28" data-revisionreceiveddate="2021-02-15"
data-accepteddate="2021-02-18" data-crossrefreflinkroot="https://doi.org/" data-medlinereflinkroot="http://www.ncbi.nlm.nih.gov/pubmed/"
data-pubmedid="33738839"><i class="wk-icon-filled-chart-r"></i><i class="wk-icon-filled-chart-white-r"></i> Metrics </button>
</section>
<section class="ejp-article-tabs" id="abstractWrap">
<h2 class="ejp-article-tabs-heading">Abstract</h2>
<div class="ejp-article-tabs__tabpanel" id="panel1" role="tabpanel" aria-labelledby="tab1">
<div id="article-abstract-content1">
<div class="ejp-article-text-abstract">
<h3>Background and Aims </h3>
<p>Recent development of multiple treatments for human hepatocellular carcinoma (HCC) has allowed for the selection of combination therapy to enhance the effectiveness of monotherapy. Optimal selection of
therapies is based on both HCC and its microenvironment. Therefore, it is critical to develop and validate preclinical animal models for testing clinical therapeutic solutions.</p>
<h3>Approach and Results </h3>
<p>We established cell line–based or patient‐derived xenograft–based humanized‐immune‐system mouse models with subcutaneous and orthotopic HCC. Mice were injected with human‐specific antibodies (Abs) to
deplete human immune cells. We analyzed the transcription profiles of HCC cells and human immune cells by using real‐time PCR and RNA sequencing. The protein level of HCC tumor cells/tissues or human immune
cells was determined by using flow cytometry, western blotting, and immunohistochemistry. The HCC tumor size was measured after single, dual‐combination, and triple‐combination treatment using
N‐(1ʹ,2‐Dihydroxy‐1,2ʹ‐binaphthalen‐4ʹ‐yl)‐4‐methoxybenzenesulfonamide (C188‐9), bevacizumab, and pembrolizumab. In this study, human immune cells in the tumor microenvironment were strongly selected and
modulated by HCC, which promoted the activation of the IL‐6/Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) signaling pathway in tumor cells and led to augmented HCC
proliferation and angiogenesis by releasing angiogenic cytokines in humanized‐immune‐system mice with HCC. In particular, intratumor human cluster of differentiation–positive
(hCD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup>) cells could produce IL‐33 through damage‐associated molecular pattern/Toll‐like receptor 4/activator protein 1, which up‐regulated IL‐6
in other intratumor immune cells and activated the JAK2/STAT3 pathway in HCC. Specific knockdown of the CD14 gene in human monocytes could impair IL‐33 production induced by cell lysates. Subsequently, we
evaluated the <em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">in vivo</em> anti‐HCC effect of C188‐9, bevacizumab, and pembrolizumab. The results showed that the anti‐HCC effect of triple‐combination
therapy was superior to that of single or dual treatments.</p>
<h3>Conclusions </h3>
<p>Humanized‐immune‐system HCC mouse models are suitable for identifying targets from cancer and immune components and for testing combinational therapies.</p>
</div>
</div>
</div>
</section>
<div class="ejp-fulltext-content js-ejp-fulltext-content">
<section id="ArticleBody">
<p id="hep31812-note-0001">Supported by the National Medical Research Council Singapore, the Virus‐Induced Cancer: Translational Oncology Research & immunologY Programme (NMRC/OFLCG/003/2018), the Senior
Clinician Scientist Award (NMRC/CSASI16nov006), the Eradication of HBV T‐cell receptor Program (NMRC/TCR/014‐NUHS/2015), a Clinician–Scientist Individual Research Grant (CIRG19may‐0051), and the National
Research Foundation Singapore (NRF) Fellowship (NRF‐NRFF2017‐03), an NRF–Israel Science Foundation joint grant (NRF2019–NRF‐ISF003‐3127), an NRF–Competitive Research Programme grant (NRF2016‐CRP001‐103), and
the Agency for Science, Technology and Research Industry Alignment Fund‐Pre‐positioning (H18/01/a0/022) to Q.C.</p>
<p id="hep31812-note-0002">Potential conflict of interest: Dr. Chee is on the speakers’ bureau for Roche. Dr. Lim advises, is on the speakers’ bureau for, and received grants from Gilead, Abbott, and Roche. He
advises AbbVie, Arbutus, Assembly, and Eisai. He received grants from Merck Sharp & Dohme Corp and Grifols.</p>
<p id="JCL-P-52">Hepatocellular carcinoma (HCC) remains one of the most common causes of cancer‐related deaths and has a high recurrence
rate.<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">(</sup><sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep31812-bib-0001">1</a></sup><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">)</sup>
HCC tumorigenesis is impacted by chronic inflammation induced by liver
injury,<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">(</sup><sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep31812-bib-0002 hep31812-bib-0003 hep31812-bib-0004">2‐4</a></sup><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">)</sup>
which promotes HCC progression and
development.<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">(</sup><sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep31812-bib-0005 hep31812-bib-0006 hep31812-bib-0007 hep31812-bib-0008">5‐8</a></sup><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">)</sup>
However, the mechanisms that underlie the crosstalk between human HCC and the human immune system remain poorly understood. Therefore, examination of the interactions between the human immune system and HCC,
which may improve existing therapy and help to identify strategies for HCC treatment, is warranted.</p>
<p id="JCL-P-53">HCC cells attract various immune cells into the tumor microenvironment by releasing multiple chemokines, including C‐X‐C motif chemokine ligand 12 (CXCL12), C‐C motif chemokine ligand 1 (CCL1),
CCL22, CXCL16, CCL5, CXCL10, and
CXCL11.<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">(</sup><sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep31812-bib-0009 hep31812-bib-0010 hep31812-bib-0011 hep31812-bib-0012 hep31812-bib-0013">9‐13</a></sup><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">)</sup>
Furthermore, HCC cells can modulate the activities and functions of immune cells and drive the acquisition of tumor‐associated phenotypes in these
cells.<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">(</sup><sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep31812-bib-0014 hep31812-bib-0015 hep31812-bib-0016 hep31812-bib-0017">14‐17</a></sup><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">)</sup>
Tumor‐associated immune cells, including T‐helper (T<sub xmlns:mrws="http://webservices.ovid.com/mrws/1.0">h</sub>) type 2 (T<sub xmlns:mrws="http://webservices.ovid.com/mrws/1.0">h</sub>2) cells, type 2 innate
lymphoid cells (ILC2s), tumor‐associated regulatory T cells, tumor‐associated macrophages (TAMs), tumor‐associated neutrophils, and myeloid‐derived suppressor cells (MDSCs) are responsible for producing various
cytokines (IL‐1, IL‐6, IL‐8, and IL‐10), growth factors (VEGF, platelet‐derived growth factor [PDGF], EGF, HGF, FGF, and insulin‐like growth factor), matrix metalloproteinase 2 (MMP‐2) and MMP‐9, and tissue
inhibitor of metalloproteinase 1 (TIMP‐1) and TIMP‐2 to create an optimal environment for the proliferation, survival, and metastasis of tumor
cells.<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">(</sup><sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep31812-bib-0018 hep31812-bib-0019 hep31812-bib-0020 hep31812-bib-0021">18‐21</a></sup><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">)</sup>
Previous studies have demonstrated that numerous signaling pathways dysregulated in HCC were associated with these HCC tumor–associated immune
cells.<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">(</sup><sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep31812-bib-0022 hep31812-bib-0023 hep31812-bib-0024">22‐24</a></sup><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">)</sup>
For example, IL‐8 released from TAMs may enhance the epithelial–mesenchymal transition (EMT) in HCC through the Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3)/Snail
pathway.<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">(</sup><sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep31812-bib-0022">22</a></sup><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">)</sup>
Similarly, activation of the JAK2/STAT3 pathway, induced by IL‐6 from TAMs, also played a critical role in HCC stem‐cell
expansion.<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">(</sup><sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep31812-bib-0023">23</a></sup><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">)</sup>
In addition, increased functional activity in the rat sarcoma/rapidly accelerated fibrosarcoma/mitogen‐activated protein kinase (MAPK), phosphoinositide 3‐kinase (PI3K)/protein kinase B (AKT)/mechanistic target
of rapamycin and JAK/STAT pathways, caused by multiple growth factors released from MDSCs, were also observed in human
HCC.<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">(</sup><sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep31812-bib-0024">24</a></sup><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">)</sup>
Although this evidence demonstrated the interactions between the human immune system and HCC, countless other mechanisms remain unclear, particularly because of the lack of a robust <em
xmlns:mrws="http://webservices.ovid.com/mrws/1.0">in vivo</em> human cancer–immune system model. The absence of sufficient models also limits the development of therapeutics targeting tumor‐associated immune
cells and their modulation pathways.</p>
<p id="JCL-P-54">Over time, various monotherapies that target HCC proliferation, angiogenesis, and immune resistance have been
developed.<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">(</sup><sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep31812-bib-0025 hep31812-bib-0026">25,26</a></sup><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">)</sup>
These include, for example, treatments counteracting elevated IL‐6 signaling. Serum IL‐6 levels are elevated in patients with HCC, compared with healthy individuals, which might enhance HCC proliferation and
angiogenesis through activation of the JAK2/STAT3 signaling
pathway.<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">(</sup><sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep31812-bib-0027 hep31812-bib-0028">27,28</a></sup><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">)</sup>
Hence, tocilizumab (IL‐6 receptor blockade) and N‐(1ʹ,2‐Dihydroxy‐1,2ʹ‐binaphthalen‐4ʹ‐yl)‐4‐methoxybenzenesulfonamide (C188‐9) (STAT3 inhibitor) were developed and achieved optimistic results in reducing HCC
growth <em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">in vivo</em> by impairing IL‐6 signaling from TAMs to
HCC.<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">(</sup><sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep31812-bib-0006 hep31812-bib-0029">6,29</a></sup><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">)</sup>
</p>
<p id="JCL-P-55">VEGF is essential for tumor growth and angiogenesis. Bevacizumab, an anti‐VEGF monoclonal antibody (Ab), has been applied to patients with HCC and has proven to be effective in clinical
trials.<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">(</sup><sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep31812-bib-0030 hep31812-bib-0031">30,31</a></sup><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">)</sup>
Similarly, immune checkpoint blockade therapies, such as nivolumab and pembrolizumab (programmed death 1 [PD‐1] blockade) and atezolizumab (programmed death ligand 1 [PD‐L1] blockade) also exerted certain
levels of anti‐HCC effects by protecting and recovering T‐cell function in animal models and
patients.<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">(</sup><sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep31812-bib-0032">32</a></sup><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">)</sup>
Despite the development of different monotherapies, patients with HCC only exhibit partial responses to these
treatments.<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">(</sup><sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep31812-bib-0033">33</a></sup><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">)</sup>
In recent years, combination therapy (polytherapy) has been considered for synergistic efficacy, which may improve the overall survival of patients with HCC by reducing their resistance to
monotherapy.<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">(</sup><sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep31812-bib-0033">33</a></sup><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">)</sup>
Previous studies have demonstrated that the combination of anti–IL‐6 and anti–PD‐L1 treatment could ameliorate the anti‐HCC efficacy <em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">in
vivo</em>.<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">(</sup><sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep31812-bib-0034">34</a></sup><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">)</sup>
In clinical settings, a combination of bevacizumab and atezolizumab treatment led to effective antitumor immune response in patients with
HCC.<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">(</sup><sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep31812-bib-0035">35</a></sup><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">)</sup>
Furthermore, combined blockade of IL‐6 and VEGF receptor also enhanced antitumor activity, as was reported in another
study.<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">(</sup><sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep31812-bib-0036">36</a></sup><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">)</sup>
Therefore, it is anticipated that the combined therapy of anti–IL‐6–or IL‐6–related signaling pathways, anti‐VEGF, and immune checkpoint blockade may be more efficacious.</p>
<p id="JCL-P-56">We have shown that an HCC mouse model can be generated through the engraftment of human HCC cell lines or patient‐derived xenografts (PDXs) into immunodeficient mice bearing human leukocyte
antigen (HLA)‐matched human immune systems (humanized
mice).<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">(</sup><sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep31812-bib-0037">37</a></sup><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">)</sup>
Intriguingly, some of the HCC‐PDX tumors regressed in the humanized mice following pembrolizumab and ipilimumab treatment, suggesting that the HCC humanized mice may represent an emerging platform for the
evaluation of cancer monotherapy or combination
therapy.<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">(</sup><sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep31812-bib-0037">37</a></sup><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">)</sup>
In the present study, we demonstrate that the human immune system in humanized mice may enhance HCC proliferation and angiogenesis through a network involving damage‐associated molecular patterns (DAMPs),
Toll‐like receptors (TLRs), cytokines, and intracellular protein phosphorylation. More importantly, triple‐combination therapy targeting STAT3‐induced HCC proliferation, VEGF‐related angiogenesis, and the PD‐1
immune checkpoint resulted in a combinational anti‐HCC effect in our humanized mouse model.</p>
<h2 class="ejp-article-outline-heading" data-level="1" id="hep31812-sec-0005">Materials and Methods</h2>
<h3 class="ejp-article-outline-heading" data-level="2" id="hep31812-sec-0006">MICE</h3>
<p id="JCL-P-57">NOD.Cg<em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">‐Prkdc</em><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">scid</sup><em
xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Il2rg</em><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">tm</sup><em
xmlns:mrws="http://webservices.ovid.com/mrws/1.0"><sup>1</sup></em><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">Wjl/SzJ</sup> (NSG) mice (The Jackson Laboratory) and humanized mice were bred and
generated, respectively, as described
earlier.<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">(</sup><sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep31812-bib-0037 hep31812-bib-0038">37,38</a></sup><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">)</sup>
All manipulations with mice were approved by Institutional Animal Care and Use Committee in Agency for Science, Technology and Research. All animal experimental procedures were conducted in accordance to the
approved protocols and Guide for the Care and Use of Laboratory Animals. All human fetal liver and HCC Patient tumor tissues with written consent were obtained from guardians of donors, and in accordance with
the ethical guidelines of Kandang Kerbau (KK) Women’s and Children’s Hospital (Singapore) and National University Hospital (Singapore). HCC humanized mice were generated by engrafting different HCC cell lines
or PDXs subcutaneously or orthotopically (intrasplenic injection with 2 × 10<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">6</sup> purified and live human tumor cells in 50 µL of saline)
according to HLA‐A (HCC‐PDX tumor 1# [A*02 and A*11] matched with hematopoietic stem cell [HSC] 1# [A*02 and A*11]; HCC‐PDX tumor 2# [A*02 and A*11] matched with HSC 1# [A*02 and A*11]; HCC‐PDX tumor 3# [A*02
and A*01] matched with HSC 2# [A*02 and A*01]; HCC‐PDX tumor 4# [A*02 and A*11] matched with HSC 1# [A*02 and A*11]; and HepG2 and LM3 cell lines [A*02 and A*24] matched with HSC 3# [A*02 and A*24]) (Supporting
Table S1). To deplete specific immune‐cell subsets in immune humanized mice, anti–human cluster of differentiation 45 (anti‐hCD45) (a human leukocyte marker), anti‐hCD4 (a human
T<sub xmlns:mrws="http://webservices.ovid.com/mrws/1.0">h</sub> cell marker), anti‐hCD8 (a human T<sub xmlns:mrws="http://webservices.ovid.com/mrws/1.0">c</sub> cell maker), anti‐hCD14 (a human monocyte
marker), anti‐hCD19 (a human B‐cell marker), and anti‐hCD56 (a human natural killer [NK] cell marker) (50 µg/mouse) were given i.v. weekly. For the evaluation of drug efficacy, small molecules or Abs were
injected into the mice either alone or in combination. Briefly, C188‐9 dissolved in DMSO was injected intraperitoneally (75 mg/kg) on a daily basis, whereas anti–human IL‐33 Ab (50 µg/mouse),
bevacizumab, and pembrolizumab (5 mg/kg) were injected i.v. on a weekly basis. Further methodological details can be found in the Supporting Information.</p>
<h2 class="ejp-article-outline-heading" data-level="1" id="hep31812-sec-0007">Results</h2>
<h3 class="ejp-article-outline-heading" data-level="2" id="hep31812-sec-0008">The Human Immune System Promotes HCC Proliferation and Angiogenesis</h3>
<p id="JCL-P-58">To explore the role of the humanized immune system with respect to HCC, we engrafted HCC‐PDX tumor tissue into NSG humanized mice and hCD45‐depleted humanized mice that were treated with
anti‐hCD45 Ab to remove the humanized immune system 2 weeks after engraftment. Interestingly, the size and weight of the HCC tumors and spleens from humanized mice increased compared with those from the NSG and
hCD45‐depleted humanized mice (Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0001', '01515467-202109000-00024');">1A</a>). Similar results were also observed in
HCC‐PDX tumors from different donors, in both subcutaneous and orthotopic models (Supporting Figs. S1A‐S6A). The expression of MKI67 (Ki67) on the HCC‐PDX tumor was quantified by using immunohistochemical
analysis, which indicated a significant increase in the number of Ki67<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells in the HCC tumor from humanized mice
(Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0001', '01515467-202109000-00024');">1B</a> and Supporting Figs. S1B‐S6B). Moreover, the
5‐ethynyl‐2′‐deoxyuridine (EDU) levels in isolated and purified HCC‐PDX tumor cells from the three groups were analyzed using flow cytometry. Similarly, we observed that the HCC‐PDX tumor cells isolated from
humanized mice had the highest EDU level among these groups (Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0001', '01515467-202109000-00024');">1C</a>).
Furthermore, angiogenesis was quantified in the vascular endothelium of the HCC‐PDX tumor by counting the vessels with a lumen (CD31 immunohistochemical staining that was both negative and positive)
(Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0001', '01515467-202109000-00024');">1D</a> and Supporting Figs. S1C‐S6C). Both the microvessel density
(MVD) and the microvessel cross‐sectional area (VCSA) were calculated (Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0001', '01515467-202109000-00024');">1D</a>
and Supporting Figs. S1D‐S6D). More vascular invasion was observed in HCC tumors in humanized mice than in both NSG and hCD45‐depleted humanized mice, suggesting that the humanized immune system could
augment HCC tumor proliferation and angiogenesis. To dissect the underlying molecular mechanisms that regulated the proliferation and angiogenesis affected by the humanized immune system, the LM3 (HCC) cell
line was selected because of its sharing the HLA‐A type with the HCC‐PDX tumor (all are HLA‐A type 2). In concordance with the results from HCC‐PDX tumors, LM3 tumors in humanized mice were larger than those in
NSG and humanized mice treated with anti‐hCD45 Abs (Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0001', '01515467-202109000-00024');">1E</a>). After 3 weeks of
engraftment, the LM3 tumors were harvested, and the purified LM3 HCC cells were subjected to RNA sequencing
(Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0001', '01515467-202109000-00024');">1F</a>). Principal component analysis (PCA) of all expressed genes
(Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0001', '01515467-202109000-00024');">1G</a>) and heatmap analysis of differentially expressed (DE) genes
(Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0001', '01515467-202109000-00024');">1H</a> and Supporting Table S2) revealed that the transcriptomic
profiles among these groups were distinct and well separated, indicating that LM3 cells were strongly influenced by the immune system. Results from the hCD45‐depleted group indicated that the immune system had
already exerted some impact on the tumors even though it had been removed 2 weeks after tumor implantation. Ingenuity pathway analysis revealed that the acute‐phase‐response signaling pathways were highly
modulated in LM3 cells from humanized mice, including triggering receptor expressed on myeloid cells 1, IL‐6, high mobility group box 1 (HMGB1), and IL‐10 signaling pathways, compared with NSG and
hCD45‐depleted humanized mice (Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0001', '01515467-202109000-00024');">1I</a>). Immunohistochemistry staining of
HCC‐PDX tumors and western blot analysis of isolated HCC‐PDX tumor cells indicated that the JAK2/STAT3 of the tumor was highly phosphorylated in humanized mice
(Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0001', '01515467-202109000-00024');">1J,K</a>). Hence, we anticipated that the humanized immune system in our
model may enhance HCC‐PDX proliferation through the activation of the JAK2/STAT3 intracellular signaling pathways in the HCC cells.</p>
<section class="ejp-r-article-images">
<figure class="ejp-r-article-images__figure">
<a href="javascript:void(0)" class="ejp-r-article-images__image-link" onclick="showSlideShowByImageID('hep31812-fig-0001', '01515467-202109000-00024')"><img class="ejp-r-article-images__img js-lazy-load lazy-load" src="javascript:void(0);" data-src="https://images.journals.lww.com/hep/ArticleViewerPreview.01515467-202109000-00024.hep31812-fig-0001.jpeg" data-srcset="https://images.journals.lww.com/hep/ArticleViewerPreview@2.01515467-202109000-00024.hep31812-fig-0001.jpeg 2x" srcset="" alt="hep31812-fig-0001"></a>
<figcaption class="ejp-r-article-images__figcaption">
<a href="javascript:void(0)" class="ejp-r-article-images__figcaption-link" onclick="showSlideShowByImageID('hep31812-fig-0001', '01515467-202109000-00024')">FIG. 1: </a>
<div class="ejp-r-article-images__figcaption-text">Human immune system–promoted HCC proliferation and angiogenesis in the Humice model. (A) Representative images of HCC‐PDX tumor 1# and spleens, and the
statistical analysis of HCC‐PDX tumor 1# weight from NSG (n = 5), Humice (n = 5), and Humice treated with anti–hCD45 Ab (50 ug/mouse/week for 4 weeks; n = 5). (B)
Immunohistochemistry staining of Ki67 in HCC‐PDX tumor 1# tissues and the statistical analysis of the proportion of Ki67<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells
(n = 20, four randomly selected photographs/each sample [total of five samples]). (C) The EDU staining of the HCC‐PDX tumor 1# cells isolated from NSG Humice and Humice treated with anti‐hCD45
Ab and the statistical analysis of EDU<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells (n = 5). (D) Immunohistochemistry staining of CD31 in tumor tissues and the statistical
analysis of the MVD and VCSA (n = 5 samples/group; four images were randomly selected for each sample for quantification [total of 20]). (E) Five million cells from the HCC cell line LM3 were
engrafted into different groups. The tumor weight was analyzed after 3 weeks (n = 4). (F) The methodology and workflow for RNA sequencing of isolating LM3 tumor cells from different mice
groups. (G) PCA of LM3 tumor cells from different groups. (H) The heatmap of top DE genes in RNA‐sequencing results. (I) The signal pathway analysis of DE genes from LM3 tumor cells between Humice and NSG
mice or Humice and Humice treated with anti‐hCD45 Abs. (J) Immunohistochemistry staining of p‐STAT3, p‐JAK2, p‐ERK1/2, p‐p38, and p‐AKT using HCC‐PDX tumor 1#. (K) Western blot analysis of p‐STAT3,
p‐JAK2, p‐ERK1/2, p‐p38, and p‐AKT from isolated HCC‐PDX tumor cells from different groups. Abbreviations: APC, allophycocyanin; ERK, extracellular signal‐regulated kinases; GAPDH, glyceraldehyde
3‐phosphate dehydrogenase; Humice, humanized mice; n.s, not significant; TREM1, triggering receptor expressed on myeloid cells 1. *<em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">P</em> < 0.05;
**<em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">P</em> < 0.01.</div>
</figcaption>
</figure>
</section>
<h3 class="ejp-article-outline-heading" data-level="2" id="hep31812-sec-0009">Intratumor hCD14 Cells Contribute to Promoting HCC Proliferation and Angiogenesis</h3>
<p id="JCL-P-59">To validate the functions of human immune cells from different organs on HCC <em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">in vitro</em>,
hCD45<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells were isolated from blood, spleen, bone marrow (BM), and tumor‐infiltrating leukocytes (TILs) of humanized mice bearing HepG2 cells and
LM3 cells (with HLA‐A2, similar to HCC‐PDX tumors 1#‐4#), and the average composition of immune‐cell subsets was analyzed
(Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0002', '01515467-202109000-00024');">2A</a>). A colony formation assay was performed by two‐dimensional
co‐culturing of hCD45<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells and HepG2 cells or LM3 cells for 10 days. The results showed that only TILs could strongly stimulate HepG2 cell and
LM3 cells proliferation when they were compared with immune cells from other origins
(Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0002', '01515467-202109000-00024');">2B</a>). Subsequently,
hCD45<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells were isolated from blood and TILs from humanized mice bearing HCC‐PDX tumor 1#. The mRNA expression levels of various chemokines,
cytokines, and growth factors were analyzed by RT–quantitative real‐time PCR; <em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">IL‐33</em>, <em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">IL‐6</em>,
<em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">CCL15</em>, <em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">VEGF</em>, <em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">CCL16</em>, <em
xmlns:mrws="http://webservices.ovid.com/mrws/1.0">PDGF</em>, <em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">IL‐8</em>, <em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">IL‐10</em>, and <em
xmlns:mrws="http://webservices.ovid.com/mrws/1.0">CXCR7</em> were highly expressed in hCD45<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> TILs
(Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0002', '01515467-202109000-00024');">2C</a> and Supporting Table S3). To further identify the subtypes of
hCD45<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> TILs that influenced HCC proliferation and angiogenesis, different immune‐cell subsets were depleted <em
xmlns:mrws="http://webservices.ovid.com/mrws/1.0">in vivo</em> using humanized mice bearing HCC‐PDX tumor 1# (Supporting Fig. S7). The weight of each HCC‐PDX tumor 1# was measured 4 weeks after
treatment, and the results revealed that hCD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> or CD19<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cell depletion could reduce HCC
tumor weight. In contrast, hCD8<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cell depletion increased tumor weight
(Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0002', '01515467-202109000-00024');">2D</a>). Immunohistochemical staining of Ki67 and EDU flow cytometry assays
showed a decrease in HCC proliferation after hCD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cell depletion
(Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0002', '01515467-202109000-00024');">2E,F</a> and Supporting Fig. S8). Moreover, angiogenesis in the HCC
tumor, indicated by the MVD and VCSA, was impaired by hCD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> or hCD19<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cell depletion
(Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0002', '01515467-202109000-00024');">2G,H</a> and Supporting Fig. S8). The presence and protein expression
levels of phospho‐JAK2 (p‐JAK2) and p‐STAT3 in the HCC tumor and the purified HCC cells were examined by using immunohistochemistry
(Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0002', '01515467-202109000-00024');">2I,J</a> and Supporting Fig. S8) and western blotting
(Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0002', '01515467-202109000-00024');">2K</a>), respectively. Our results showed that only
hCD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cell depletion could significantly diminish the expression of JAK2 and STAT3 in the tumor. In addition,
hCD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> or CD19<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cell depletion also altered the composition of human immune‐cell subsets
of TILs (Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0002', '01515467-202109000-00024');">2L,M</a>). After the depletion of
hCD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells, the proportion of total CD8<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells, central memory
T<sub xmlns:mrws="http://webservices.ovid.com/mrws/1.0">h</sub> cells (T<sub xmlns:mrws="http://webservices.ovid.com/mrws/1.0">h</sub>CMs), effector memory cytotoxic T
(T<sub xmlns:mrws="http://webservices.ovid.com/mrws/1.0">c</sub>) cells (T<sub xmlns:mrws="http://webservices.ovid.com/mrws/1.0">c</sub>EMs), and central memory
T<sub xmlns:mrws="http://webservices.ovid.com/mrws/1.0">c</sub> cells (T<sub xmlns:mrws="http://webservices.ovid.com/mrws/1.0">c</sub>CMs) increased, whereas the proportion of effector memory
T<sub xmlns:mrws="http://webservices.ovid.com/mrws/1.0">h</sub> cells (T<sub xmlns:mrws="http://webservices.ovid.com/mrws/1.0">h</sub>EMs), type 1 macrophages (MØ1s) or type 2 macrophages (MØ2s), and
mononuclear MDSCs (M‐MDSCs) decreased (Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0002', '01515467-202109000-00024');">2L</a>). The total number of
CD8<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells, CD19<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells,
T<sub xmlns:mrws="http://webservices.ovid.com/mrws/1.0">h</sub>CMs, T<sub xmlns:mrws="http://webservices.ovid.com/mrws/1.0">c</sub>EMs, and T<sub xmlns:mrws="http://webservices.ovid.com/mrws/1.0">c</sub>CMs
increased per gram of tumor tissue, whereas effector memory T<sub xmlns:mrws="http://webservices.ovid.com/mrws/1.0">h</sub> cells (T<sub xmlns:mrws="http://webservices.ovid.com/mrws/1.0">h</sub>EMs), MØ1s or
MØ2s, and M‐MDSCs decreased in hCD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cell–depleted tumor tissues (Supporting Fig. S9A). Similarly, a depletion in
hCD19<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells also led to an increase in the percentage of total CD8<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells and
T<sub xmlns:mrws="http://webservices.ovid.com/mrws/1.0">c</sub>CMs and a decrease in the proportion of MØ2s
(Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0002', '01515467-202109000-00024');">2M</a>). In terms of the cell number per gram of tumor tissue, total
CD8<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells, T<sub xmlns:mrws="http://webservices.ovid.com/mrws/1.0">h</sub>CMs, T<sub xmlns:mrws="http://webservices.ovid.com/mrws/1.0">c</sub>EMs,
T<sub xmlns:mrws="http://webservices.ovid.com/mrws/1.0">c</sub>CMs, hCD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup>hCD16<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">−</sup> cells,
and early‐stage MDSCs increased after hCD19<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup>‐cell depletion (Supporting Fig. S9B). Taken together, the intratumor
hCD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells could stimulate HCC tumor proliferation and angiogenesis by modulating the profile of the immune cells in the tumor and plausibly
through the activation of the IL6/JAK2/STAT3 signaling pathway.</p>
<section class="ejp-r-article-images">
<figure class="ejp-r-article-images__figure">
<a href="javascript:void(0)" class="ejp-r-article-images__image-link" onclick="showSlideShowByImageID('hep31812-fig-0002', '01515467-202109000-00024')"><img class="ejp-r-article-images__img js-lazy-load lazy-load" src="javascript:void(0);" data-src="https://images.journals.lww.com/hep/ArticleViewerPreview.01515467-202109000-00024.hep31812-fig-0002.jpeg" data-srcset="https://images.journals.lww.com/hep/ArticleViewerPreview@2.01515467-202109000-00024.hep31812-fig-0002.jpeg 2x" srcset="" alt="hep31812-fig-0002"></a>
<figcaption class="ejp-r-article-images__figcaption">
<a href="javascript:void(0)" class="ejp-r-article-images__figcaption-link" onclick="showSlideShowByImageID('hep31812-fig-0002', '01515467-202109000-00024')">FIG. 2: </a>
<div class="ejp-r-article-images__figcaption-text">hCD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> TILs are one of the major players in HCC proliferation and angiogenesis. (A) The
average proportion of multiple human immune cells (hCD45<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup>) in blood, spleen, BM, and TILs from HepG2 or LM3‐engrafted Humice, which were used
in an HepG2 or LM3 co‐culture <em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">in vitro</em> experiment. (B) The HCC clone‐formation analysis. HepG2 or LM3 cells are co‐cultured with human immune
cells from blood, spleen, BM, and TILs of HepG2‐engrafted Humice for 10 days. The ratio was 1:10, exchanging new medium and adding new human immune cells every two days. The statistical analysis of
the size of clone is shown (n = 50). (C) Total RNA was extracted from blood or hCD45<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> TILs from Humice without the HCC‐PDX tumor and
HCC‐PDX tumor 1#–bearing Humice. Gene expression profiles are analyzed using RT–quantitative real‐time PCR (n = 3). A heat map of the gene expression is shown. (D) HCC‐PDX tumor 1# was engrafted
into NSG and Humice, which were treated with saline, anti–hCD4 Abs, anti‐hCD8 Abs, anti‐hCD19 Abs, anti‐hCD14 Abs, and anti‐hCD56 Abs. (E) The HCC‐PDX tumor 1# cells from different groups were analyzed
using EDU staining (n = 5). (F‐J) Immunohistochemistry staining of Ki67, CD31, p‐JAK2 and p‐STAT3 were performed in HCC‐PDX tumor tissues. The statistical results of (F)
Ki67<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup>, (G) MVD, (H) VCSA, (I) p‐JAK2, and (J) p‐STAT3 are shown (n = 5 samples/group; four images were randomly selected for each
sample for quantification [total of 20]). (K) Western blot analysis of the p‐STAT3 and p‐JAK2 level in isolated HCC‐PDX tumor cells from different groups. (L‐M) The changes in human immune cells’
proportion in TILs after saline and (L) anti‐hCD14 Ab or (M) anti‐hCD19 Ab injection (n = 5). Abbreviations: e‐MDSC, early‐stage MDSC; Humice, humanized mice; k, thousand; PMN‐MDSC,
polymorphonuclear leukocyte–MDSC; T<sub xmlns:mrws="http://webservices.ovid.com/mrws/1.0">c</sub>E, effector T<sub xmlns:mrws="http://webservices.ovid.com/mrws/1.0">c</sub> cell; TcN, naive cytotoxic T
cells; T<sub xmlns:mrws="http://webservices.ovid.com/mrws/1.0">h</sub>E, effector T<sub xmlns:mrws="http://webservices.ovid.com/mrws/1.0">h</sub> cell; ThN, naive T helper cells; Treg, regulatory T cell;
W, with; W/O, without. *<em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">P</em> < 0.05; **<em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">P</em> < 0.01.</div>
</figcaption>
</figure>
</section>
<h3 class="ejp-article-outline-heading" data-level="2" id="hep31812-sec-0010">Intratumor Human Immune Cells are Strongly Modulated by HCC Tumors</h3>
<p id="JCL-P-60">To characterize the phenotypes and functions of the humanized immune system in the absence or presence of an HCC tumor burden, we isolated multiple immune‐cell subsets, including
CD4<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup>, CD8<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup>, CD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup>,
CD19<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup>, and CD56<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells, from the spleen and from among the TILs of humanized mice
bearing an HCC‐PDX tumor and analyzed their RNA profiles (Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0003', '01515467-202109000-00024');">3A</a>). Through
PCA and heatmap analysis, it was found that the profiles of CD4<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup>
(Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0003', '01515467-202109000-00024');">3B</a>), CD8<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup>
(Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0003', '01515467-202109000-00024');">3C</a>), CD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup>
(Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0003', '01515467-202109000-00024');">3D</a>), CD19<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup>
(Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0003', '01515467-202109000-00024');">3E</a>), and
CD56<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> (Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0003', '01515467-202109000-00024');">3F</a>)
cells among the groups were distinct and well separated. The list of DE genes was detected and calculated for CD4<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup>,
CD8<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup>, CD19<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup>, CD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup>, and
CD56<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells (Supporting Table S2). Despite minor differences between splenic immune cells from humanized mice with and without HCC, the
intratumor human immune cells were significantly different, including in terms of the expression of surface markers, chemokines, cytokines, and functional proteins. For example, cell migration (<em
xmlns:mrws="http://webservices.ovid.com/mrws/1.0">CCL13</em> and <em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">CCL18</em>), angiogenesis and invasion (<em
xmlns:mrws="http://webservices.ovid.com/mrws/1.0">CCL2</em>, <em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">CCL7</em>, <em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">CCL9</em>, <em
xmlns:mrws="http://webservices.ovid.com/mrws/1.0">CCL10</em>, <em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">IL‐8</em>, <em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">IL‐10</em>, <em
xmlns:mrws="http://webservices.ovid.com/mrws/1.0">PDGFA</em>, <em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">VEGFA</em>, <em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">EGF</em>, <em
xmlns:mrws="http://webservices.ovid.com/mrws/1.0">MMP7</em>, <em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">MMP9</em>, and <em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">MMP19</em>), and MØ2
type markers (<em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">CD163</em> and peroxisome proliferator–activated receptor gamma genes) were found to be up‐regulated in
hCD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> TILs, whereas MØ1 type maker (<em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">CD86</em>) and phagocytosis markers (neutrophil cytosol
factor 1 [<em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">NCF‐1</em>], phosphatidylinositol 4‐phosphate 5‐kinase type‐1 gamma [<em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">PIP5K1C</em>],
vasodilator‐stimulated phosphoprotein [<em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">VASP</em>], hematopoietic cell kinase [<em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">HCK</em>],
phosphatidylinositol‐4,5‐bisphosphate 3‐kinase, catalytic subunit gamma [<em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">PIK3CG</em>], spleen tyrosine kinase [<em
xmlns:mrws="http://webservices.ovid.com/mrws/1.0">SYK</em>], actin related protein 2/3 complex subunit 4 [<em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">ARPC4</em>], <em
xmlns:mrws="http://webservices.ovid.com/mrws/1.0">AKT1</em>, WASP family member 2 [<em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">WASF2</em>], vav guanine nucleotide exchange factor 1 [<em
xmlns:mrws="http://webservices.ovid.com/mrws/1.0">VAV1</em>], actin related protein 2/3 complex subunit 1B [<em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">ARPC1B</em>], P21 (RAC1) activated kinase 1
[<em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">PAK1</em>], cofilin 1 [<em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">CFL1</em>] and AKT serine/threonine kinase 2 [AKT2]) were down‐regulated.
These results suggested that HCC tumors could alter human immune cells in humanized mice, particularly on intratumor human immune cells.</p>
<section class="ejp-r-article-images">
<figure class="ejp-r-article-images__figure">
<a href="javascript:void(0)" class="ejp-r-article-images__image-link" onclick="showSlideShowByImageID('hep31812-fig-0003', '01515467-202109000-00024')"><img class="ejp-r-article-images__img js-lazy-load lazy-load" src="javascript:void(0);" data-src="https://images.journals.lww.com/hep/ArticleViewerPreview.01515467-202109000-00024.hep31812-fig-0003.jpeg" data-srcset="https://images.journals.lww.com/hep/ArticleViewerPreview@2.01515467-202109000-00024.hep31812-fig-0003.jpeg 2x" srcset="" alt="hep31812-fig-0003"></a>
<figcaption class="ejp-r-article-images__figcaption">
<a href="javascript:void(0)" class="ejp-r-article-images__figcaption-link" onclick="showSlideShowByImageID('hep31812-fig-0003', '01515467-202109000-00024')">FIG. 3: </a>
<div class="ejp-r-article-images__figcaption-text">Human immune cells from TILs were modulated by HCC tumors. Multiple kinds of human immune cells are isolated from spleen (in HCC‐PDX tumor 1#–bearing
humanized mice and non–HCC humanized mice) and HCC‐PDX tumor 1# tissue. PCA and heatmap analysis are performed using RNA‐sequencing results. (A) The workflow of isolation of multiple kinds of human immune
cells for RNA sequencing. (B) Results of hCD4<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells (human T<sub xmlns:mrws="http://webservices.ovid.com/mrws/1.0">h</sub> cells). (C) Results
of hCD8<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells (human T<sub xmlns:mrws="http://webservices.ovid.com/mrws/1.0">c</sub> cells). (D) Results of
hCD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells (human monocytes). (E) Results of hCD19<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells (human B cells). (F)
Results of hCD56<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells (human NK cells). Abbreviations: W, with; W/O, without.</div>
</figcaption>
</figure>
</section>
<h3 class="ejp-article-outline-heading" data-level="2" id="hep31812-sec-0011">IL‐33 Secreted From Intratumor hCD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> Cells Up‐Regulates IL‐6 Expression
in Multiple Intratumor Immune Cells and Enhances HCC Proliferation</h3>
<p id="JCL-P-61">Previous studies have shown that serum IL‐33 levels are higher in patients with HCC than in healthy
donors.<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">(</sup><sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep31812-bib-0039">39</a></sup><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">)</sup>
Consistent with these clinical findings, our results also verified the elevation of IL‐6 and IL‐33 expression in intratumor hCD45<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells
(Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0002', '01515467-202109000-00024');">2C</a>). In our HCC‐PDX humanized mouse model,
IL‐33<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells were only present in intratumor hCD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells, and these HCC cells did not
express IL‐33 (data not shown), whereas IL‐6<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells were detected among the CD4<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup>,
CD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup>, and lineage (Lin)<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">−</sup> TILs
(Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0004', '01515467-202109000-00024');">4A‐C</a>). Therefore, the correlation between the IL‐6 level in the
captioned immune cells and the IL‐33 level in intratumor hCD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells was analyzed in HCC samples from 10 patients. The results showed that the IL‐33
level in intratumor hCD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells was closely correlated with the IL‐6 level in intratumor
hCD4<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> and hCD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells but was weakly correlated with the intratumor
hCD19<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells and Lin<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">−</sup> cells
(Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0004', '01515467-202109000-00024');">4A</a>). Interestingly, ILC groups from
Lin<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">−</sup> cells were found in our model, particularly in BM and among TILs (Supporting Fig. S10A). The major ILC subtype in the BM and among TILs
were ILC1 and ILC2, respectively (Supporting Fig. S10B). Meanwhile, the majority of the ILC2s could express IL‐6, whereas other ILC subsets, such as ILC1,
NCR<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup>ILC3, and NCR<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">−</sup>ILC3, did not express IL‐6
(Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0004', '01515467-202109000-00024');">4E</a>). Interleukin 1 receptor‐like 1 (ST2) is a member of the IL‐1
receptor family, which is the receptor of IL‐33. We found that ST2 was highly expressed in intratumor CD4<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup>,
CD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup>, and Lin<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">−</sup> cells (Supporting Fig. S11A). Furthermore, the proportion of
ST2<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> IL‐6<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells was much higher than that of
ST2<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">−</sup> IL‐6<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells in CD4<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup>,
CD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup>, and Lin<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">−</sup> cells (Supporting Fig. S11B), suggesting that IL‐33 could modulate
IL‐6 expression through the ST2 receptor. To confirm the regulatory effect of IL‐33 on HCC <em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">in vivo</em>, anti–human IL‐33 Ab was injected into HCC‐PDX
humanized mice to neutralize IL‐33. After 4 weeks of treatment, the tumor weight for these mice was drastically reduced compared with that of their saline‐injected counterparts
(Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0004', '01515467-202109000-00024');">4F</a>). Meanwhile, human IL‐33 neutralization led to a decrease in the IL‐6
level in intratumor CD4<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup>, CD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup>, and
Lin<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">−</sup> cells
(Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0004', '01515467-202109000-00024');">4G</a>) and led to lower activation of JAK2 and STAT3 in HCC cells
(Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0004', '01515467-202109000-00024');">4H</a>). Furthermore, the MVD and VCSA suggested that IL‐33 was also
involved in angiogenesis (Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0004', '01515467-202109000-00024');">4I,J</a>). After human IL‐33 neutralization, the
proportions of intratumor Th2 and regulatory T cells decreased, whereas the proportion of T<sub xmlns:mrws="http://webservices.ovid.com/mrws/1.0">c</sub>EMs increased, suggesting that
CD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> monocyte–derived IL‐33 may also be involved in regulating other immune‐cell types in the tumor environment
(Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0004', '01515467-202109000-00024');">4K</a>). These results suggested that IL‐33 from intratumor
hCD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells could up‐regulate IL‐6 expression in multiple cell types, thereby enhancing HCC proliferation.</p>
<section class="ejp-r-article-images">
<figure class="ejp-r-article-images__figure">
<a href="javascript:void(0)" class="ejp-r-article-images__image-link" onclick="showSlideShowByImageID('hep31812-fig-0004', '01515467-202109000-00024')"><img class="ejp-r-article-images__img js-lazy-load lazy-load" src="javascript:void(0);" data-src="https://images.journals.lww.com/hep/ArticleViewerPreview.01515467-202109000-00024.hep31812-fig-0004.jpeg" data-srcset="https://images.journals.lww.com/hep/ArticleViewerPreview@2.01515467-202109000-00024.hep31812-fig-0004.jpeg 2x" srcset="" alt="hep31812-fig-0004"></a>
<figcaption class="ejp-r-article-images__figcaption">
<a href="javascript:void(0)" class="ejp-r-article-images__figcaption-link" onclick="showSlideShowByImageID('hep31812-fig-0004', '01515467-202109000-00024')">FIG. 4: </a>
<div class="ejp-r-article-images__figcaption-text">IL‐33 from CD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> TILs could up‐regulate IL‐6 expression in TILs’ multiple immune cells and
enhance HCC proliferation and angiogenesis. (A) Correlation of IL‐33 levels in monocytes and IL‐6 levels in CD4<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup>,
CD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup>, CD19<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup>, and
Lin<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">−</sup> TILs of patients with HCC. (B‐D) Expression of IL‐33 and IL‐6 in hCD4<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup>,
CD8<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup>, CD19<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup>, CD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup>,
and Lin− cells from blood, spleen, and BM and from among TILs in HCC‐PDX tumor 1# humanized mice models. The statistical results of (C) IL‐33 and (D) IL‐6 are shown. (E) IL‐6 expression in ILCs from
spleen and TILs. The statistical result is shown. (F) HCC‐PDX tumor 1# weight after 4 weeks of treatment with saline and anti–IL‐33 Abs. (G) Changes in IL‐6 level in TILs’ multiple human immune cells
after anti–human IL‐33 Ab treatment. (H) Western blot analysis of p‐STAT3 and p‐JAK2 from isolated HCC cells from saline and anti‐IL33 Ab treatment groups. (I‐J) Tumor angiogenesis analysis in HCC‐PDX
tumor 1# tissues from saline and anti‐IL33 Ab treatment groups. The statistical results of (I) MVD and (J) VCSA are shown (n = 5 samples/group, four images were randomly selected for each sample
for quantification [total of 20]). (K) Changes in the proportion of multiple human immune cells after anti‐IL33 Ab treatment in TILs. Abbreviations: e‐MDSC, early‐stage MDSC; PMN‐MDSC, polymorphonuclear
leukocyte–MDSC; T<sub xmlns:mrws="http://webservices.ovid.com/mrws/1.0">c</sub>E, effector T<sub xmlns:mrws="http://webservices.ovid.com/mrws/1.0">c</sub> cell; TcN, naive cytotoxic T cells;
T<sub xmlns:mrws="http://webservices.ovid.com/mrws/1.0">h</sub>E, effector T<sub xmlns:mrws="http://webservices.ovid.com/mrws/1.0">h</sub> cell; ThN, naive T helper cells; Treg, regulatory T cell. *<em
xmlns:mrws="http://webservices.ovid.com/mrws/1.0">P</em> < 0.05; **<em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">P</em> < 0.01.</div>
</figcaption>
</figure>
</section>
<h3 class="ejp-article-outline-heading" data-level="2" id="hep31812-sec-0012">Co‐receptor CD14 Is Essential for IL‐33 Production Through Damp (HMGB1)/TLR4/Activator Protein 1 Pathway</h3>
<p id="JCL-P-62">To clarify the mechanism of IL‐33 production from intratumor hCD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells only, we induced IL‐33 expression using primary human immune
cells and U937 cells <em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">in vitro</em>. We attempted to detect IL‐33 expression induced by using different reagents, including co‐culture with HepG2, Hep3B,
Huh7, and PLC5 cell lines and stimulation by lipopolysaccharide (LPS), IL‐33, IL‐6, HepG2 lysates, Hep3B lysates, Huh7 lysates, and PLC5 lysates. We observed that only HepG2 lysates and LPS could induce high
levels of IL‐33 in primary human immune cells (Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0005', '01515467-202109000-00024');">5A</a>). Meanwhile, we
stimulated U937 cells using HepG2 lysates. However, no IL‐33 expression caused by the direct addition of HepG2 lysates to U937 cells was observed
(Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0005', '01515467-202109000-00024');">5B</a>). U937 is a monocytic cell line, and low levels of CD14 and
1,25‐dihydroxyvitamin D3 (VD3) may induce CD14 expression in U937; these are results we validated (Supporting Fig. S12). We observed that VD3 could induce CD14 expression and that HepG2 lysates stimulated
the induction of IL‐33 in VD3‐treated U937 cells (Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0005', '01515467-202109000-00024');">5B</a>). The flow cytometry
plot also indicated that only CD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells expressed IL‐33
(Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0005', '01515467-202109000-00024');">5B</a>). In VD3‐treated U937 cells, HepG2 lysates, Hep3B lysates, PLC5
lysates, and LPS could induce high levels of IL‐33. We also performed specific targeted hCD14 gene knockdown in U937 cells using five short‐hairpin RNAs (shRNAs) (Supporting Fig. S13). TRC1.5 vector
controls and shRNAs expressing lentiviral particles were generated using third‐generation lentivirus packaging systems. The results indicated that hCD14 shRNAs could significantly impair CD14 expression induced
by VD3 in U937 cells (Supporting Fig. S13B). As a result, the intracellular level of IL‐33 induced by VD3 and HepG2 lysates was down‐regulated in hCD14‐silenced U937 cells (Supporting Fig. S13C). In
conclusion, CD14 is an essential molecule for IL‐33 production. By analyzing the network of highly expressed genes in intratumor CD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells, we
found that activator protein 1 (AP‐1) was as a key transcription factor because of its regulation of many of the up‐regulated genes. Similar results, including activation of the AP‐1 pathway, can also be
observed in the RT–quantitative real‐time PCR heatmap of CD45<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> TILs (Supporting Fig. S14A), U937 cells treated with VD3, HepG2 lysates
(Supporting Fig. S14B), and healthy donor CD45<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells treated with HepG2 lysates (Supporting Fig. S14C). To further validate the role of
AP‐1 signaling in IL‐33 expression, we treated primary hCD45<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells with LPS, HCC lysates (HepG2), (R)‐Ethyl 6‐(N‐(2‐chloro‐4 fluorophenyl)
sulfamoyl) cyclohex‐1‐enecarboxylate (TAK‐242) (inhibitor of TLR4) and (E,E,Z,E)‐3‐Methyl‐7‐(4‐methylphenyl)‐9‐(2,6,6‐trimethyl‐1‐cyclohexen‐1‐yl)‐2,4,6,8‐nonatetraenoic acid (SR‐11302) (inhibitor of AP‐1). The
results showed that either blockage of TLR4 or inhibition of AP‐1 can suppress LPS‐ or HCC lysate–induced IL‐33 expression
(Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0005', '01515467-202109000-00024');">5D</a>). Additionally, we found that LPS and HCC lysates could increase Jun
family (JUNB, c‐JUN, and JUND) protein levels in hCD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells. However, TAK‐242 and SR‐11302 can mitigate the elevation of Jun Proto‐Oncogene
(JUN)‐family proteins (Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0005', '01515467-202109000-00024');">5E</a>). We also confirmed that AP‐1 can bind multiple
motifs in the promoter region of IL‐33 in U397 cells (Supporting Fig. S15A,B). HCC lysates can enhance the binding ability of AP‐1 (JUN family) to the promoter of IL‐33. TAK‐242 and SR‐11302 can mitigate
the effect of HCC lysates (Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0005', '01515467-202109000-00024');">5F</a>). Moreover, HMGB1 protein is a type of DAMP
that is typically located in the nucleus as a nuclear factor. However, it can also be translocated to the cytoplasm and released into the extracellular matrix, linking inflammation and HCC. HMGB1 may activate
several intracellular signaling pathways (NF‐κB or AP‐1) that regulate monocyte‐induced cytokine synthesis by binding TLRs 2, 4, 5, and 9. Earlier studies have also demonstrated that HMGB1 is highly expressed
in HCC tissues compared with paratumor and normal tissues and that it also promotes HCC proliferation and angiogenesis. To determine the role of HMGB1 in IL‐33 synthesis, we treated primary
hCD45<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells with HCC lysates and anti‐HMGB1 neutralizing Abs. The results indicated that anti‐HMGB1 neutralizing Abs could attenuate HCC
lysate–induced IL‐33 levels in CD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> monocytes
(Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0005', '01515467-202109000-00024');">5G</a>). Furthermore, increased supernatant HMGB1 levels were observed in
interferon‐gamma (IFN‐gamma)–treated HCC cells (Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0005', '01515467-202109000-00024');">5H</a>). Overall, IL‐33 could
be synthesized by CD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells through the DAMP(HMGB1)/TLR4/AP‐1 pathway.</p>
<section class="ejp-r-article-images">
<figure class="ejp-r-article-images__figure">
<a href="javascript:void(0)" class="ejp-r-article-images__image-link" onclick="showSlideShowByImageID('hep31812-fig-0005', '01515467-202109000-00024')"><img class="ejp-r-article-images__img js-lazy-load lazy-load" src="javascript:void(0);" data-src="https://images.journals.lww.com/hep/ArticleViewerPreview.01515467-202109000-00024.hep31812-fig-0005.jpeg" data-srcset="https://images.journals.lww.com/hep/ArticleViewerPreview@2.01515467-202109000-00024.hep31812-fig-0005.jpeg 2x" srcset="" alt="hep31812-fig-0005"></a>
<figcaption class="ejp-r-article-images__figcaption">
<a href="javascript:void(0)" class="ejp-r-article-images__figcaption-link" onclick="showSlideShowByImageID('hep31812-fig-0005', '01515467-202109000-00024')">FIG. 5: </a>
<div class="ejp-r-article-images__figcaption-text">CD14 is an essential molecule for IL‐33 generation induced by DAMPs (HMGB1) from HCC through the TLR4/AP‐1 pathway. (A) IL‐33 expression levels in
hCD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells after stimulating hCD34<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">−</sup> cells from three healthy donors with
different reagents (n = 3). (B) The IL‐33 level in U937 cells following stimulation by different reagents with or without VD3 pretreatment (n = 3). (C) Network for highly expressed
transcription factors in hCD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> TILs. (D) IL‐33 expression levels in hCD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells
combinatorically treated with HepG2 lysates, TAK‐242 (TLR4 inhibitor), and SR‐11302 (AP‐1 transcription factor inhibitor). (E) JUN protein levels, including JUNB, c‐JUN, and JUND, in U937 cells
(pretreated with VD3) following combinatorial treatment with HepG2 lysates, TAK‐242 and SR‐11302. (F) ChIP analysis was performed in U937 cells using anti‐JUNB Ab, anti–c‐JUN Ab, and anti‐JUND. ChIP DNA
was analyzed using real‐time PCR (n = 4). (G) The effect of HMGB1 neutralizing Ab on lysate‐induced IL‐33 expression (n = 3). (H) Western blot analysis of HMGB1 levels from the
supernatant after IFN‐gamma treatment of LM3 cells for 24 hours. Abbreviations: ChIP, chromatin immunoprecipitation; MFI, mean fluorescence intensity; n.s, not significant; Q, quadrant. *<em
xmlns:mrws="http://webservices.ovid.com/mrws/1.0">P</em> < 0.05; **<em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">P</em> < 0.01.</div>
</figcaption>
</figure>
</section>
<h3 class="ejp-article-outline-heading" data-level="2" id="hep31812-sec-0013">hCD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> Monocytes Among TILs are Crucial for Combinatorial Immunotherapy
on HCC</h3>
<p id="JCL-P-63">The above data proved that the presence of intratumor CD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells enhances HCC proliferation and angiogenesis by activating the
JAK2/STAT3 pathway or releasing angiogenic cytokines (VEGF and so on). HCC‐PDX humanized mice were treated with C188‐9 (STAT3 inhibitor) or bevacizumab (VEGF inhibitor) alone or in combination with
pembrolizumab, and the additive effects were observed following treatment
(Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0006', '01515467-202109000-00024');">6A,B</a>). Next, the efficacy and safety of triple‐combination therapy using
C188‐9, bevacizumab, and pembrolizumab were evaluated and showed a more significant anti‐HCC effect
(Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0006', '01515467-202109000-00024');">6C</a>). Similar results were consistently observed from subcutaneous
(Supporting Figs. S1G, S2G and S3G) and orthotopic mouse models reconstituted with PDXs from different donors (Supporting Figs. S4D, S5D and S6D). The Ki‐67 immunohistochemical staining revealed that
HCC tumors treated with triple‐combination therapy had the lowest level of proliferation
(Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0006', '01515467-202109000-00024');">6D</a> and Supporting Fig. S15). Besides this, MVD and VCSA results
also indicated that triple‐combination therapy could reduce angiogenesis
(Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0006', '01515467-202109000-00024');">6E,F</a> and Supporting Fig. S15). Interestingly, the phosphorylation
of STAT3 in HCC tumors was reduced after triple‐combination therapy, albeit with an increase in the tumor size following pembrolizumab treatment
(Fig <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0006', '01515467-202109000-00024');">6G,I</a> and Supporting Fig. S16). Meanwhile, the expression of JAK2 was
unchanged after triple‐combination therapy (Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0006', '01515467-202109000-00024');">6H,I</a> and Supporting
Fig. S16). To further investigate the role of individual human immune‐cell types in this triple‐combination therapy, we compared the anti‐HCC effect of triple‐combination therapy when hCD14 and hCD8 cells
were depleted separately in both subcutaneous (HCC‐PDX tumor 1#) (Supporting Fig. S17) and orthotopic models (HCC‐PDX tumors 1# and 2#) (Supporting Figs. S18 and S19). The results revealed that the
anti‐HCC effect of triple‐combination therapy were greatly hampered without hCD8 or hCD14 cells in HCC humanized mice. It confirmed that these two human immune‐cell types were both critical in this combination
therapy. Taken together, the results showed that triple‐combination therapy using C188‐9, bevacizumab, and pembrolizumab could significantly increase the efficacy of the anti‐HCC response <em
xmlns:mrws="http://webservices.ovid.com/mrws/1.0">in vivo</em> compared with monotherapy or dual‐therapy.</p>
<section class="ejp-r-article-images">
<figure class="ejp-r-article-images__figure">
<a href="javascript:void(0)" class="ejp-r-article-images__image-link" onclick="showSlideShowByImageID('hep31812-fig-0006', '01515467-202109000-00024')"><img class="ejp-r-article-images__img js-lazy-load lazy-load" src="javascript:void(0);" data-src="https://images.journals.lww.com/hep/ArticleViewerPreview.01515467-202109000-00024.hep31812-fig-0006.jpeg" data-srcset="https://images.journals.lww.com/hep/ArticleViewerPreview@2.01515467-202109000-00024.hep31812-fig-0006.jpeg 2x" srcset="" alt="hep31812-fig-0006"></a>
<figcaption class="ejp-r-article-images__figcaption">
<a href="javascript:void(0)" class="ejp-r-article-images__figcaption-link" onclick="showSlideShowByImageID('hep31812-fig-0006', '01515467-202109000-00024')">FIG. 6: </a>
<div class="ejp-r-article-images__figcaption-text">hCD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> myeloid cells from TILs are one of the potential target cells for developing
combinatorial HCC immunotherapy. (A) The HCC‐PDX tumor weight after 4 weeks of treatment with C188‐9 (n = 6), pembrolizumab (n = 6), and combination treatment (n = 6). (B)
The HCC‐PDX tumor weight after 4 weeks of treatment with bevacizumab (n = 4), pembrolizumab (n = 4), and combination treatment (n = 4). (C) The HCC‐PDX tumor weight after
3.5 weeks of treatment with saline (n = 6), C188‐9 + bevacizumab (n = 6), pembrolizumab + bevacizumab (n = 6), pembrolizumab + C188‐9
(n = 6) and combination treatment (n = 6). (D‐G) Immunohistochemistry staining of Ki67, CD31, p‐STAT3 and p‐JAK2. The statistical results of (D)
Ki67<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup>, (E) MVD, (F) VCSA, (G) p‐STAT3, and (H) p‐JAK2 are shown (n = 5 samples/group, four images were randomly selected for each
sample for quantification [total of 20]). (I) Western blot analysis of p‐STAT3 and p‐JAK2 levels from different groups. Abbreviations: APC, allophycocyanin; n.s, not significant. *<em
xmlns:mrws="http://webservices.ovid.com/mrws/1.0">P</em> < 0.05; **<em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">P</em> < 0.01.</div>
</figcaption>
</figure>
</section>
<p id="JCL-P-64">In summary, our humanized‐immune‐system HCC mouse model provides a useful <em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">in vivo</em> platform for testing HCC combinational immunotherapy
on the basis of the dissection of molecular features of the human immune microenvironment and human tumors. A general picture of tumor–immune‐cell interaction is proposed in our study
(Fig. <a href="javascript:void(0)" onclick="javascript:showSlideShowByImageID('hep31812-fig-0007', '01515467-202109000-00024');">7</a>). Initially, when the human immune system is exposed to an HCC tumor,
it becomes activated and releases proinflammatory cytokines, such as IFN‐gamma. The HCC tumor senses the immune responses and generates resistant reactions by releasing DAMPs, such as HMGB1, to immunomodulate
CD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> monocytes. For example, this occurs through the binding of DAMPs to TLR4 and the subsequent synthesis of IL‐33 through the TLR4/AP‐1 signaling
pathway and VEGF, and so on. IL‐33 stimulates CD4<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells, CD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells, and ILC2s to
release IL‐6, stimulating HCC proliferation through the JAK2/STAT3 pathway and VEGF‐related angiogenesis to overcome the killing activity of the immune system. In this context, we demonstrated that a triple
therapy comprising C188‐9 to inhibit STAT3‐related HCC proliferation induced by IL‐6, bevacizumab to block VEGF‐induced angiogenesis from intratumor monocytes, and pembrolizumab to block PD‐1–triggered T‐cell
exhaustion induced by PD‐L1/2 has a combinational effect.</p>
<section class="ejp-r-article-images">
<figure class="ejp-r-article-images__figure">
<a href="javascript:void(0)" class="ejp-r-article-images__image-link" onclick="showSlideShowByImageID('hep31812-fig-0007', '01515467-202109000-00024')"><img class="ejp-r-article-images__img js-lazy-load lazy-load" src="javascript:void(0);" data-src="https://images.journals.lww.com/hep/ArticleViewerPreview.01515467-202109000-00024.hep31812-fig-0007.jpeg" data-srcset="https://images.journals.lww.com/hep/ArticleViewerPreview@2.01515467-202109000-00024.hep31812-fig-0007.jpeg 2x" srcset="" alt="hep31812-fig-0007"></a>
<figcaption class="ejp-r-article-images__figcaption">
<a href="javascript:void(0)" class="ejp-r-article-images__figcaption-link" onclick="showSlideShowByImageID('hep31812-fig-0007', '01515467-202109000-00024')">FIG. 7: </a>
<div class="ejp-r-article-images__figcaption-text">The DAMP/TLR4/AP‐1/IL‐33/IL‐6 model and combinational anti‐HCC effect of triple‐combination treatment (immune checkpoint blockades, anti‐HCC proliferation
therapy, and angiogenesis inhibitors).</div>
</figcaption>
</figure>
</section>
<h2 class="ejp-article-outline-heading" data-level="1" id="hep31812-sec-0014">Discussion</h2>
<p id="JCL-P-65">The human immune system is instrumental in modulating HCC progression. On the one hand, cytotoxic effector cells eliminate HCC cells, whereas tumor‐associated immune cells stimulate the
proliferation, angiogenesis, EMT, invasion, and metastasis of the
HCC.<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">(</sup><sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep31812-bib-0040 hep31812-bib-0041 hep31812-bib-0042">40‐42</a></sup><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">)</sup>
In addition, several inflammatory signaling pathways in HCC, namely JAK/STAT, MAPK, PI3K/AKT, and extracellular signal‐regulated kinases1/2 pathways are induced by the immune
cells.<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">(</sup><sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep31812-bib-0022 hep31812-bib-0023 hep31812-bib-0024 hep31812-bib-0043 hep31812-bib-0044">22‐24,43,44</a></sup><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">)</sup>
In our humanized‐immune‐system HCC mouse model, increased HCC proliferation was associated with activation of the JAK/STAT pathway in the tumor cells, and VEGF‐induced angiogenesis was also triggered by the
human immune system. These results suggest that the human immune system could alter HCC progression by changing the signaling pathways in our humanized‐immune‐system HCC mouse model, in a way similar to that
observed in patients with HCC.</p>
<p id="JCL-P-66">Different human immune‐cell subsets, such as T cells, B cells, monocytes, NK cells, and NK T cells, were present in the HCC tumor
microenvironment.<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">(</sup><sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep31812-bib-0045">45</a></sup><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">)</sup>
These human immune cells may promote or inhibit HCC growth, depending on the immune responses elicited. For example, depletion of CD4<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> T cells and
CD8<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> T cells could accelerate HCC
progression,<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">(</sup><sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep31812-bib-0046 hep31812-bib-0047">46,47</a></sup><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">)</sup>
which was also seen in our model. By contrast, we also demonstrated that depletion of B cells, monocytes, and macrophages could attenuate the growth and angiogenesis of HCC, consistent with findings in relation
to other
models.<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">(</sup><sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep31812-bib-0023 hep31812-bib-0048">23,48</a></sup><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">)</sup>
In our study, intratumor hCD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells triggered HCC proliferation through IL‐33 and triggered angiogenesis through VEGF. The angiogenesis seen in
this model is likely of mouse origin; however, human VEGF is highly conserved in mice and could thus stimulate mouse endothelial cells and be validated in our
model.<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">(</sup><sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep31812-bib-0049">49</a></sup><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">)</sup>
CD14 is a co‐receptor of TLR4 and the TLR4/AP‐1 pathway, which has been reported to up‐regulate IL‐33
expression.<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">(</sup><sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep31812-bib-0050 hep31812-bib-0051">50,51</a></sup><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">)</sup>
Consistent with findings from earlier studies, we found that CD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells could up‐regulate IL‐33 after stimulation with HCC lysates <em
xmlns:mrws="http://webservices.ovid.com/mrws/1.0">in vitro</em>, and we further proved that intratumor CD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells are the only immune‐cell type
responsible for IL‐33–induced HCC proliferation <em xmlns:mrws="http://webservices.ovid.com/mrws/1.0">in vivo</em>. The AP‐1 (JUN and FOS [Fos proto‐oncogene]) signaling pathway was activated in intratumor
CD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells and HCC lysate–treated primary CD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells, in which the expression of IL‐33
was reduced after TLR4 and AP‐1 inhibition. Another study demonstrated that HMGB1 could induce IL‐33 expression by binding with
TLR4.<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">(</sup><sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep31812-bib-0052">52</a></sup><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">)</sup>
Our results indicated that the increased IL‐33 expression level induced by HCC lysates was hampered after HMGB1 neutralization. On the basis of these results, we demonstrated that the DAMP
(HMGB1)/TLR4/AP‐1/IL‐33 pathway was critical for HCC survival and proliferation. It also appeared that intratumor hCD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells and their associated
pathways could serve as targets for anticancer treatment. Besides CD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells, other immune‐cell types in the tumor microenvironment all exhibited
significant differential RNA‐sequencing profiles compared with their counterparts in peripheral organs, such as blood and spleen, suggesting that HCC tumors have robust selection and learning capabilities
regarding immune cells, enabling them to escape immune surveillance, which is an interesting avenue for further study of the individual functions of various immune subsets in tumors. However, HCC intracellular
signaling pathways were also significantly impacted by the immune system, as evidenced by the comparison of tumors from mice with and without the human immune system. These changes may contribute to the
evolution of the tumor, selection of mutations, and development of drug resistance. Study of the pool of molecular changes in this model, whereby different conditions could be created by manipulating immune
components, could facilitate enhanced understanding of the complexity of heterogeneity, mutation burden, and drug resistance and may be further developed into potential therapeutic targets. When combining the
discoveries from the angles of the tumor and immune system, our model may subsequently be used to validate the targets and the interfering strategies developed against these targets in single or combined
approaches.</p>
<p id="JCL-P-67">In addition to target identification, this model also demonstrated its usefulness in testing existing anticancer and repurposed drugs without putting patients at risk, particularly in
combination‐therapy settings. A combination therapy that targets HCC and the tumor microenvironment showed a synergistic effect and has been identified as a promising treatment regimen for patients with
HCC.<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">(</sup><sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep31812-bib-0025 hep31812-bib-0026 hep31812-bib-0033">25,26,33</a></sup><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">)</sup>
Recently, the results of a phase III IMbrave150 trial (a combination of atezolizumab [Tecentriq] and bevacizumab [Avastin]) indicated that the therapy could markedly decrease the risk of progression or death in
patients with HCC, compared with treatment with sorafenib
(Nexavar).<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">(</sup><sup><a class="ejp-citation-link js-ejp-citation-link" data-reference-links="hep31812-bib-0026 hep31812-bib-0035">26,35</a></sup><sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">)</sup>
Hence, there is an urgent need to validate existing combination therapies and to explore therapies with the aid of preclinical animal models in HCC‐PDX and HCC microenvironments that are similar to those
encountered in patients with HCC. However, the risk and cost of combining different drugs that possess various toxicity levels have increased significantly. As such, it is difficult and costly to conduct
combinational clinical trials. Our results indicate that monotherapy, dual therapy, and triple therapy could be used to validate the anti‐HCC effects and side effects in humanized mice. Monotherapy, such as the
depletion of hCD14<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells, neutralization of human IL‐33, and the use of C188‐9, bevacizumab, and pembrolizumab, resulted in differential anti‐HCC
effects. Dual therapy using the combination of C188‐9 and pembrolizumab and the combination of bevacizumab and pembrolizumab in humanized mice showed the additive effects compared with the aforementioned
monotherapy. Furthermore, triple therapy using pembrolizumab, bevacizumab, and C188‐9 was evaluated in our HCC, immune system–humanized mouse model and resulted in an improved combinational effect compared with
the monotherapy and dual therapy. This suggested that triple‐targeting of HCC proliferation, angiogenesis, and the immune checkpoint together may offer a combination therapy scheme for HCC treatment. In
conclusion, our HCC humanized‐immune‐system mouse model provides a platform for studying the interaction between the HCC tumor and human immune cells and for testing combination therapy that targets the
molecular features of HCC and the HCC immune‐system microenvironment.</p>
<h2 class="ejp-article-outline-heading" data-level="1" id="hep31812-sec-0016">Authors Contributions</h2>
<p id="JCL-P-68">Y.Z. designed and performed the experiments, analyzed and interpreted data, and prepared the manuscript. J.W., S.Y.F., S.Y.T., J.Y.C., W.W.S.T., and M.L. performed the experiments and analyzed
data; W.N.L., T.W.H.S., S.H., J.K.Y.C., C.E.C., G.H.L., H.C.T., S.G.L., and Y.W. contributed research tools and reagents and prepared the manuscript. Q.C. conceived the study, designed the experiments,
supervised the project, and prepared the manuscript.</p>
</section>
<section id="article-references" class="article-references js-article-references article-references--show">
<h2 class="ejp-article-outline-heading" data-level="1" id="hep31812-sec-0015">Acknowledgment</h2>
<p id="JCL-P-69">We thank the KK Women’s and Children’s Hospital and National University Hospital for provision of human fetal liver/cord blood and HCC tumor samples.</p>
<h2 class="ejp-article-outline-heading" data-level="1" id="hep31812-bibl-0001">References</h2>
<div id="hep31812-bib-0001" class="article-references__item js-article-reference">1. Villanueva A. Hepatocellular carcinoma. N Engl J Med 2019;380:1450‐1462.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-52"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=Hepatocellular+carcinoma&publication_year=2019&author=A+Villanueva" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Hepatocellular+carcinoma&publication_year=2019&author=A+Villanueva');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0002" class="article-references__item js-article-reference">2. Bakiri L, Hamacher R, Graña O, Guío‐Carrión A, Campos‐Olivas R, Martinez L, et al. Liver carcinogenesis by FOS‐dependent
inflammation and cholesterol dysregulation. J Exp Med 2017;214:1387‐1409.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-52"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=Liver+carcinogenesis+by+FOS%e2%80%90dependent+inflammation+and+cholesterol+dysregulation&publication_year=2017&author=L+&author=R+&author=O+Gra%c3%b1a&author=A+Gu%c3%ado%e2%80%90Carri%c3%b3n&author=R+Campos%e2%80%90Olivas&author=L+Martinez" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Liver+carcinogenesis+by+FOS%e2%80%90dependent+inflammation+and+cholesterol+dysregulation&publication_year=2017&author=L+&author=R+&author=O+Gra%c3%b1a&author=A+Gu%c3%ado%e2%80%90Carri%c3%b3n&author=R+Campos%e2%80%90Olivas&author=L+Martinez');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div class="article-references__outer-item--with-shadow">
<div id="hep31812-bib-0003" class="article-references__item js-article-reference">3. Shalapour S, Lin XJ, Bastian IN, Brain J, Burt AD, Aksenov AA, et al. Inflammation‐induced
IgA<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> cells dismantle anti‐liver cancer immunity. Nature 2017;551:340‐345.<div>
<ul class="article-references__item-links article-references__item-links--hide">
<li class="internal-links"><a href="#JCL-P-52"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=Inflammation%e2%80%90induced+IgA+cells+dismantle+anti%e2%80%90liver+cancer+immunity&publication_year=2017&author=S+Shalapour&author=XJ+Lin&author=IN+Bastian&author=J+Brain&author=AD+Burt&author=AA+Aksenov" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Inflammation%e2%80%90induced+IgA+cells+dismantle+anti%e2%80%90liver+cancer+immunity&publication_year=2017&author=S+Shalapour&author=XJ+Lin&author=IN+Bastian&author=J+Brain&author=AD+Burt&author=AA+Aksenov');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
</div>
<div id="hep31812-bib-0004" class="article-references__item js-article-reference article-references__item--hide">4. Todoric J, Antonucci L, Karin M. Targeting inflammation in cancer prevention and therapy. Cancer
Prev Res 2016;9:895‐905.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-52"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=Targeting+inflammation+in+cancer+prevention+and+therapy&publication_year=2016&author=J+&author=L+&author=M+Karin" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Targeting+inflammation+in+cancer+prevention+and+therapy&publication_year=2016&author=J+&author=L+&author=M+Karin');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0005" class="article-references__item js-article-reference article-references__item--hide">5. Huang W, Chen Z, Zhang L, Tian D, Wang D, Fan D, et al. Interleukin‐8 induces expression of
FOXC1 to promote transactivation of CXCR1 and CCL2 in hepatocellular carcinoma cell lines and formation of metastases in mice. Gastroenterology 2015;149:1053‐1067, e14.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-52"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=Interleukin%e2%80%908+induces+expression+of+FOXC1+to+promote+transactivation+of+CXCR1+and+CCL2+in+hepatocellular+carcinoma+cell+lines+and+formation+of+metastases+in+mice&publication_year=2015&author=W+Huang&author=Z+Chen&author=L+Zhang&author=D+Tian&author=D+Wang&author=D+Fan" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Interleukin%e2%80%908+induces+expression+of+FOXC1+to+promote+transactivation+of+CXCR1+and+CCL2+in+hepatocellular+carcinoma+cell+lines+and+formation+of+metastases+in+mice&publication_year=2015&author=W+Huang&author=Z+Chen&author=L+Zhang&author=D+Tian&author=D+Wang&author=D+Fan');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0006" class="article-references__item js-article-reference article-references__item--hide">6. Wan S, Zhao E, Kryczek I, Vatan L, Sadovskaya A, Ludema G, et al. Tumor‐associated macrophages
produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells. Gastroenterology 2014;147:1393‐1404.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-52"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=Tumor%e2%80%90associated+macrophages+produce+interleukin+6+and+signal+via+STAT3+to+promote+expansion+of+human+hepatocellular+carcinoma+stem+cells&publication_year=2014&author=S+Wan&author=E+Zhao&author=I+Kryczek&author=L+Vatan&author=A+Sadovskaya&author=G+Ludema" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Tumor%e2%80%90associated+macrophages+produce+interleukin+6+and+signal+via+STAT3+to+promote+expansion+of+human+hepatocellular+carcinoma+stem+cells&publication_year=2014&author=S+Wan&author=E+Zhao&author=I+Kryczek&author=L+Vatan&author=A+Sadovskaya&author=G+Ludema');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0007" class="article-references__item js-article-reference article-references__item--hide">7. Ma S, Cheng Q, Cai Y, Gong H, Wu Y, Yu X, et al. IL‐17A produced by gammadelta T cells promotes
tumor growth in hepatocellular carcinoma. Cancer Res 2014;74:1969‐1982.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-52"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=IL%e2%80%9017A+produced+by+gammadelta+T+cells+promotes+tumor+growth+in+hepatocellular+carcinoma&publication_year=2014&author=S+Ma&author=Q+Cheng&author=Y+Cai&author=H+Gong&author=Y+Wu&author=X+Yu" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=IL%e2%80%9017A+produced+by+gammadelta+T+cells+promotes+tumor+growth+in+hepatocellular+carcinoma&publication_year=2014&author=S+Ma&author=Q+Cheng&author=Y+Cai&author=H+Gong&author=Y+Wu&author=X+Yu');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0008" class="article-references__item js-article-reference article-references__item--hide">8. Shao Y, Lo CM, Ling CC, Liu XB, Ng K‐P, Chu ACY, et al. Regulatory B cells accelerate
hepatocellular carcinoma progression via CD40/CD154 signaling pathway. Cancer Lett 2014;355:264‐272.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-52"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=Regulatory+B+cells+accelerate+hepatocellular+carcinoma+progression+via+CD40%2fCD154+signaling+pathway&publication_year=2014&author=Y+Shao&author=CM+Lo&author=CC+Ling&author=XB+Liu&author=K%e2%80%90P+Ng&author=ACY+Chu" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Regulatory+B+cells+accelerate+hepatocellular+carcinoma+progression+via+CD40%2fCD154+signaling+pathway&publication_year=2014&author=Y+Shao&author=CM+Lo&author=CC+Ling&author=XB+Liu&author=K%e2%80%90P+Ng&author=ACY+Chu');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0009" class="article-references__item js-article-reference article-references__item--hide">9. Ghanem I, Riveiro ME, Paradis V, Faivre S, de Parga PM, Raymond E. Insights on the CXCL12‐CXCR4
axis in hepatocellular carcinoma carcinogenesis. Am J Transl Res 2014;6:340‐352.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-53"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=Insights+on+the+CXCL12%e2%80%90CXCR4+axis+in+hepatocellular+carcinoma+carcinogenesis&publication_year=2014&author=I+Ghanem&author=ME+Riveiro&author=V+Paradis&author=S+Faivre&author=PM+de+Parga&author=E+Raymond" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Insights+on+the+CXCL12%e2%80%90CXCR4+axis+in+hepatocellular+carcinoma+carcinogenesis&publication_year=2014&author=I+Ghanem&author=ME+Riveiro&author=V+Paradis&author=S+Faivre&author=PM+de+Parga&author=E+Raymond');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0010" class="article-references__item js-article-reference article-references__item--hide">10. Wiedemann GM, Rohrle N, Makeschin MC, Fesseler J, Endres S, Mayr D, et al. Peritumoural CCL1
and CCL22 expressing cells in hepatocellular carcinomas shape the tumour immune infiltrate. Pathology 2019;51:586‐592.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-53"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=Peritumoural+CCL1+and+CCL22+expressing+cells+in+hepatocellular+carcinomas+shape+the+tumour+immune+infiltrate&publication_year=2019&author=GM+Wiedemann&author=N+Rohrle&author=MC+Makeschin&author=J+Fesseler&author=S+Endres&author=D+Mayr" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Peritumoural+CCL1+and+CCL22+expressing+cells+in+hepatocellular+carcinomas+shape+the+tumour+immune+infiltrate&publication_year=2019&author=GM+Wiedemann&author=N+Rohrle&author=MC+Makeschin&author=J+Fesseler&author=S+Endres&author=D+Mayr');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0011" class="article-references__item js-article-reference article-references__item--hide">11. Chew V, Lee YH, Pan LU, Nasir NJM, Lim CJ, Chua C, et al. Immune activation underlies a
sustained clinical response to Yttrium‐90 radioembolisation in hepatocellular carcinoma. Gut 2019;68:335‐346.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-53"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=Immune+activation+underlies+a+sustained+clinical+response+to+Yttrium%e2%80%9090+radioembolisation+in+hepatocellular+carcinoma&publication_year=2019&author=V+Chew&author=YH+Lee&author=LU+Pan&author=NJM+Nasir&author=CJ+Lim&author=C+Chua" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Immune+activation+underlies+a+sustained+clinical+response+to+Yttrium%e2%80%9090+radioembolisation+in+hepatocellular+carcinoma&publication_year=2019&author=V+Chew&author=YH+Lee&author=LU+Pan&author=NJM+Nasir&author=CJ+Lim&author=C+Chua');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0012" class="article-references__item js-article-reference article-references__item--hide">12. Chew V, Chen J, Lee D, Loh E, Lee J, Lim KH, et al. Chemokine‐driven lymphocyte infiltration:
an early intratumoural event determining long‐term survival in resectable hepatocellular carcinoma. Gut 2012;61:427‐438.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-53"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=Chemokine%e2%80%90driven+lymphocyte+infiltration%3a+an+early+intratumoural+event+determining+long%e2%80%90term+survival+in+resectable+hepatocellular+carcinoma&publication_year=2012&author=V+Chew&author=J+Chen&author=D+Lee&author=E+Loh&author=J+Lee&author=KH+Lim" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Chemokine%e2%80%90driven+lymphocyte+infiltration%3a+an+early+intratumoural+event+determining+long%e2%80%90term+survival+in+resectable+hepatocellular+carcinoma&publication_year=2012&author=V+Chew&author=J+Chen&author=D+Lee&author=E+Loh&author=J+Lee&author=KH+Lim');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0013" class="article-references__item js-article-reference article-references__item--hide">13. Liang CM, Chen L, Hu H, Ma HY, Gao LL, Qin J, et al. Chemokines and their receptors play
important roles in the development of hepatocellular carcinoma. World J Hepatol 2015;7:1390‐1402.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-53"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=Chemokines+and+their+receptors+play+important+roles+in+the+development+of+hepatocellular+carcinoma&publication_year=2015&author=CM+Liang&author=L+Chen&author=H+Hu&author=HY+Ma&author=LL+Gao&author=J+Qin" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Chemokines+and+their+receptors+play+important+roles+in+the+development+of+hepatocellular+carcinoma&publication_year=2015&author=CM+Liang&author=L+Chen&author=H+Hu&author=HY+Ma&author=LL+Gao&author=J+Qin');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0014" class="article-references__item js-article-reference article-references__item--hide">14. Sachdeva M, Chawla YK, Arora SK. Immunology of hepatocellular carcinoma. World J Hepatol
2015;7:2080‐2090.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-53"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=Immunology+of+hepatocellular+carcinoma&publication_year=2015&author=M+Sachdeva&author=YK+Chawla&author=SK+Arora" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Immunology+of+hepatocellular+carcinoma&publication_year=2015&author=M+Sachdeva&author=YK+Chawla&author=SK+Arora');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0015" class="article-references__item js-article-reference article-references__item--hide">15. Flores‐Borja F, Irshad S, Gordon P, Wong F, Sheriff I, Tutt A, et al. Crosstalk between innate
lymphoid cells and other immune cells in the tumor microenvironment. J Immunol Res 2016;2016:7803091.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-53"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=Crosstalk+between+innate+lymphoid+cells+and+other+immune+cells+in+the+tumor+microenvironment&publication_year=2016&author=F+Flores%e2%80%90Borja&author=S+Irshad&author=P+Gordon&author=F+Wong&author=I+Sheriff&author=A+Tutt" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Crosstalk+between+innate+lymphoid+cells+and+other+immune+cells+in+the+tumor+microenvironment&publication_year=2016&author=F+Flores%e2%80%90Borja&author=S+Irshad&author=P+Gordon&author=F+Wong&author=I+Sheriff&author=A+Tutt');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0016" class="article-references__item js-article-reference article-references__item--hide">16. Shi C, Chen Y, Chen Y, Yang Y, Bing W, Qi J.
CD4<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> CD25<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> regulatory T cells promote hepatocellular carcinoma invasion via
TGF‐beta1‐induced epithelial‐mesenchymal transition. Onco Targets Ther 2019;12:279‐289.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-53"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=CD4+CD25+regulatory+T+cells+promote+hepatocellular+carcinoma+invasion+via+TGF%e2%80%90beta1%e2%80%90induced+epithelial%e2%80%90mesenchymal+transition&publication_year=2019&author=C+Shi&author=Y+Chen&author=Y+Chen&author=Y+Yang&author=W+Bing&author=J+Qi" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=CD4+CD25+regulatory+T+cells+promote+hepatocellular+carcinoma+invasion+via+TGF%e2%80%90beta1%e2%80%90induced+epithelial%e2%80%90mesenchymal+transition&publication_year=2019&author=C+Shi&author=Y+Chen&author=Y+Chen&author=Y+Yang&author=W+Bing&author=J+Qi');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0017" class="article-references__item js-article-reference article-references__item--hide">17. Zhou SL, Yin D, Hu ZQ, Luo CB, Zhou ZJ, Xin HY, et al. A Positive feedback loop between cancer
stem‐like cells and tumor‐associated neutrophils controls hepatocellular carcinoma progression. Hepatology 2019;70:1214‐1230.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-53"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=A+Positive+feedback+loop+between+cancer+stem%e2%80%90like+cells+and+tumor%e2%80%90associated+neutrophils+controls+hepatocellular+carcinoma+progression&publication_year=2019&author=SL+&author=D+&author=ZQ+&author=CB+&author=ZJ+&author=HY+Xin" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=A+Positive+feedback+loop+between+cancer+stem%e2%80%90like+cells+and+tumor%e2%80%90associated+neutrophils+controls+hepatocellular+carcinoma+progression&publication_year=2019&author=SL+&author=D+&author=ZQ+&author=CB+&author=ZJ+&author=HY+Xin');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0018" class="article-references__item js-article-reference article-references__item--hide">18. Budhu A, Wang XW. The role of cytokines in hepatocellular carcinoma. J Leukoc Biol
2006;80:1197‐1213.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-53"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=The+role+of+cytokines+in+hepatocellular+carcinoma&publication_year=2006&author=A+Budhu&author=XW+Wang" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=The+role+of+cytokines+in+hepatocellular+carcinoma&publication_year=2006&author=A+Budhu&author=XW+Wang');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0019" class="article-references__item js-article-reference article-references__item--hide">19. Wang X, Ding J, Feng Y, Weng L, Zhao G, Xiang J, et al. Targeting of growth factors in the
treatment of hepatocellular carcinoma: the potentials of polysaccharides. Oncol Lett 2017;13:1509‐1517.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-53"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=Targeting+of+growth+factors+in+the+treatment+of+hepatocellular+carcinoma%3a+the+potentials+of+polysaccharides&publication_year=2017&author=X+Wang&author=J+Ding&author=Y+Feng&author=L+Weng&author=G+Zhao&author=J+Xiang" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Targeting+of+growth+factors+in+the+treatment+of+hepatocellular+carcinoma%3a+the+potentials+of+polysaccharides&publication_year=2017&author=X+Wang&author=J+Ding&author=Y+Feng&author=L+Weng&author=G+Zhao&author=J+Xiang');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0020" class="article-references__item js-article-reference article-references__item--hide">20. Chen R, Cui J, Xu C, Xue T, Guo K, Gao D, et al. The significance of MMP‐9 over MMP‐2 in HCC
invasiveness and recurrence of hepatocellular carcinoma after curative resection. Ann Surg Oncol 2012;19(Suppl. 3):S375‐S384.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-53"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=The+significance+of+MMP%e2%80%909+over+MMP%e2%80%902+in+HCC+invasiveness+and+recurrence+of+hepatocellular+carcinoma+after+curative+resection&publication_year=2012&author=R+&author=J+&author=C+Xu&author=T+Xue&author=K+Guo&author=D+Gao" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=The+significance+of+MMP%e2%80%909+over+MMP%e2%80%902+in+HCC+invasiveness+and+recurrence+of+hepatocellular+carcinoma+after+curative+resection&publication_year=2012&author=R+&author=J+&author=C+Xu&author=T+Xue&author=K+Guo&author=D+Gao');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0021" class="article-references__item js-article-reference article-references__item--hide">21. Giannelli G, Bergamini C, Marinosci F, Fransvea E, Quaranta M, Lupo L, et al. Clinical role of
MMP‐2/TIMP‐2 imbalance in hepatocellular carcinoma. Int J Cancer 2002;97:425‐431.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-53"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=Clinical+role+of+MMP%e2%80%902%2fTIMP%e2%80%902+imbalance+in+hepatocellular+carcinoma&publication_year=2002&author=G+Giannelli&author=C+Bergamini&author=F+Marinosci&author=E+Fransvea&author=M+Quaranta&author=L+Lupo" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Clinical+role+of+MMP%e2%80%902%2fTIMP%e2%80%902+imbalance+in+hepatocellular+carcinoma&publication_year=2002&author=G+Giannelli&author=C+Bergamini&author=F+Marinosci&author=E+Fransvea&author=M+Quaranta&author=L+Lupo');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0022" class="article-references__item js-article-reference article-references__item--hide">22. Fu XT, Dai Z, Song K, Zhang ZJ, Zhou ZJ, Zhou SL, et al. Macrophage‐secreted IL‐8 induces
epithelial–mesenchymal transition in hepatocellular carcinoma cells by activating the JAK2/STAT3/Snail pathway. Int J Oncol 2015;46:587‐596.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-53"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=Macrophage%e2%80%90secreted+IL%e2%80%908+induces+epithelial%e2%80%93mesenchymal+transition+in+hepatocellular+carcinoma+cells+by+activating+the+JAK2%2fSTAT3%2fSnail+pathway&publication_year=2015&author=XT+&author=Z+&author=K+&author=ZJ+Zhang&author=ZJ+Zhou&author=SL+Zhou" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Macrophage%e2%80%90secreted+IL%e2%80%908+induces+epithelial%e2%80%93mesenchymal+transition+in+hepatocellular+carcinoma+cells+by+activating+the+JAK2%2fSTAT3%2fSnail+pathway&publication_year=2015&author=XT+&author=Z+&author=K+&author=ZJ+Zhang&author=ZJ+Zhou&author=SL+Zhou');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0023" class="article-references__item js-article-reference article-references__item--hide">23. Kong L, Zhou Y, Bu H, Lv T, Shi Y, Yang J. Deletion of interleukin‐6 in monocytes/macrophages
suppresses the initiation of hepatocellular carcinoma in mice. J Exp Clin Cancer Res 2016;35:131.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-53"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=Deletion+of+interleukin%e2%80%906+in+monocytes%2fmacrophages+suppresses+the+initiation+of+hepatocellular+carcinoma+in+mice&publication_year=2016&author=L+Kong&author=Y+Zhou&author=H+Bu&author=T+Lv&author=Y+Shi&author=J+Yang" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Deletion+of+interleukin%e2%80%906+in+monocytes%2fmacrophages+suppresses+the+initiation+of+hepatocellular+carcinoma+in+mice&publication_year=2016&author=L+Kong&author=Y+Zhou&author=H+Bu&author=T+Lv&author=Y+Shi&author=J+Yang');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0024" class="article-references__item js-article-reference article-references__item--hide">24. Trikha P, Carson WE III. Signaling pathways involved in MDSC regulation. Biochim Biophys Acta
2014;1846:55‐65.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-53"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=Signaling+pathways+involved+in+MDSC+regulation&publication_year=2014&author=P+&author=WE+" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Signaling+pathways+involved+in+MDSC+regulation&publication_year=2014&author=P+&author=WE+');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0025" class="article-references__item js-article-reference article-references__item--hide">25. Stotz M, Gerger A, Haybaeck J, Kiesslich T, Bullock MD, Pichler M. Molecular targeted therapies
in hepatocellular carcinoma: past, present and future. Anticancer Res 2015;35:5737‐5744.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-54"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=Molecular+targeted+therapies+in+hepatocellular+carcinoma%3a+past%2c+present+and+future&publication_year=2015&author=M+Stotz&author=A+Gerger&author=J+Haybaeck&author=T+Kiesslich&author=MD+Bullock&author=M+Pichler" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Molecular+targeted+therapies+in+hepatocellular+carcinoma%3a+past%2c+present+and+future&publication_year=2015&author=M+Stotz&author=A+Gerger&author=J+Haybaeck&author=T+Kiesslich&author=MD+Bullock&author=M+Pichler');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0026" class="article-references__item js-article-reference article-references__item--hide">26. Kudo M. Targeted and immune therapies for hepatocellular carcinoma: predictions for 2019 and
beyond. World J Gastroenterol 2019;25:789‐807.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-54"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=Targeted+and+immune+therapies+for+hepatocellular+carcinoma%3a+predictions+for+2019+and+beyond&publication_year=2019&author=M+Kudo" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Targeted+and+immune+therapies+for+hepatocellular+carcinoma%3a+predictions+for+2019+and+beyond&publication_year=2019&author=M+Kudo');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0027" class="article-references__item js-article-reference article-references__item--hide">27. Bergmann J, Müller M, Baumann N, Reichert M, Heneweer C, Bolik J, et al. IL‐6 trans‐signaling
is essential for the development of hepatocellular carcinoma in mice. Hepatology 2017;65:89‐103.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-54"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=IL%e2%80%906+trans%e2%80%90signaling+is+essential+for+the+development+of+hepatocellular+carcinoma+in+mice&publication_year=2017&author=J+&author=M+&author=N+&author=M+&author=C+Heneweer&author=J+Bolik" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=IL%e2%80%906+trans%e2%80%90signaling+is+essential+for+the+development+of+hepatocellular+carcinoma+in+mice&publication_year=2017&author=J+&author=M+&author=N+&author=M+&author=C+Heneweer&author=J+Bolik');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0028" class="article-references__item js-article-reference article-references__item--hide">28. Shakiba E, Ramezani M, Sadeghi M. Evaluation of serum interleukin‐6 levels in hepatocellular
carcinoma patients: a systematic review and meta‐analysis. Clin Exp Hepatol 2018;4:182‐190.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-54"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=Evaluation+of+serum+interleukin%e2%80%906+levels+in+hepatocellular+carcinoma+patients%3a+a+systematic+review+and+meta%e2%80%90analysis&publication_year=2018&author=E+Shakiba&author=M+Ramezani&author=M+Sadeghi" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Evaluation+of+serum+interleukin%e2%80%906+levels+in+hepatocellular+carcinoma+patients%3a+a+systematic+review+and+meta%e2%80%90analysis&publication_year=2018&author=E+Shakiba&author=M+Ramezani&author=M+Sadeghi');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0029" class="article-references__item js-article-reference article-references__item--hide">29. Jung KH, Yoo W, Stevenson HL, Deshpande D, Shen H, Gagea M, et al. Multifunctional effects of a
small‐molecule STAT3 inhibitor on NASH and hepatocellular carcinoma in mice. Clin Cancer Res 2017;23:5537‐5546.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-54"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=Multifunctional+effects+of+a+small%e2%80%90molecule+STAT3+inhibitor+on+NASH+and+hepatocellular+carcinoma+in+mice&publication_year=2017&author=KH+&author=W+&author=HL+Stevenson&author=D+Deshpande&author=H+Shen&author=M+Gagea" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Multifunctional+effects+of+a+small%e2%80%90molecule+STAT3+inhibitor+on+NASH+and+hepatocellular+carcinoma+in+mice&publication_year=2017&author=KH+&author=W+&author=HL+Stevenson&author=D+Deshpande&author=H+Shen&author=M+Gagea');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0030" class="article-references__item js-article-reference article-references__item--hide">30. Siegel AB, Cohen EI, Ocean A, Lehrer D, Goldenberg A, Knox JJ, et al. Phase II trial evaluating
the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008;26:2992‐2998.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-55"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=Phase+II+trial+evaluating+the+clinical+and+biologic+effects+of+bevacizumab+in+unresectable+hepatocellular+carcinoma&publication_year=2008&author=AB+Siegel&author=EI+Cohen&author=A+Ocean&author=D+Lehrer&author=A+Goldenberg&author=JJ+Knox" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Phase+II+trial+evaluating+the+clinical+and+biologic+effects+of+bevacizumab+in+unresectable+hepatocellular+carcinoma&publication_year=2008&author=AB+Siegel&author=EI+Cohen&author=A+Ocean&author=D+Lehrer&author=A+Goldenberg&author=JJ+Knox');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0031" class="article-references__item js-article-reference article-references__item--hide">31. Fang P, Hu JH, Cheng ZG, Liu ZF, Wang JL, Jiao SC. Efficacy and safety of bevacizumab for the
treatment of advanced hepatocellular carcinoma: a systematic review of phase II trials. PLoS One 2012;7:e49717.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-55"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+bevacizumab+for+the+treatment+of+advanced+hepatocellular+carcinoma%3a+a+systematic+review+of+phase+II+trials&publication_year=2012&author=P+Fang&author=JH+Hu&author=ZG+Cheng&author=ZF+Liu&author=JL+Wang&author=SC+Jiao" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+bevacizumab+for+the+treatment+of+advanced+hepatocellular+carcinoma%3a+a+systematic+review+of+phase+II+trials&publication_year=2012&author=P+Fang&author=JH+Hu&author=ZG+Cheng&author=ZF+Liu&author=JL+Wang&author=SC+Jiao');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0032" class="article-references__item js-article-reference article-references__item--hide">32. Scheiner B, Kirstein MM, Hucke F, Finkelmeier F, Schulze K, von Felden J, et al. Programmed
cell death protein‐1 (PD‐1)‐targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real‐world cohort. Aliment Pharmacol Ther 2019;49:1323‐1333.
<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-55"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=Programmed+cell+death+protein%e2%80%901+(PD%e2%80%901)%e2%80%90targeted+immunotherapy+in+advanced+hepatocellular+carcinoma%3a+efficacy+and+safety+data+from+an+international+multicentre+real%e2%80%90world+cohort&publication_year=2019&author=B+&author=MM+&author=F+Hucke&author=F+Finkelmeier&author=K+Schulze&author=J+von+Felden" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Programmed+cell+death+protein%e2%80%901+(PD%e2%80%901)%e2%80%90targeted+immunotherapy+in+advanced+hepatocellular+carcinoma%3a+efficacy+and+safety+data+from+an+international+multicentre+real%e2%80%90world+cohort&publication_year=2019&author=B+&author=MM+&author=F+Hucke&author=F+Finkelmeier&author=K+Schulze&author=J+von+Felden');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0033" class="article-references__item js-article-reference article-references__item--hide">33. Pinter M, Peck‐Radosavljevic M. Review article: systemic treatment of hepatocellular carcinoma.
Aliment Pharmacol Ther 2018;48:598‐609.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-55"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=Review+article%3a+systemic+treatment+of+hepatocellular+carcinoma&publication_year=2018&author=M+Pinter&author=M+Peck%e2%80%90Radosavljevic" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Review+article%3a+systemic+treatment+of+hepatocellular+carcinoma&publication_year=2018&author=M+Pinter&author=M+Peck%e2%80%90Radosavljevic');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0034" class="article-references__item js-article-reference article-references__item--hide">34. Liu H, Shen J, Lu K. IL‐6 and PD‐L1 blockade combination inhibits hepatocellular carcinoma
cancer development in mouse model. Biochem Biophys Res Commun 2017;486:239‐244.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-55"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=IL%e2%80%906+and+PD%e2%80%90L1+blockade+combination+inhibits+hepatocellular+carcinoma+cancer+development+in+mouse+model&publication_year=2017&author=H+&author=J+&author=K+Lu" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=IL%e2%80%906+and+PD%e2%80%90L1+blockade+combination+inhibits+hepatocellular+carcinoma+cancer+development+in+mouse+model&publication_year=2017&author=H+&author=J+&author=K+Lu');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0035" class="article-references__item js-article-reference article-references__item--hide">35. Medavaram S, Zhang Y. Emerging therapies in advanced hepatocellular carcinoma. Exp Hematol
Oncol 2018;7:17.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-55"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=Emerging+therapies+in+advanced+hepatocellular+carcinoma&publication_year=2018&author=S+Medavaram&author=Y+Zhang" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Emerging+therapies+in+advanced+hepatocellular+carcinoma&publication_year=2018&author=S+Medavaram&author=Y+Zhang');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0036" class="article-references__item js-article-reference article-references__item--hide">36. Eichten A, Su J, Adler AP, Zhang LI, Ioffe E, Parveen AA, et al. Resistance to anti‐VEGF
therapy mediated by autocrine IL6/STAT3 signaling and overcome by IL6 blockade. Cancer Res 2016;76:2327‐2339.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-55"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=Resistance+to+anti%e2%80%90VEGF+therapy+mediated+by+autocrine+IL6%2fSTAT3+signaling+and+overcome+by+IL6+blockade&publication_year=2016&author=A+&author=J+&author=AP+&author=LI+&author=E+Ioffe&author=AA+Parveen" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Resistance+to+anti%e2%80%90VEGF+therapy+mediated+by+autocrine+IL6%2fSTAT3+signaling+and+overcome+by+IL6+blockade&publication_year=2016&author=A+&author=J+&author=AP+&author=LI+&author=E+Ioffe&author=AA+Parveen');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0037" class="article-references__item js-article-reference article-references__item--hide">37. Zhao Y, Shuen TWH, Toh TB, Chan XY, Liu M, Tan SY, et al. Development of a new patient‐derived
xenograft humanised mouse model to study human‐specific tumour microenvironment and immunotherapy. Gut 2018;67:1845‐1854.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-56"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=Development+of+a+new+patient%e2%80%90derived+xenograft+humanised+mouse+model+to+study+human%e2%80%90specific+tumour+microenvironment+and+immunotherapy&publication_year=2018&author=Y+Zhao&author=TWH+Shuen&author=TB+Toh&author=XY+Chan&author=M+Liu&author=SY+Tan" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Development+of+a+new+patient%e2%80%90derived+xenograft+humanised+mouse+model+to+study+human%e2%80%90specific+tumour+microenvironment+and+immunotherapy&publication_year=2018&author=Y+Zhao&author=TWH+Shuen&author=TB+Toh&author=XY+Chan&author=M+Liu&author=SY+Tan');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0038" class="article-references__item js-article-reference article-references__item--hide">38. Zhao Y, Liu M, Chan XY, Tan SY, Subramaniam S, Fan Y, et al. Uncovering the mystery of opposite
circadian rhythms between mouse and human leukocytes in humanized mice. Blood 2017;130:1995‐2005.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-57"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=Uncovering+the+mystery+of+opposite+circadian+rhythms+between+mouse+and+human+leukocytes+in+humanized+mice&publication_year=2017&author=Y+Zhao&author=M+Liu&author=XY+Chan&author=SY+Tan&author=S+Subramaniam&author=Y+Fan" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Uncovering+the+mystery+of+opposite+circadian+rhythms+between+mouse+and+human+leukocytes+in+humanized+mice&publication_year=2017&author=Y+Zhao&author=M+Liu&author=XY+Chan&author=SY+Tan&author=S+Subramaniam&author=Y+Fan');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0039" class="article-references__item js-article-reference article-references__item--hide">39. Zhang P, Liu XK, Chu Z, Ye JC, Li KL, Zhuang WL, et al. Detection of interleukin‐33 in serum
and carcinoma tissue from patients with hepatocellular carcinoma and its clinical implications. J Int Med Res 2012;40:1654‐1661.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-61"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=Detection+of+interleukin%e2%80%9033+in+serum+and+carcinoma+tissue+from+patients+with+hepatocellular+carcinoma+and+its+clinical+implications&publication_year=2012&author=P+&author=XK+&author=Z+Chu&author=JC+Ye&author=KL+Li&author=WL+Zhuang" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Detection+of+interleukin%e2%80%9033+in+serum+and+carcinoma+tissue+from+patients+with+hepatocellular+carcinoma+and+its+clinical+implications&publication_year=2012&author=P+&author=XK+&author=Z+Chu&author=JC+Ye&author=KL+Li&author=WL+Zhuang');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0040" class="article-references__item js-article-reference article-references__item--hide">40. Makarova‐Rusher OV, Medina‐Echeverz J, Duffy AG, Greten TF. The yin and yang of evasion and
immune activation in HCC. J Hepatol 2015;62:1420‐1429.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-65"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=The+yin+and+yang+of+evasion+and+immune+activation+in+HCC&publication_year=2015&author=OV+Makarova%e2%80%90Rusher&author=J+Medina%e2%80%90Echeverz&author=AG+Duffy&author=TF+Greten" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=The+yin+and+yang+of+evasion+and+immune+activation+in+HCC&publication_year=2015&author=OV+Makarova%e2%80%90Rusher&author=J+Medina%e2%80%90Echeverz&author=AG+Duffy&author=TF+Greten');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0041" class="article-references__item js-article-reference article-references__item--hide">41. Chen Y, Hao X, Sun R, Wei H, Tian Z. Natural killer cell‐derived interferon‐gamma promotes
hepatocellular carcinoma through the epithelial cell adhesion molecule‐epithelial‐to‐mesenchymal transition axis in hepatitis B virus transgenic mice. Hepatology 2019;69:1735‐1750.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-65"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=Natural+killer+cell%e2%80%90derived+interferon%e2%80%90gamma+promotes+hepatocellular+carcinoma+through+the+epithelial+cell+adhesion+molecule%e2%80%90epithelial%e2%80%90to%e2%80%90mesenchymal+transition+axis+in+hepatitis+B+virus+transgenic+mice&publication_year=2019&author=Y+Chen&author=X+Hao&author=R+Sun&author=H+Wei&author=Z+Tian" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Natural+killer+cell%e2%80%90derived+interferon%e2%80%90gamma+promotes+hepatocellular+carcinoma+through+the+epithelial+cell+adhesion+molecule%e2%80%90epithelial%e2%80%90to%e2%80%90mesenchymal+transition+axis+in+hepatitis+B+virus+transgenic+mice&publication_year=2019&author=Y+Chen&author=X+Hao&author=R+Sun&author=H+Wei&author=Z+Tian');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0042" class="article-references__item js-article-reference article-references__item--hide">42. Disis ML. Immune regulation of cancer. J Clin Oncol 2010;28:4531‐4538.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-65"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=Immune+regulation+of+cancer&publication_year=2010&author=ML+Disis" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Immune+regulation+of+cancer&publication_year=2010&author=ML+Disis');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0043" class="article-references__item js-article-reference article-references__item--hide">43. Capece D, Fischietti M, Verzella D, Gaggiano A, Cicciarelli G, Tessitore A, et al. The
inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor‐associated macrophages. Biomed Res Int 2013;2013:187204.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-65"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=The+inflammatory+microenvironment+in+hepatocellular+carcinoma%3a+a+pivotal+role+for+tumor%e2%80%90associated+macrophages&publication_year=2013&author=D+Capece&author=M+Fischietti&author=D+Verzella&author=A+Gaggiano&author=G+Cicciarelli&author=A+Tessitore" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=The+inflammatory+microenvironment+in+hepatocellular+carcinoma%3a+a+pivotal+role+for+tumor%e2%80%90associated+macrophages&publication_year=2013&author=D+Capece&author=M+Fischietti&author=D+Verzella&author=A+Gaggiano&author=G+Cicciarelli&author=A+Tessitore');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0044" class="article-references__item js-article-reference article-references__item--hide">44. Nikolaou K, Sarris M, Talianidis I. Molecular pathways: the complex roles of inflammation
pathways in the development and treatment of liver cancer. Clin Cancer Res 2013;19:2810‐2816.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-65"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=Molecular+pathways%3a+the+complex+roles+of+inflammation+pathways+in+the+development+and+treatment+of+liver+cancer&publication_year=2013&author=K+Nikolaou&author=M+Sarris&author=I+Talianidis" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Molecular+pathways%3a+the+complex+roles+of+inflammation+pathways+in+the+development+and+treatment+of+liver+cancer&publication_year=2013&author=K+Nikolaou&author=M+Sarris&author=I+Talianidis');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0045" class="article-references__item js-article-reference article-references__item--hide">45. Garnelo M, Tan A, Her Z, Yeong J, Lim CJ, Chen J, et al. Interaction between
tumour‐infiltrating B cells and T cells controls the progression of hepatocellular carcinoma. Gut 2017;66:342‐351.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-66"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=Interaction+between+tumour%e2%80%90infiltrating+B+cells+and+T+cells+controls+the+progression+of+hepatocellular+carcinoma&publication_year=2017&author=M+&author=A+&author=Z+Her&author=J+Yeong&author=CJ+Lim&author=J+Chen" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Interaction+between+tumour%e2%80%90infiltrating+B+cells+and+T+cells+controls+the+progression+of+hepatocellular+carcinoma&publication_year=2017&author=M+&author=A+&author=Z+Her&author=J+Yeong&author=CJ+Lim&author=J+Chen');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0046" class="article-references__item js-article-reference article-references__item--hide">46. Ma C, Kesarwala AH, Eggert T, Medina‐Echeverz J, Kleiner DE, Jin P, et al. NAFLD causes
selective CD4<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> T lymphocyte loss and promotes hepatocarcinogenesis. Nature 2016;531:253‐257.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-66"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=NAFLD+causes+selective+CD4+T+lymphocyte+loss+and+promotes+hepatocarcinogenesis&publication_year=2016&author=C+Ma&author=AH+Kesarwala&author=T+Eggert&author=J+Medina%e2%80%90Echeverz&author=DE+Kleiner&author=P+Jin" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=NAFLD+causes+selective+CD4+T+lymphocyte+loss+and+promotes+hepatocarcinogenesis&publication_year=2016&author=C+Ma&author=AH+Kesarwala&author=T+Eggert&author=J+Medina%e2%80%90Echeverz&author=DE+Kleiner&author=P+Jin');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0047" class="article-references__item js-article-reference article-references__item--hide">47. Endig J, Buitrago‐Molina LE, Marhenke S, Reisinger F, Saborowski A, Schütt J, et al. Dual role
of the adaptive immune system in liver injury and hepatocellular carcinoma development. Cancer Cell 2016;30:308‐323.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-66"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=Dual+role+of+the+adaptive+immune+system+in+liver+injury+and+hepatocellular+carcinoma+development&publication_year=2016&author=J+&author=LE+&author=S+&author=F+Reisinger&author=A+Saborowski&author=J+Sch%c3%bctt" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Dual+role+of+the+adaptive+immune+system+in+liver+injury+and+hepatocellular+carcinoma+development&publication_year=2016&author=J+&author=LE+&author=S+&author=F+Reisinger&author=A+Saborowski&author=J+Sch%c3%bctt');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0048" class="article-references__item js-article-reference article-references__item--hide">48. He H, Wu J, Zang M, Wang W, Chang X, Chen X, et al.
CCR6<sup xmlns:mrws="http://webservices.ovid.com/mrws/1.0">+</sup> B lymphocytes responding to tumor cell‐derived CCL20 support hepatocellular carcinoma progression via enhancing angiogenesis. Am J Cancer Res
2017;7:1151‐1163.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-66"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=CCR6+B+lymphocytes+responding+to+tumor+cell%e2%80%90derived+CCL20+support+hepatocellular+carcinoma+progression+via+enhancing+angiogenesis&publication_year=2017&author=H+&author=J+&author=M+&author=W+&author=X+Chang&author=X+Chen" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=CCR6+B+lymphocytes+responding+to+tumor+cell%e2%80%90derived+CCL20+support+hepatocellular+carcinoma+progression+via+enhancing+angiogenesis&publication_year=2017&author=H+&author=J+&author=M+&author=W+&author=X+Chang&author=X+Chen');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0049" class="article-references__item js-article-reference article-references__item--hide">49. Gerber HP, Wu X, Yu L, Wiesmann C, Liang XH, Lee CV, et al. Mice expressing a humanized form of
VEGF‐A may provide insights into the safety and efficacy of anti‐VEGF antibodies. Proc Natl Acad Sci U S A 2007;104:3478‐3483.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-66"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=Mice+expressing+a+humanized+form+of+VEGF%e2%80%90A+may+provide+insights+into+the+safety+and+efficacy+of+anti%e2%80%90VEGF+antibodies&publication_year=2007&author=HP+Gerber&author=X+Wu&author=L+Yu&author=C+Wiesmann&author=XH+Liang&author=CV+Lee" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Mice+expressing+a+humanized+form+of+VEGF%e2%80%90A+may+provide+insights+into+the+safety+and+efficacy+of+anti%e2%80%90VEGF+antibodies&publication_year=2007&author=HP+Gerber&author=X+Wu&author=L+Yu&author=C+Wiesmann&author=XH+Liang&author=CV+Lee');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0050" class="article-references__item js-article-reference article-references__item--hide">50. He Z, Riva M, Björk P, Swärd K, Mörgelin M, Leanderson T, et al. CD14 is a co‐receptor for TLR4
in the S100A9‐induced pro‐inflammatory response in monocytes. PLoS One 2016;11:e0156377.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-66"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=CD14+is+a+co%e2%80%90receptor+for+TLR4+in+the+S100A9%e2%80%90induced+pro%e2%80%90inflammatory+response+in+monocytes&publication_year=2016&author=Z+He&author=M+Riva&author=P+Bj%c3%b6rk&author=K+Sw%c3%a4rd&author=M+M%c3%b6rgelin&author=T+Leanderson" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=CD14+is+a+co%e2%80%90receptor+for+TLR4+in+the+S100A9%e2%80%90induced+pro%e2%80%90inflammatory+response+in+monocytes&publication_year=2016&author=Z+He&author=M+Riva&author=P+Bj%c3%b6rk&author=K+Sw%c3%a4rd&author=M+M%c3%b6rgelin&author=T+Leanderson');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0051" class="article-references__item js-article-reference article-references__item--hide">51. Ho JE, Chen WY, Chen MH, Larson MG, McCabe EL, Cheng S, et al. Common genetic variation at the
IL1RL1 locus regulates IL‐33/ST2 signaling. J Clin Invest 2013;123:4208‐4218.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-66"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=Common+genetic+variation+at+the+IL1RL1+locus+regulates+IL%e2%80%9033%2fST2+signaling&publication_year=2013&author=JE+&author=WY+&author=MH+Chen&author=MG+Larson&author=EL+McCabe&author=S+Cheng" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Common+genetic+variation+at+the+IL1RL1+locus+regulates+IL%e2%80%9033%2fST2+signaling&publication_year=2013&author=JE+&author=WY+&author=MH+Chen&author=MG+Larson&author=EL+McCabe&author=S+Cheng');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div id="hep31812-bib-0052" class="article-references__item js-article-reference article-references__item--hide">52. Chang J, Xia Y, Wasserloos K, Deng M, Blose KJ, Vorp DA, et al. Cyclic stretch induced IL‐33
production through HMGB1/TLR‐4 signaling pathway in murine respiratory epithelial cells. PLoS One 2017;12:e0184770.<div>
<ul class="article-references__item-links">
<li class="internal-links"><a href="#JCL-P-66"> Cited Here</a> | </li>
<li>
<a href="https://scholar.google.com/scholar_lookup?title=Cyclic+stretch+induced+IL%e2%80%9033+production+through+HMGB1%2fTLR%e2%80%904+signaling+pathway+in+murine+respiratory+epithelial+cells&publication_year=2017&author=J+Chang&author=Y+Xia&author=K+Wasserloos&author=M+Deng&author=KJ+Blose&author=DA+Vorp" onclick="javascript:window.open('https://scholar.google.com/scholar_lookup?title=Cyclic+stretch+induced+IL%e2%80%9033+production+through+HMGB1%2fTLR%e2%80%904+signaling+pathway+in+murine+respiratory+epithelial+cells&publication_year=2017&author=J+Chang&author=Y+Xia&author=K+Wasserloos&author=M+Deng&author=KJ+Blose&author=DA+Vorp');return false" target="_blank">Google Scholar</a>
</li>
</ul>
</div>
</div>
<div class="article-references__button-container"><button class="article-references__button">View full references list</button></div>
<section id="footnote-group">
<p id="">Author names in bold designate shared co–first authorship.</p>
</section>
</section>
<section class="ej-article-copyright">© 2021 The Authors. Hepatology published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.</section>
</div><button class="ejp-toggle-fulltext-button js-ejp-toggle-fulltext-button">View full article text</button>
</article>
</div>
<div id="emailToColleaguePopupExtender__1604761164_backgroundElement" class="Popup-Overlay" style="display: none; position: fixed; left: 0px; top: 0px; z-index: 10000;"></div>
<div id="OpenExportToPopupExtender_1745200279_backgroundElement" class="Popup-Overlay" style="display: none; position: fixed; left: 0px; top: 0px; z-index: 10000;"></div>
</div>
<div id="article-metrics">
<div id="article-metrics-container">
</div>
</div>
<div id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_divOutlineHTML"></div>
<script type="text/javascript" src="https://lww.com/_layouts/15/1033/Scripts/wk/SlideShowPopup.js?v=05.20.00.150" defer="true">
</script>
<script type="text/javascript" src="https://lww.com/_layouts/15/1033/Scripts/wk/zoom.js?v=05.20.00.150" defer="true">
</script>
<script>
var sample = 6;
var smPos = 153;
var spPos = 153;
var sW;
var sH;
var articleImageDialogModal = $('#ArticleImageDialogModal');
function setImage(imageUrl) {
var $container = $("#zoom_container");
var width = $container.width();
$container.z("destroy").css("background-image", "url(/_layouts/1033/images/oaks.journals/preloader.gif)").z({
width: width,
image_url: imageUrl,
responsive: true,
responsive_maintain_ratio: true,
max_WIDTH: '1200',
max_HEIGHT: '1200',
initial_ZOOM: 100,
initial_POSITION: '0,0'
});
return false;
}
</script>
<div id="ArticleImageModal" class="wk-modal wk-modal-slideshow horizontally-centered large fixed-vertical ejp-modal" role="dialog" style="display: none;">
<div class="modal-dialog">
<section class="modal-content wk-modal-content wk-modal-slideshow__content">
<header class="wk-modal-header ejp-modal-header">
<button onclick="return displaySlideShowModal(false);" aria-label="close dialog" class="wk-button-icon wk-modal-close ejp-modal-close" data-dismiss="wk-modal"><i class="fa fa-times"></i></button>
</header>
<div class="modal-body wk-modal-body wk-modal-slideshow__body flex flex-column">
<div id="zoom_container" class="wk-modal-slideshow__zoom-container"></div>
<div id="ZoomContainerDetails" class="wk-modal-slideshow__zoom-container-details pa3">
<h3>
<div class="wk-modal-slideshow__title"></div>
</h3>
<div class="wk-modal-slideshow__description"></div>
<h4>Source</h4>
<div class="wk-modal-slideshow__source-article mb4">
<a href="javascript:void(0);" id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_sourceArticleUrl" onclick="HideSlideShow();">Analysis and Validation of Human Targets and Treatments Using a Hepatocellular Carcinoma–Immune Humanized Mouse Model</a>
</div>
<div id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_citationdiv" class="wk-modal-slideshow__source-citation mb4"> Hepatology74(3):1395-1410, September 2021. </div>
</div>
</div>
<div class="modal-footer wk-modal-footer wk-modal-slideshow__footer pa2 flex flex-column flex-wrap">
<div class="wk-modal-slideshow__zoom-controls flex justify-between items-center mb2">
<div id="zoom_buttons" class="wk-modal-slideshow__zoom-buttons flex justify-between">
<a href="#" onmousedown="$('#zoom_container').z('zoomIn')" onclick="return false" title="Zoom In" class="ph3"><i class="fa fa-plus-square white"></i></a>
<a href="#" onmousedown="$('#zoom_container').z('zoomOut')" onclick="return false" title="Zoom Out" class="ph3"><i class="fa fa-minus-square white"></i></a>
</div>
<div class="wk-modal-slideshow__list-pager flex pr3">
<a href="javascript:void(0);" onclick="MovePrevious();" id="anchorPrev" title="Previous"><i class="fa fa-arrow-circle-left white"></i></a>
<span id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_imageCountStatus" class="wk-modal-slideshow__list-pager-text mh3 tc white"></span>
<a href="javascript:void(0);" onclick="MoveNext();" id="anchorNext" title="Next"><i class="fa fa-arrow-circle-right white"></i></a>
</div>
</div>
<ul class="wk-modal-slideshow__action-controls flex justify-between">
<li class="pv2 ph3">
<a href="javascript:void(0);" onclick="ShowFullSize('01515467-202109000-00024');" class="white tc">
<i class="fa fa-arrows-alt mb2 db white"></i>
<span class="wk-modal-slideshow__action-controls-text">Full-Size</span>
</a>
</li>
<li id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_lnkEmailToColleague" class="pv2 ph3">
<a href="javascript:void(0);" onclick="slideShow_EmailLinkClicked(imageIndex);" class="white tc">
<i class="fa fa-envelope mb2 db white"></i>
<span class="wk-modal-slideshow__action-controls-text">Email</span>
</a>
</li>
<li id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_lnkFavorites" class="pv2 ph3">
<button class="user-menu__link user-menu__link--add-to-favorites js-ejp-login-btn white tc" type="button"
data-config="{"eventName":"AddToFavoritesFromSlideShow","eventDetail":{"items":["Image|hep:2021:09000:00024|{0}|"],"an":"01515467-202109000-00024"},"eventOptions":{"bubbles":true,"cancelable":true,"composed":false},"loginDetail":{"isLoginOptional":false,"promptLogin":true,"loginPromptText":"To save this item, login or register"},"isNull":false}">
<i class="fa fa-folder mb2 db white"></i>
<span class="wk-modal-slideshow__action-controls-text">+ Favorites</span>
</button>
</li>
<li class="pv2 ph3">
<button class="user-menu__link user-menu__link--ppt-download js-ejp-login-btn" type="button"
data-config="{"eventName":"PPTDownload","eventDetail":{"url":"https://journals.lww.com:443/hep/fulltext/2021/09000/analysis_and_validation_of_human_targets_and.24.aspx?Ppt=Article|hep:2021:09000:00024|10.1002/hep.31812|","gating":false},"eventOptions":{"bubbles":true,"cancelable":true,"composed":false},"loginDetail":{"isLoginOptional":true,"promptLogin":false},"isNull":false}">
<i class="fa fa-file-powerpoint-o mb2 db white"></i>
<span class="wk-modal-slideshow__action-controls-text">Export</span>
</button>
</li>
<li class="wk-modal-slideshow__view-gallery pv2 ph3">
<a href="javascript:void(0);" id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_imageGalleryUrl" class="white tc" onclick="slideShow_NavigateToUrl('/hep/pages/imagegallery.aspx?year=2021&issue=09000&article=00024')">
<i class="fa fa-th-large mb2 db white"></i>
<span class="wk-modal-slideshow__action-controls-text">View in Gallery</span>
</a>
</li>
</ul>
</div>
</section>
</div>
</div>
<input type="hidden" name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$slideShowUserControl$callShowImage" id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_callShowImage">
<input type="hidden" name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$slideShowUserControl$popupImageId" id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_popupImageId"
value="hep31812-fig-0001">
<input type="hidden" name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$slideShowUserControl$IsExportToPPT" id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_IsExportToPPT"
value="false">
<input type="hidden" name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$slideShowUserControl$keyword" id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_keyword">
<input type="hidden" name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$slideShowUserControl$image_url" id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_image_url">
<input type="hidden" name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$slideShowUserControl$image_description"
id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_image_description">
<input type="hidden" name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$slideShowUserControl$image_sourceTitle"
id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_image_sourceTitle">
<input type="hidden" name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$slideShowUserControl$image_sourceUrl" id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_image_sourceUrl">
<input type="hidden" name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$slideShowUserControl$image_sourceInfo"
id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_image_sourceInfo">
<input type="hidden" name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$slideShowUserControl$image_key" id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_image_key">
<input type="hidden" name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$slideShowUserControl$image_fullSizeUrl"
id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_image_fullSizeUrl">
<input type="hidden" name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$slideShowUserControl$image_imageGalleryUrl"
id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_slideShowUserControl_image_imageGalleryUrl">
<input type="hidden" id="NoOfImages" name="NoOfImages" value="7">
<script type="text/javascript" src="https://lww.com/_layouts/15/1033/Scripts/wk/EmailToColleague.js?v=05.20.00.150" defer="true">
</script>
<a id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_hypEmailToColleague" href="javascript:" style="display:none;"></a>
<div id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_pnlEmailToColleague" class="wk-modal-table" style="display: none; position: fixed; z-index: 100001;">
<div class="wk-modal-cell">
<div id="ej-box-modal-drop-shadow" class="wk-modal horizontally-centered small wk-modal-with-overlay wk-modal-small ejp-modal email-to-colleague" tabindex="-1" role="dialog" style="position: static;">
<div id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_pnlMain" class="js-main-panel"
onkeypress="javascript:return WebForm_FireDefaultButton(event, 'ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_btnSend')">
<section class="wk-modal-content">
<header class="wk-modal-header ejp-modal-header">
<div class="wk-modal-title ejp-modal-title">
<strong>
<span id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_lblEmailToColleague">Email to Colleague</span></strong>
</div>
<button aria-label="close dialog" class="primary-button wk-button-icon wk-modal-close ejp-modal-close js-close ">
<i class="fa fa-times"></i>
</button>
</header>
<div class="wk-modal-body">
<div class="wk-field-item">
<div class="wk-field-header">
<div id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_divErrorMessage" class="js-error-message-div ej-error-message-panel" style="display: none; color: red; font-style: italic">
<p class="ej-error-message-icon">
<span id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_lblErrorMessage" class="js-error-message-label">Colleague's E-mail is Invalid</span>
</p>
</div>
</div>
</div>
<div class="wk-field-item">
<div class="wk-field-header"> Your Name: </div>
<div class="wk-field-body">
<input name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$emailToColleague$txtYourName" type="text" id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_txtYourName"
class="js-name">
</div>
</div>
<div class="wk-field-item">
<div class="wk-field-header">
<span id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_lblColleaguesEmail" class="js-collegaues-email-lbl">Colleague's Email:</span>
</div>
<div class="wk-field-body no-bottom-margin">
<input name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$emailToColleague$txtColleaguesEmail" type="text"
id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_txtColleaguesEmail" class="js-collegaues-email">
</div>
<div class="wk-field-header"><span class="ej-form-comments">Separate multiple e-mails with a (;).</span></div>
</div>
<div class="wk-field-item">
<div class="wk-field-header"> Message: </div>
<div class="wk-field-body">
<textarea name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$emailToColleague$txtMessage" rows="2" cols="20"
id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_txtMessage" class="js-message">Thought you might appreciate this item(s) I saw in Hepatology.</textarea>
</div>
</div>
<div class="wk-button-bar">
<div class="wk-button-group-left">
<input type="submit" name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$emailToColleague$btnSend" value="Send"
id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_btnSend" class="js-send-button primary-button grecaptcha-email-colleague-c2460e352eae4a2783c34ea52d941822">
<input type="button" value="Cancel" id="btnCancel" class="secondary-button js-close">
</div>
</div>
<div class="wk-field-item wk-email-colleague-captcha-bar">
<div class="wk-field-body">
<div id="div-recaptcha-c2460e352eae4a2783c34ea52d941822" class="div-recaptcha-container" data-uniqueclassidentifier="grecaptcha-email-colleague-c2460e352eae4a2783c34ea52d941822"
data-sitekey="6LeeoSAUAAAAACFv8yNuINPv8IWyXHJ6uN447qEK" data-callback="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_captchaCallBack" data-badge="inline" data-size="invisible"
data-type="image">
</div>
</div>
</div>
</div>
</section>
</div>
<div id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_pnlSuccessMessage" class="js-success-message-panel" style="display: none;">
<section class="wk-modal-content">
<header class="wk-modal-header ejp-modal-header">
<div class="wk-modal-title ejp-modal-title"></div>
<button aria-label="close dialog" class="primary-button wk-button-icon wk-modal-close ejp-modal-close js-close "><i class="fa fa-times"></i></button>
</header>
<div class="wk-modal-body">
<div class="wk-field-item">
<br>
<p>
<span id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_lblMessageSent">Your message has been successfully sent to your colleague.</span>
</p>
<br>
</div>
<div class="wk-button-bar">
<div class="wk-button-group-left">
<input type="button" value="Close Window" id="btnClose" class="primary-button js-close">
</div>
</div>
</div>
</section>
</div>
<div id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_pnlErrorMessage" class="js-error-message-panel" style="display: none;">
<section class="wk-modal-content">
<header class="wk-modal-header ejp-modal-header">
<div class="wk-modal-title ejp-modal-title"></div>
<button aria-label="close dialog" class="primary-button wk-button-icon wk-modal-close ejp-modal-close js-close "><i class="fa fa-times"></i></button>
</header>
<div class="wk-modal-body">
<br>
<div class="wk-field-item">
<span id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_lblInvalidEmail" style="color:Red;">Some error has occurred while processing your request. Please try after some
time.</span>
</div>
<br>
<div class="wk-button-bar">
<div class="wk-button-group-left">
<input type="button" value="Close Window" id="btnEClose" class="primary-button js-close">
</div>
</div>
</div>
</section>
</div>
</div>
<input type="hidden" name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$emailToColleague$hiddenEmailToColleague"
id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_hiddenEmailToColleague">
<input type="hidden" name="ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$emailToColleague$hiddenIsUser" id="ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_hiddenIsUser">
</div>
</div>
<script type="text/javascript">
window.emailToColleaguePopups = window.emailToColleaguePopups || [];
var ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_captchaCallBack = function() {
ejpAnalytics.track('emailColleaguereCAPTCHA');
ejpAnalytics.track('emailColleagueComplete');
__doPostBack('ctl00$ctl29$g_66d092b4_9819_4479_a267_faf7b1636d3d$ctl00$emailToColleague$btnSend', '')
};
var initEmailToColleaguectl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague = function() {
window.emailToColleaguePopups['ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague'] = new
EmailToColleagueComponent('ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_pnlEmailToColleague', 'div-recaptcha-c2460e352eae4a2783c34ea52d941822',
'grecaptcha-email-colleague-c2460e352eae4a2783c34ea52d941822', 'emailToColleaguePopupExtender_579494353', 'ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_hiddenEmailToColleague',
'ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_hiddenIsUser', '01515467-202109000-00024');
}
Sys.WebForms.PageRequestManager.getInstance().add_pageLoaded(initEmailToColleaguectl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague);
</script>
<input type="hidden" id="selectedItems" name="selectedItems" value="">
<div id="emailToColleaguePopupExtender_579494353_backgroundElement" class="Popup-Overlay" style="display: none; position: fixed; left: 0px; top: 0px; z-index: 10000;"></div>
</div>
<div class="ms-clear"></div>
</div>
</div>
</div>
</div>
</div>
<div id="ctl00_PlaceHolderMain_ResponsivePageLayoutRenderer_ResponsiveLayoutRowRepeater_ctl01_ResponsiveLayoutColumnRepeater_ctl01_ResponsiveLayoutColumn"
class=" wk-column-12 wk-column-4-m wk-column-4-l wk-column-4-xl wk-column-4-xxl">
<div class="ms-webpart-zone ms-fullWidth">
<div id="MSOZoneCell_WebPartWPQ1" class="s4-wpcell-plain ms-webpartzone-cell ms-webpart-cell-vertical-inline-table ms-webpart-cell-vertical ms-fullWidth ">
<div class="ms-webpart-chrome ms-webpart-chrome-vertical ms-webpart-chrome-fullWidth ">
<div webpartid="32bb86ac-479e-413d-a966-f55007095b64" haspers="false" id="WebPartWPQ1" width="100%" class="ms-WPBody noindex " allowdelete="false" style="">
<div id="ctl00_ctl29_g_32bb86ac_479e_413d_a966_f55007095b64">
<div id="ctl00_ctl29_g_32bb86ac_479e_413d_a966_f55007095b64_ctl00_adContainer" class="ej-advertisement ej-advertisement-middle">
<div class="ej-advertisement-content">
<div>
<div id="ga_35f06cb8-3384-4399-8fdd-38a485cb9428" class="ad-slot-container ad-slot-container-ga_35f06cb8-3384-4399-8fdd-38a485cb9428" data-sizemap="[[[0, 0], [[300, 250]]]]"
data-adpath="/15726702761/Desktop/hep/Article/Right" data-autoload="no" data-outofpage="no" data-sticky="no" data-slottargeting="" data-displayslug="yes" data-sticky-duration="0" data-name="Right"></div>
</div>
</div>
</div>
</div>
<div class="ms-clear"></div>
</div>
</div>
<div class="ms-PartSpacingVertical"></div>
</div>
<div id="MSOZoneCell_WebPartWPQ2" class="s4-wpcell-plain ms-webpartzone-cell ms-webpart-cell-vertical-inline-table ms-webpart-cell-vertical ms-fullWidth ">
<div class="ms-webpart-chrome ms-webpart-chrome-vertical ms-webpart-chrome-fullWidth ">
<div webpartid="aafef93a-60d4-4d6f-a190-4cfc0e5a1711" haspers="false" id="WebPartWPQ2" width="100%" class="ms-WPBody noindex " allowdelete="false" style="">
<div id="ctl00_ctl29_g_aafef93a_60d4_4d6f_a190_4cfc0e5a1711">
<div class="js-advanced-recommendation-widget"
data-config="{"serviceUrl":null,"displayMode":"ListView","headerText":"Related Articles","hash":"1","itemsPerPage":6,"renderOnServer":false,"showConsoleLog":false,"shouldShowSpeciality":"0","kind":"Article","title":"Analysis and Validation of Human Targets and Treatments Using a Hepatocellular Carcinoma–Immune Humanized Mouse Model","wkmrid":"JOURNAL/hepa/04.03/01515467-202109000-00024/root/v/2024-01-14T211357Z/r/text-xml","imageHandlerUrl":"https://images.journals.lww.com/hep","accessionNumber":"01515467-202109000-00024","fontSize":"small","displayImage":false,"showJournalTitle":false,"showPublicationDate":false}">
<div id="AdvancedRecommendation_1718853116245">
<div class="ejp-uc--small">
<header class="ejp-heading-2">
<h2>Related Articles</h2>
</header>
<section class="ejp-uc ">
<ul class="ejp-uc__list" role="feed">
<li class="ejp-uc__list-item">
<article class="ejp-uc__article">
<div class="ejp-uc__article-body ejp-uc__article-body--with-image">
<h3 class="ejp-uc__article-title">
<a href="/10.1002/hep.31840" target="_self" class="ejp-uc__article-title-link">Mechanistic Rationales Guiding Combination Hepatocellular Carcinoma Therapies Involving Immune Checkpoint Inhibitors</a></h3>
</div>
</article>
</li>
<li class="ejp-uc__list-item">
<article class="ejp-uc__article">
<div class="ejp-uc__article-body ejp-uc__article-body--with-image">
<h3 class="ejp-uc__article-title"><a href="/10.1002/hep.31706" target="_self" class="ejp-uc__article-title-link">Immune Checkpoint Inhibitors in Combinations for Hepatocellular Carcinoma</a></h3>
</div>
</article>
</li>
<li class="ejp-uc__list-item">
<article class="ejp-uc__article">
<div class="ejp-uc__article-body ejp-uc__article-body--with-image">
<h3 class="ejp-uc__article-title">
<a href="/10.1002/hep.32740" target="_self" class="ejp-uc__article-title-link">The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma</a></h3>
</div>
</article>
</li>
<li class="ejp-uc__list-item">
<article class="ejp-uc__article">
<div class="ejp-uc__article-body ejp-uc__article-body--with-image">
<h3 class="ejp-uc__article-title">
<a href="/10.1097/HEP.0000000000000600" target="_self" class="ejp-uc__article-title-link">Spatial proximity of tumor-immune interactions predicts patient outcome in hepatocellular carcinoma</a></h3>
</div>
</article>
</li>
<li class="ejp-uc__list-item">
<article class="ejp-uc__article">
<div class="ejp-uc__article-body ejp-uc__article-body--with-image">
<h3 class="ejp-uc__article-title">
<a href="/10.1002/hep.31489" target="_self" class="ejp-uc__article-title-link">Spontaneous Regression of Hepatocellular Carcinoma: When the Immune System Stands Up to Cancer</a></h3>
</div>
</article>
</li>
<li class="ejp-uc__list-item">
<article class="ejp-uc__article">
<div class="ejp-uc__article-body ejp-uc__article-body--with-image">
<h3 class="ejp-uc__article-title">
<a href="/10.1002/hep.32672" target="_self" class="ejp-uc__article-title-link">Letter to the editor: Hepatitis B virus reactivation in immune checkpoint inhibitor‐based combination therapies for hepatocellular carcinoma</a>
</h3>
</div>
</article>
</li>
</ul>
</section>
</div>
</div>
</div>
</div>
<div class="ms-clear"></div>
</div>
</div>
<div class="ms-PartSpacingVertical"></div>
</div>
<div id="MSOZoneCell_WebPartWPQ3" class="s4-wpcell-plain ms-webpartzone-cell ms-webpart-cell-vertical-inline-table ms-webpart-cell-vertical ms-fullWidth ">
<div class="ms-webpart-chrome ms-webpart-chrome-vertical ms-webpart-chrome-fullWidth ">
<div webpartid="f8dbebef-5133-4869-9c15-1309ceb7f1b8" haspers="false" id="WebPartWPQ3" width="100%" class="ms-WPBody noindex " allowdelete="false" style="">
<div id="ctl00_ctl29_g_f8dbebef_5133_4869_9c15_1309ceb7f1b8">
<div id="ctl00_ctl29_g_f8dbebef_5133_4869_9c15_1309ceb7f1b8_ctl00_adContainer" class="ej-advertisement ej-advertisement-middle">
<div class="ej-advertisement-content">
<div>
<div id="ga_c3e82d7f-238a-48eb-8184-5b68622e91ee" class="ad-slot-container ad-slot-container-ga_c3e82d7f-238a-48eb-8184-5b68622e91ee" data-sizemap="[[[0, 0], [[300, 250]]]]"
data-adpath="/15726702761/Desktop/hep/Article/Right" data-autoload="no" data-outofpage="no" data-sticky="no" data-slottargeting="" data-displayslug="yes" data-sticky-duration="0" data-name="Right"></div>
</div>
</div>
</div>
</div>
<div class="ms-clear"></div>
</div>
</div>
<div class="ms-PartSpacingVertical"></div>
</div>
<div id="MSOZoneCell_WebPartWPQ4" class="s4-wpcell-plain ms-webpartzone-cell ms-webpart-cell-vertical-inline-table ms-webpart-cell-vertical ms-fullWidth ">
<div class="ms-webpart-chrome ms-webpart-chrome-vertical ms-webpart-chrome-fullWidth ">
<div webpartid="d72f615e-1372-4fb5-8072-8dd9848345b1" haspers="false" id="WebPartWPQ4" width="100%" class="ms-WPBody noindex " allowdelete="false" style="">
<div id="ctl00_ctl29_g_d72f615e_1372_4fb5_8072_8dd9848345b1">
<div data-config="{"serviceUrl":null,"displayMode":null,"hash":"1","itemsPerPage":40,"renderOnServer":false}"></div>
<section id="ctl00_ctl29_g_d72f615e_1372_4fb5_8072_8dd9848345b1_ctl01_divRecentActivity" class="content-box cb-collapsible">
<div class="ejp-uc--small">
<header class="ejp-heading-2">
<h2 aria-expanded="false"> Readers Of this Article Also Read </h2>
</header>
<div id="ej-box-01-body">
<div id="ej-articlesWithTerms">
<ul>
<li class="ejp-uc__list-item">
<h3 class="ejp-uc__article-title">
<a title="" href="https://journals.lww.com/hep/fulltext/2021/11000/transcriptomics_identify_thrombospondin_2_as_a.17.aspx" onmouseover="javascript:event.cancelBubble = true;Tooltip_Article('Transcriptomics Identify Thrombospondin‐2 as a Biomarker for NASH and Advanced Liver Fibrosis', 'Kozumi Kazuhiro; Kodama, Takahiro; Murai, Hiroki; Sakane, Sadatsugu; Govaere, Olivier; Cockell, Simon; Motooka, Daisuke; Kakita, Naruyasu; Yamada, Yukinori; Kondo, Yasuteru; Tahata, Yuki; Yamada, Ryoko; Hikita, Hayato; Sakamori, Ryotaro; Kamada, Yoshihiro; Daly, Ann K.; Anstee, Quentin M.; Tatsumi, Tomohide; Morii, Eiichi; Takehara, Tetsuo', 'Hepatology', 'November 2021', '74', '5' , 'p 2452-2466');" onmouseout="javascript:Tooltip_MouseOut()" class="ejp-uc__article-title-link">Transcriptomics Identify Thrombospondin‐2 as a Biomarker for NASH and Advanced...</a>
</h3>
</li>
<li class="ejp-uc__list-item">
<h3 class="ejp-uc__article-title">
<a title="" href="https://journals.lww.com/hep/abstract/2023/03000/macrophage_specific_fgf12_promotes_liver_fibrosis.12.aspx" onmouseover="javascript:event.cancelBubble = true;Tooltip_Article('Macrophage‐specific FGF12 promotes liver fibrosis progression in mice', 'Li Santie; Zhou, Bin; Xue, Mei; Zhu, Junjie; Tong, Gaozan; Fan, Junfu; Zhu, Kunxuan; Hu, Zijing; Chen, Rui; Dong, Yonggan; Chen, Yiming; Lee, Kwang Youl; Li, Xiaokun; Jin, Litai; Cong, Weitao', 'Hepatology', 'March 2023', '77', '3' , 'p 816-833');" onmouseout="javascript:Tooltip_MouseOut()" class="ejp-uc__article-title-link">Macrophage‐specific FGF12 promotes liver fibrosis progression in mice</a>
</h3>
</li>
<li class="ejp-uc__list-item">
<h3 class="ejp-uc__article-title">
<a title="" href="https://journals.lww.com/hep/fulltext/2018/08000/endothelial_notch_activation_reshapes_the.27.aspx" onmouseover="javascript:event.cancelBubble = true;Tooltip_Article('Endothelial Notch activation reshapes the angiocrine of sinusoidal endothelia to aggravate liver fibrosis and blunt regeneration in mice', 'Duan Juan‐Li; Ruan, Bai; Yan, Xian‐Chun; Liang, Liang; Song, Ping; Yang, Zi‐Yan; Liu, Yuan; Dou, Ke‐Feng; Han, Hua; Wang, Lin', 'Hepatology', 'August 2018', '68', '2' , 'p 677-690');" onmouseout="javascript:Tooltip_MouseOut()" class="ejp-uc__article-title-link">Endothelial Notch activation reshapes the angiocrine of sinusoidal endothelia...</a>
</h3>
</li>
<li class="ejp-uc__list-item">
<h3 class="ejp-uc__article-title">
<a title="" href="https://journals.lww.com/hep/fulltext/2018/06000/11beta_hydroxysteroid_dehydrogenase_1_deficiency.19.aspx" onmouseover="javascript:event.cancelBubble = true;Tooltip_Article('11Beta‐hydroxysteroid dehydrogenase‐1 deficiency or inhibition enhances hepatic myofibroblast activation in murine liver fibrosis', 'Zou Xiantong; Ramachandran, Prakash; Kendall, Timothy J.; Pellicoro, Antonella; Dora, Elena; Aucott, Rebecca L.; Manwani, Kajal; Man, Tak Yung; Chapman, Karen E.; Henderson, Neil C.; Forbes, Stuart J.; Webster, Scott P.; Iredale, John P.; Walker, Brian R.; Michailidou, Zoi', 'Hepatology', 'June 2018', '67', '6' , 'p 2167-2181');" onmouseout="javascript:Tooltip_MouseOut()" class="ejp-uc__article-title-link">11Beta‐hydroxysteroid dehydrogenase‐1 deficiency or inhibition enhances hepatic ...</a>
</h3>
</li>
<li class="ejp-uc__list-item">
<h3 class="ejp-uc__article-title">
<a title="" href="https://journals.lww.com/hep/abstract/2017/04000/hepatostat__liver_regeneration_and_normal_liver.30.aspx" onmouseover="javascript:event.cancelBubble = true;Tooltip_Article('Hepatostat: Liver regeneration and normal liver tissue maintenance', 'Michalopoulos George K.', 'Hepatology', 'April 2017', '65', '4' , 'p 1384-1392');" onmouseout="javascript:Tooltip_MouseOut()" class="ejp-uc__article-title-link">Hepatostat: Liver regeneration and normal liver tissue maintenance</a>
</h3>
</li>
</ul>
</div>
</div>
</div>
</section>
</div>
<div class="ms-clear"></div>
</div>
</div>
<div class="ms-PartSpacingVertical"></div>
</div>
<div id="MSOZoneCell_WebPartWPQ5" class="s4-wpcell-plain ms-webpartzone-cell ms-webpart-cell-vertical-inline-table ms-webpart-cell-vertical ms-fullWidth ">
<div class="ms-webpart-chrome ms-webpart-chrome-vertical ms-webpart-chrome-fullWidth ">
<div webpartid="88b6780f-ddf0-4eb6-a222-0ad6973af05c" haspers="false" id="WebPartWPQ5" width="100%" class="ms-WPBody noindex " allowdelete="false" style="">
<div id="ctl00_ctl29_g_88b6780f_ddf0_4eb6_a222_0ad6973af05c">
<div id="ctl00_ctl29_g_88b6780f_ddf0_4eb6_a222_0ad6973af05c_ctl00_adContainer" class="ej-advertisement ej-advertisement-bannercombo">
<div class="ej-advertisement-content">
<div>
<div id="ga_38c370d1-febb-4d5b-b07e-329ed144baf1" class="ad-slot-container ad-slot-container-ga_38c370d1-febb-4d5b-b07e-329ed144baf1"
data-sizemap="[[[1050, 200], [[300, 600], [300, 250], [160, 600]]], [[730, 600], [[300, 600], [300, 250]]], [ [ 0, 0 ], [ [300, 250] ] ] ]" data-adpath="/15726702761/Desktop/hep/Article/Right1" data-autoload="no"
data-outofpage="no" data-sticky="no" data-slottargeting="" data-displayslug="yes" data-sticky-duration="0" data-name="Right1"></div>
</div>
</div>
</div>
</div>
<div class="ms-clear"></div>
</div>
</div>
<div class="ms-PartSpacingVertical"></div>
</div>
<div id="MSOZoneCell_WebPartWPQ6" class="s4-wpcell-plain ms-webpartzone-cell ms-webpart-cell-vertical-inline-table ms-webpart-cell-vertical ms-fullWidth ">
<div class="ms-webpart-chrome ms-webpart-chrome-vertical ms-webpart-chrome-fullWidth ">
<div webpartid="532eb91a-d961-4c77-9820-2c9418dc1e03" haspers="false" id="WebPartWPQ6" width="100%" class="ms-WPBody noindex " allowdelete="false" style="">
<div id="ctl00_ctl29_g_532eb91a_d961_4c77_9820_2c9418dc1e03">
<div class="js-ejp-universalMostPopular-webpart"
data-config="{"serviceUrl":"https://services.journals.lww.com/IntegrationServices/MostPopularDataService.svc/GetMostPopularItems?timeframe=90d&journalIds=hep&publisher=LWW&results=5&numberOfSymbolsInSubtitle=275&hash=1&displayCustomIndicator=False","headerText":"Most Popular","headerUrl":null,"displayMode":"ListView","hash":"1","shouldShowImage":false,"shouldShowSpeciality":"JournalSpeciality","showArticleDescription":false,"showJournalTitle":false,"viewAllLink":null,"fontSize":"small","showSpecialitySection":false,"showPublicationDate":false,"showIndicators":false}">
<section class="ejp-uc ejp-uc--small ">
<header class="ejp-heading-2">
<h2>Most Popular</h2>
</header>
<div>
<ul class="ejp-uc__list" role="feed">
<li class="ejp-uc__list-item">
<article class="ejp-uc__article ejp-uc--small">
<div class="ejp-uc__article-body ">
<h2 class="ejp-uc__article-title">
<a href="https://journals.lww.com/hep/fulltext/2021/08000/diagnosis,_evaluation,_and_management_of_ascites,.38.aspx" target="_self" class="ejp-uc__article-title-link">Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases</a>
</h2>
<div class="ejp-uc__article-info">
<div class="ejp-journal-title-and-date"></div>
</div>
</div>
</article>
</li>
<li class="ejp-uc__list-item">
<article class="ejp-uc__article ejp-uc--small">
<div class="ejp-uc__article-body ">
<h2 class="ejp-uc__article-title">
<a href="https://journals.lww.com/hep/fulltext/2023/05000/aasld_practice_guidance_on_the_clinical_assessment.31.aspx" target="_self" class="ejp-uc__article-title-link">AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease</a>
</h2>
<div class="ejp-uc__article-info">
<div class="ejp-journal-title-and-date"></div>
</div>
</div>
</article>
</li>
<li class="ejp-uc__list-item">
<article class="ejp-uc__article ejp-uc--small">
<div class="ejp-uc__article-body ">
<h2 class="ejp-uc__article-title">
<a href="https://journals.lww.com/hep/fulltext/2024/05000/aasld_practice_guidance_on_risk_stratification_and.22.aspx" target="_self" class="ejp-uc__article-title-link">AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis</a>
</h2>
<div class="ejp-uc__article-info">
<div class="ejp-journal-title-and-date"></div>
</div>
</div>
</article>
</li>
<li class="ejp-uc__list-item">
<article class="ejp-uc__article ejp-uc--small">
<div class="ejp-uc__article-body ">
<h2 class="ejp-uc__article-title">
<a href="https://journals.lww.com/hep/fulltext/2023/12000/aasld_practice_guidance_on_prevention,_diagnosis,.27.aspx" target="_self" class="ejp-uc__article-title-link">AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma</a>
</h2>
<div class="ejp-uc__article-info">
<div class="ejp-journal-title-and-date"></div>
</div>
</div>
</article>
</li>
<li class="ejp-uc__list-item">
<article class="ejp-uc__article ejp-uc--small">
<div class="ejp-uc__article-body ">
<h2 class="ejp-uc__article-title">
<a href="https://journals.lww.com/hep/fulltext/2020/08000/diagnosis_and_management_of_autoimmune_hepatitis.24.aspx" target="_self" class="ejp-uc__article-title-link">Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases</a>
</h2>
<div class="ejp-uc__article-info">
<div class="ejp-journal-title-and-date"></div>
</div>
</div>
</article>
</li>
</ul>
</div>
</section>
</div>
</div>
<div class="ms-clear"></div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
<div class="wk-grid-container-no-margin" id="AddRowBottomContainer">
</div>
</div>
<div style="display:none" id="hidZone">
<menu class="ms-hide">
<ie:menuitem id="MSOMenu_Help" iconsrc="/_layouts/15/images/HelpIcon.gif" onmenuclick="MSOWebPartPage_SetNewWindowLocation(MenuWebPart.getAttribute('helpLink'), MenuWebPart.getAttribute('helpMode'))" text="Help" type="option"
style="display:none">
</ie:menuitem>
</menu>
</div>
</div>
<div id="DeltaFormDigest">
<script type="text/javascript">
//<![CDATA[
var formDigestElement = document.getElementsByName('__REQUESTDIGEST')[0];
if (!((formDigestElement == null) || (formDigestElement.tagName.toLowerCase() != 'input') || (formDigestElement.type.toLowerCase() != 'hidden') || (formDigestElement.value == null) || (formDigestElement.value.length <= 0))) {
formDigestElement.value = '0x90F685307FA1DC88B17541C12D3D0E7B908331ACFDACA6B3355C3068F9FF69F8D3E502DEC19B0DD81137F9861930CF76FD748A74B7F8482C8BDEF7B59E347D86,20 Jun 2024 03:11:54 -0000';
_spPageContextInfo.updateFormDigestPageLoaded = new Date();
}
//]]>
</script>
</div>
</div>
<!-- Footer Delegate Control -->
<footer class="ejp-footer">
<div class="container wk-grid-page-container">
<a class="ejp-footer__back-to-top-link"><i class="fa fa-angle-up b ejp-footer__back-to-top-link-icon"></i>Back to Top</a>
<div class="ejp-footer__main-content">
<!-- Footer smart control -->
<div class="ejp-footer__smart-control-section">
<section class="ejp-footer__smart-control-section-wrapper js-section-alert">
<div class="ejp-footer__smart-control-section-image-container">
<img src="https://images.journals.lww.com/hep/XLargeThumb.01515467-202407000-00000.CV.jpeg" id="ctl00_ctl56_FooterSmartControl_ctl00_imgAlertControl" alt="Current Issue Cover Image" class="">
</div>
<div class="ejp-footer__smart-control-section-text-holder">
<h4 id="ctl00_ctl56_FooterSmartControl_ctl00_headerAlertControl">Never Miss an Issue</h4>
<div class="js-section-alert__content">
<span id="ctl00_ctl56_FooterSmartControl_ctl00_spanBodyAlertControl" class="ejp-footer__smart-control-section-info">Get new journal Tables of Contents sent right to your email inbox</span>
<input name="ctl00$ctl56$FooterSmartControl$ctl00$userEmailAlertControl" type="text" id="ctl00_ctl56_FooterSmartControl_ctl00_userEmailAlertControl" class="js-section-alert__email" placeholder="Type your email">
<span class="js-section-alert--error"></span>
<button id="ctl00_ctl56_FooterSmartControl_ctl00_buttonAlertControl" type="button" class="js-section-alert__subscribe-button" data-alert-type="Etoc"
data-subscribed-msg="You are now subscribed to receive eTOC alerts whenever new issues are published">Get New Issue Alerts</button>
</div>
</div>
</section>
<script type="text/javascript">
(function($) {
$("#smartWpMostPopularLink").on('click', function() {
window.location = "https://journals.lww.com/hep/pages/viewallmostpopulararticles.aspx?WT.mc_id=HPxADx20100319xMP";
});
})(jQuery);
</script>
</div>
<div class="ejp-footer__info-holder">
<div id="ctl00_ctl56_divLeftColumn" class="ejp-footer__info-left-wrapper">
<div class="ejp-footer__info-block">
<h4 class="ejp-footer__info-block-header">Browse Journal Content</h4>
<ul class="ejp-footer__info-block-two-col-list">
<li id="ctl00_ctl56_liRegister">
<a id="ctl00_ctl56_lnkRegister" href="https://journals.lww.com/hep/pages/register.aspx?ContextUrl=%2fhep%2ffulltext%2f2021%2f09000%2fanalysis_and_validation_of_human_targets_and.24.aspx">Register on the website</a></li>
<li id="ctl00_ctl56_liSubscribe" role="presentation"><a id="ctl00_ctl56_lnkSubscribe" href="https://shop.lww.com/p/0270-9139" target="_blank">Subscribe</a></li>
<li id="ctl00_ctl56_liHyperSubscribeToEtoc">
<a rel="nofollow" title="" href="javascript:javascript: alerts_ShowSubscribeeTOCPopup('Hepatology','hep','eTOC', 'eTOC');;" onclick="javascript: alerts_ShowSubscribeeTOCPopup('Hepatology','hep','eTOC', 'eTOC');"><span id="ctl00_ctl56_alertLinkControl_defaultText" class="hideOnFixed">Get eTOC Alerts</span></a>
</li>
</ul>
</div>
</div>
<div id="ctl00_ctl56_divRightColumn" class="ejp-footer__info-right-wrapper">
<div class="ejp-footer__info-block ejp-footer__info-block--custom-service">
<h4 class="ejp-footer__info-block-header">Customer Service</h4>
<ul>
<li><span class="ejp-footer--show-on-mobile">Contact us at:</span>
<ul>
<li class="ejp-footer__contacts-wrapper ejp-footer__email-settings">
<div class="ejp-footer--show-on-mobile">Support:</div>
<a href="https://www.tfaforms.com/4966570" id="ctl00_ctl56_custSupport" target="_blank">Submit a Service Request</a>
</li>
<li class="ejp-footer__contacts-wrapper ejp-footer__phone-settings">
<div class="ejp-footer--show-on-mobile ejp-footer__phone-settings--version">
<div id="ctl00_ctl56_telMobileCustom">TEL:</div>
</div>
<div class="ejp-footer__phone-settings--holder">
<div>800-638-3030 (within the USA)</div>
<div>301-223-2300 (outside of the USA)</div>
</div>
</li>
</ul>
</li>
</ul>
<ul>
<li>
<button id="ot-sdk-btn" class="ot-sdk-show-settings ot-ejp-btn" onclick="return false;">Manage Cookie Preferences</button>
</li>
</ul>
</div>
</div>
</div>
<span id="ctl00_ctl56_FooterConfiguration" class="js-config-provider"
data-config="{"loginConfiguration":{"serviceUrl":"https://services.journals.lww.com/IntegrationServices/AccountService.svc/Login","registerUrl":"https://journals.lww.com/hep/pages/register.aspx?ContextUrl=%2fhep%2ffulltext%2f2021%2f09000%2fanalysis_and_validation_of_human_targets_and.24.aspx","forgotPasswordUrl":"https://journals.lww.com/hep/pages/forgotpassword.aspx?ContextUrl=%2fhep%2ffulltext%2f2021%2f09000%2fanalysis_and_validation_of_human_targets_and.24.aspx","redirectUrl":"https://journals.lww.com/hep/pages/login.aspx?ContextUrl=%2fhep%2ffulltext%2f2021%2f09000%2fanalysis_and_validation_of_human_targets_and.24.aspx","tokenKey":"AppSsoToken","ssoLoginOptions":[{"loginHref":"https://login.journals.lww.com/OneID/Login.aspx?PartnerIdpId=https://my.aasld.org&Login_type=SocietySso&returnUrl=https%3a%2f%2fjournals.lww.com%2fhep%2fpages%2farticleviewer.aspx%3fyear%3d2021%26issue%3d09000%26article%3d00024%26type%3dFulltext","imageSrc":"/aasldpubs/PublishingImages/logos/Logo.jpg","linkPrefixText":"AASLD members log in here","linkText":"AASLD members log in here"}],"customerService":{"customerServiceUSPhone":"(800) 638-3030","customerServiceInternationalPhone":"301-223-2300","customerServiceEmail":"customerservice@lww.com"},"useAlternativeAccountLinks":false},"commonConfiguration":{"commonEndpoints":{"addToFavoritesServiceUrl":"https://journals.lww.com/hep/_layouts/15/OAKS.Journals/UserCollectionsService.svc/AddToFavorites","saveSearchServiceUrl":"https://journals.lww.com/hep/_layouts/15/OAKS.Journals/UserCollectionsService.svc/SaveSearch","counterDataServiceUrl":"https://journals.lww.com/hep/_layouts/15/OAKS.Journals/DualAccessService.svc/SendCounterDataRequestByAN"},"kaltura":{"partnerId":"1315631","playerId":"52253872","kalturaWidgetUrl":"https://cdnapisec.kaltura.com/p/1315631/embedPlaykitJs/uiconf_id/52253872"},"brightCove":{"brightCoveScriptUrl":"https://players.brightcove.net/2324982687001/HyP0JSARx_default/index.min.js","dataAccount":"2324982687001","dataPlayer":"HyP0JSARx"},"math":{"libUrl":"https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"},"recoWidget":{"journals":[{"Id":"hep","Version":"04.03","ProductCode":"hepa"}],"pubFilter":{},"clientId":"ejp_v3","libUrl":"https://assets.ovid.com/widget/v3/widget.js"},"sciteBadge":{"libUrl":"https://cdn.scite.ai/badge/scite-badge-latest.min.js"}}}"></span>
</div>
<div class="ejp-footer__bottom-links">
<ul class="ejp-footer__useful-links">
<li><a id="ctl00_ctl56_hlkPrivacy" href="https://journals.lww.com/hep/_layouts/oaks.journals/privacy.aspx">Privacy Policy</a></li>
<li><a id="ctl00_ctl56_hlkLegal" href="https://journals.lww.com/hep/_layouts/oaks.journals/disclaimer.aspx">Legal Disclaimer</a></li>
<li><a id="ctl00_ctl56_hlkTermsOfUse" href="https://journals.lww.com/hep/_layouts/oaks.journals/terms.aspx">Terms of Use</a></li>
<li><a id="ctl00_ctl56_hlkNIHPublicAccess" href="https://www.wolterskluwer.com/en/solutions/lippincott-journals/lippincott-open-access" target="_blank">Open Access Policy</a></li>
<li><a id="ctl00_ctl56_hlkCAPrivacyChoices" href="https://privacyportal-de.onetrust.com/webform/2217e117-526b-4696-8a98-8c402f8f2b81/5b049ba3-0106-4b77-a7da-5d12238c90a4" target="_blank">Your California Privacy Choices</a>
<img src="/_layouts/1033/IMAGES/OAKS.Journals/CAPrivacyPolicy.png" id="ctl00_ctl56_imgCAPrivacyPolicyChoices" class="wk-footer__ca-privacy-logo" alt="California Consumer Privacy Act (CCPA) Opt-Out Icon">
</li>
</ul>
<ul class="ejp-footer__copyright-block">
<li><span>Copyright © 2024</span></li>
<li><span><span>American Association for the Study of Liver Diseases -</span> <a href="https://www.wolterskluwer.com/en/health" target="_blank">Wolters Kluwer Health, Inc. All rights reserved.</a></span></li>
</ul>
</div>
</div>
</footer>
</div>
</div>
<!--Scripts -->
<!--<script src="~/js/ejp-scripts.js"></script> -->
<script>
$(document).on('click', '.yamm .dropdown-menu', function(e) {
e.stopPropagation();
});
</script>
<!-- Additional custom controls -->
<!-- High Impact Advertisement -->
<div id="ctl00_ctl59_adContainer" class="ej-advertisement ejp-advertisement-highimpact js-advertisement-highimpact">
<div class="ej-advertisement-content">
<div>
<div id="ga_3e3d9c73-919a-47c1-bfab-4cd89c7fb635" class="ad-slot-container ad-slot-container-ga_3e3d9c73-919a-47c1-bfab-4cd89c7fb635" data-sizemap="[[[992, 500], [[300, 250]]], [[768, 180], [[728, 90]]], [[0, 0], [[300, 50]]]]"
data-adpath="/15726702761/Desktop/hep/HighImpact" data-autoload="yes" data-outofpage="no" data-sticky="yes" data-slottargeting="" data-displayslug="yes" data-sticky-duration="10" data-name="HighImpact"></div>
</div>
</div>
</div>
<!-- Page View Pixel Advertisement -->
<div style="display: none">
<div id="ctl00_ctl60_adContainer" class="ej-advertisement ejp-advertisement-pageviewpixel js-advertisement-pageviewpixel">
<div class="ej-advertisement-content">
<div>
<div id="ga_85ae562f-7b00-4666-baea-7afe64c6bac8" class="ad-slot-container ad-slot-container-ga_85ae562f-7b00-4666-baea-7afe64c6bac8" data-sizemap="[[[10000, 10000], [[1, 1]]]]" data-adpath="/15726702761/Desktop/hep/Article/PageViewPixel"
data-autoload="yes" data-outofpage="no" data-sticky="no" data-slottargeting="" data-displayslug="no" data-sticky-duration="0" data-name="PageViewPixel"></div>
</div>
</div>
</div>
</div>
<!-- Bottom Banner -->
<!-- QuantcastTracker - don't have key in configuration DB, seems like controls is deprecated -->
<!---->
<script type="text/javascript">
//<![CDATA[
var Page_Validators = new Array(document.getElementById("ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_cvEmailError"));
//]]>
</script>
<script type="text/javascript">
//<![CDATA[
var ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_cvEmailError = document.all ? document.all["ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_cvEmailError"] : document.getElementById(
"ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_cvEmailError");
ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_cvEmailError.display = "Dynamic";
ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_cvEmailError.validationGroup = "EmailValidationGroup";
ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_cvEmailError.evaluationfunction = "CustomValidatorEvaluateIsValid";
//]]>
</script>
<script type="text/javascript">
//<![CDATA[
var _spFormDigestRefreshInterval = 1440000;
window.SPThemeUtils && SPThemeUtils.ApplyCurrentTheme(true);
IsSPSocialSwitchEnabled = function() {
return true;
};
var _fV4UI = true;
function _RegisterWebPartPageCUI() {
var initInfo = {
editable: false,
isEditMode: false,
allowWebPartAdder: false,
listId: "{b807cb8a-3cdf-4126-b475-cf89c1612eb3}",
itemId: 77,
recycleBinEnabled: true,
enableMinorVersioning: false,
enableModeration: false,
forceCheckout: false,
rootFolderUrl: "\u002fhep\u002fPages",
itemPermissions: {
High: 0,
Low: 200769
}
};
SP.Ribbon.WebPartComponent.registerWithPageManager(initInfo);
var wpcomp = SP.Ribbon.WebPartComponent.get_instance();
var hid;
hid = document.getElementById("_wpSelected");
if (hid != null) {
var wpid = hid.value;
if (wpid.length > 0) {
var zc = document.getElementById(wpid);
if (zc != null) wpcomp.selectWebPart(zc, false);
}
}
hid = document.getElementById("_wzSelected");
if (hid != null) {
var wzid = hid.value;
if (wzid.length > 0) {
wpcomp.selectWebPartZone(null, wzid);
}
}
};
function __RegisterWebPartPageCUI() {
ExecuteOrDelayUntilScriptLoaded(_RegisterWebPartPageCUI, "sp.ribbon.js");
}
_spBodyOnLoadFunctionNames.push("__RegisterWebPartPageCUI");
var __wpmExportWarning =
'This Web Part Page has been personalized. As a result, one or more Web Part properties may contain confidential information. Make sure the properties contain information that is safe for others to read. After exporting this Web Part, view properties in the Web Part description file (.WebPart) by using a text editor such as Microsoft Notepad.';
var __wpmCloseProviderWarning =
'You are about to close this Web Part. It is currently providing data to other Web Parts, and these connections will be deleted if this Web Part is closed. To close this Web Part, click OK. To keep this Web Part, click Cancel.';
var __wpmDeleteWarning = 'You are about to permanently delete this Web Part. Are you sure you want to do this? To delete this Web Part, click OK. To keep this Web Part, click Cancel.';
var lblColleaguesEmail = $get('ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_lblColleaguesEmail');
var Page_ValidationActive = false;
if (typeof(ValidatorOnLoad) == "function") {
ValidatorOnLoad();
}
function ValidatorOnSubmit() {
if (Page_ValidationActive) {
return ValidatorCommonOnSubmit();
} else {
return true;
}
}
//]]>
</script>
<script type="text/javascript">
SP.SOD.set_prefetch(0);
</script>
<script type="text/javascript">
//<![CDATA[
WPSC.Init(document);
var varPartWPQ1 = WPSC.WebPartPage.Parts.Register('WPQ1', '32bb86ac-479e-413d-a966-f55007095b64', document.getElementById('WebPartWPQ1'));
var varPartWPQ2 = WPSC.WebPartPage.Parts.Register('WPQ2', 'aafef93a-60d4-4d6f-a190-4cfc0e5a1711', document.getElementById('WebPartWPQ2'));
var varPartWPQ3 = WPSC.WebPartPage.Parts.Register('WPQ3', 'f8dbebef-5133-4869-9c15-1309ceb7f1b8', document.getElementById('WebPartWPQ3'));
var varPartWPQ4 = WPSC.WebPartPage.Parts.Register('WPQ4', 'd72f615e-1372-4fb5-8072-8dd9848345b1', document.getElementById('WebPartWPQ4'));
var varPartWPQ5 = WPSC.WebPartPage.Parts.Register('WPQ5', '88b6780f-ddf0-4eb6-a222-0ad6973af05c', document.getElementById('WebPartWPQ5'));
var varPartWPQ6 = WPSC.WebPartPage.Parts.Register('WPQ6', '532eb91a-d961-4c77-9820-2c9418dc1e03', document.getElementById('WebPartWPQ6'));
WPSC.WebPartPage.WebURL = 'https:\u002f\u002fjournals.lww.com\u002fhep';
WPSC.WebPartPage.WebServerRelativeURL = '\u002fhep';
var g_clientIdDeltaPlaceHolderMain = "DeltaPlaceHolderMain";
var g_clientIdDeltaPlaceHolderUtilityContent = "DeltaPlaceHolderUtilityContent";
WebForm_AutoFocus('ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_txtYourName');
Sys.Application.add_init(function() {
$create(AjaxControlToolkit.ModalPopupBehavior, {
"BackgroundCssClass": "Popup-Overlay",
"DropShadow": true,
"PopupControlID": "ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_pnlunSubscribeToAlerts",
"dynamicServicePath": "/hep/pages/articleviewer.aspx",
"id": "unSubscribeToAlerts"
}, null, null, $get("ctl00_ctl51_Header_UserActionTools_ucUnsubscribeToAlertsUserControl_dummyTargetControl"));
});
Sys.Application.add_init(function() {
$create(AjaxControlToolkit.ModalPopupBehavior, {
"BackgroundCssClass": "Popup-Overlay",
"DropShadow": true,
"PopupControlID": "ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_pnlSubscribeToEtoc",
"dynamicServicePath": "/hep/pages/articleviewer.aspx",
"id": "subscribeToEtoc"
}, null, null, $get("ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_dummyTargetControl"));
});
document.getElementById('ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_cvEmailError').dispose = function() {
Array.remove(Page_Validators, document.getElementById('ctl00_ctl51_Header_UserActionTools_SubscribeToEtocPopupControl_cvEmailError'));
}
g_QuickLaunchControlIds.push("zz1_TopNavigationMenu");
_spBodyOnLoadFunctionNames.push('QuickLaunchInitDroppable');
var g_zz1_TopNavigationMenu = null;
function init_zz1_TopNavigationMenu() {
if (g_zz1_TopNavigationMenu == null) g_zz1_TopNavigationMenu = $create(SP.UI.AspMenu, null, null, null, $get('zz1_TopNavigationMenu'));
}
if (g_spPreFetchKeys) {
{
g_spPreFetchKeys.push('SP.Core.js');
}
}
EnsureScriptFunc('SP.Core.js', 'SP.UI.AspMenu', init_zz1_TopNavigationMenu);
Sys.Application.add_init(function() {
$create(AjaxControlToolkit.ModalPopupBehavior, {
"BackgroundCssClass": "Popup-Overlay",
"PopupControlID": "ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_pnlEmailToColleague",
"dynamicServicePath": "/hep/pages/articleviewer.aspx",
"id": "emailToColleaguePopupExtender__1604761164"
}, null, null, $get("ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_emailToColleagueControl_hypEmailToColleague"));
});
Sys.Application.add_init(function() {
$create(AjaxControlToolkit.ModalPopupBehavior, {
"BackgroundCssClass": "Popup-Overlay",
"PopupControlID": "ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_exportToCitationManager_pnlExportTo",
"dynamicServicePath": "/hep/pages/articleviewer.aspx",
"id": "OpenExportToPopupExtender_1745200279"
}, null, null, $get("ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_ucArticleTools_exportToCitationManager_hypExportToCitationManager"));
});
Sys.Application.add_init(function() {
$create(AjaxControlToolkit.ModalPopupBehavior, {
"BackgroundCssClass": "Popup-Overlay",
"PopupControlID": "ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_pnlEmailToColleague",
"dynamicServicePath": "/hep/pages/articleviewer.aspx",
"id": "emailToColleaguePopupExtender_579494353"
}, null, null, $get("ctl00_ctl29_g_66d092b4_9819_4479_a267_faf7b1636d3d_ctl00_emailToColleague_hypEmailToColleague"));
});
//]]>
</script>
</form>Text Content
You may be trying to access this site from a secured browser on the server.
Please enable scripts and reload this page.
* AASLD Publications
* Hepatology
* Liver Transplantation
* Clinical Liver Disease
* Hepatology Communications
Visit our other sites
* AASLD Publications
* Hepatology
* Liver Transplantation
* Clinical Liver Disease
* Hepatology Communications
* AASLD Publications
* Hepatology
* Liver Transplantation
* Clinical Liver Disease
* Hepatology Communications
* Log in
* or
* Register
* Subscribe to journalSubscribe
* Get new issue alertsGet alerts
* AASLD Member? Login here
Subscribe to eTOC
SECONDARY LOGO
Enter your Email address:
Wolters Kluwer Health may email you for journal alerts and information, but is
committed to maintaining your privacy and will not share your personal
information without your express consent. For more information, please refer to
our Privacy Policy.
JOURNAL LOGO
Articles
Articles
Advanced Search
Toggle navigation
Subscribe Register Login
* Browsing History
* Home
* Browse
* Articles in Press
* Current Issue
* All Issues
* Collections
* Review Articles
* Graphical Abstracts
* Top Cited Articles
* Top Altmetric Articles
* Multi-journal Article Collections
* About
* About the Journal
* About AASLD
* Editorial Board
* Instructions for Authors
* Advertising
* Permissions
* Open Access
* Reprints
* For Authors
* Instructions for Authors
* Submit an Article
* Language Editing Services
* Graphical Abstract Guidelines
* Resources
* Publish with Us
* AASLD Career Center
* Joint GI Society Statement on Racism
* What is Hepatology looking for 2.0?
* COVID-19 Resources
* LiverLearning
* Liver Connect Forums
* Become a Member
* AASLD Guidelines
* Submit an Article
Articles
Articles
Advanced Search
September 2021 - Volume 74 - Issue 3
* Previous Article
* Next Article
* Outline
* Materials and Methods
* MICE
* Results
* The Human Immune System Promotes HCC Proliferation and Angiogenesis
* Intratumor hCD14 Cells Contribute to Promoting HCC Proliferation and
Angiogenesis
* Intratumor Human Immune Cells are Strongly Modulated by HCC Tumors
* IL‐33 Secreted From Intratumor hCD14+ Cells Up‐Regulates IL‐6 Expression in
Multiple Intratumor Immune Cells and Enhances HCC Proliferation
* Co‐receptor CD14 Is Essential for IL‐33 Production Through Damp
(HMGB1)/TLR4/Activator Protein 1 Pathway
* hCD14+ Monocytes Among TILs are Crucial for Combinatorial Immunotherapy on
HCC
* Discussion
* Authors Contributions
* Acknowledgment
* References
* Images
* Slideshow
* Gallery
* Export PowerPoint file
* Download
* PDF
* EPUB
* Cite
*
* Copy
* Export to RIS
* Export to EndNote
* Share
* Email
* Facebook
* Twitter
* LinkedIn
* Favorites
* Permissions
* More
* Cite
* Permissions
* Image Gallery
Article as EPUB
Export All Images to PowerPoint File Add to My Favorites
Email to Colleague
Colleague's E-mail is Invalid
Your Name:
Colleague's Email:
Separate multiple e-mails with a (;).
Message:
Thought you might appreciate this item(s) I saw in Hepatology.
Your message has been successfully sent to your colleague.
Some error has occurred while processing your request. Please try after some
time.
Export to
End Note Procite Reference Manager
Save my selection
Original Articles: Hepatobiliary Malignancies
ANALYSIS AND VALIDATION OF HUMAN TARGETS AND TREATMENTS USING A HEPATOCELLULAR
CARCINOMA–IMMUNE HUMANIZED MOUSE MODEL
Zhao, Yue1,*; Wang, Jiaxu2,*; Liu, Wai Nam1; Fong, Shin Yie1; Shuen, Timothy Wai
Ho3; Liu, Min1; Harden, Sarah1; Tan, Sue Yee1; Cheng, Jia Ying1; Tan, Wilson Wei
Sheng1; Chan, Jerry Kok Yen4,5; Chee, Cheng Ean6; Lee, Guan Huei7; Toh, Han
Chong3; Lim, Seng Gee7; Wan, Yue2; Chen, Qingfeng*,1,8
Author Information
1Institute of Molecular and Cell BiologyAgency for Science, Technology and
ResearchSingapore
2Genome Institute of SingaporeAgency for Science, Technology and
ResearchSingapore
3Division of Medical OncologyNational Cancer Centre SingaporeSingapore
4Department of Reproductive MedicineKandang Kerbau Women’s and Children's
HospitalSingapore
5Experimental Fetal Medicine GroupYong Loo Lin School of MedicineNational
University of SingaporeSingapore
6Department of Hematology‐OncologyNational University Cancer InstituteSingapore
7Division of Gastroenterology and HepatologyNational University Health
SystemSingapore
8Department of Microbiology and ImmunologyYong Loo Lin School of
MedicineNational University of SingaporeSingapore
*ADDRESS CORRESPONDENCE AND REPRINT REQUESTS TO:
Qingfeng Chen, Ph.D.
Institute of Molecular and Cell Biology, Agency for Science, Technology and
Research (A*STAR)
Proteos, 61 Biopolis Drive
Singapore 138673, Singapore
E.mail: qchen@imcb.a-star.edu.sg
Tel: +65‐65869873
*These authors contributed equally to this work.
This is an open access article under the terms of the Creative Commons
Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution
in any medium, provided the original work is properly cited, the use is
non‐commercial and no modifications or adaptations are made.
Hepatology 74(3):p 1395-1410, September 2021. | DOI: 10.1002/hep.31812
* Open
Metrics
ABSTRACT
BACKGROUND AND AIMS
Recent development of multiple treatments for human hepatocellular carcinoma
(HCC) has allowed for the selection of combination therapy to enhance the
effectiveness of monotherapy. Optimal selection of therapies is based on both
HCC and its microenvironment. Therefore, it is critical to develop and validate
preclinical animal models for testing clinical therapeutic solutions.
APPROACH AND RESULTS
We established cell line–based or patient‐derived xenograft–based
humanized‐immune‐system mouse models with subcutaneous and orthotopic HCC. Mice
were injected with human‐specific antibodies (Abs) to deplete human immune
cells. We analyzed the transcription profiles of HCC cells and human immune
cells by using real‐time PCR and RNA sequencing. The protein level of HCC tumor
cells/tissues or human immune cells was determined by using flow cytometry,
western blotting, and immunohistochemistry. The HCC tumor size was measured
after single, dual‐combination, and triple‐combination treatment using
N‐(1ʹ,2‐Dihydroxy‐1,2ʹ‐binaphthalen‐4ʹ‐yl)‐4‐methoxybenzenesulfonamide (C188‐9),
bevacizumab, and pembrolizumab. In this study, human immune cells in the tumor
microenvironment were strongly selected and modulated by HCC, which promoted the
activation of the IL‐6/Janus kinase 2 (JAK2)/signal transducer and activator of
transcription 3 (STAT3) signaling pathway in tumor cells and led to augmented
HCC proliferation and angiogenesis by releasing angiogenic cytokines in
humanized‐immune‐system mice with HCC. In particular, intratumor human cluster
of differentiation–positive (hCD14+) cells could produce IL‐33 through
damage‐associated molecular pattern/Toll‐like receptor 4/activator protein 1,
which up‐regulated IL‐6 in other intratumor immune cells and activated the
JAK2/STAT3 pathway in HCC. Specific knockdown of the CD14 gene in human
monocytes could impair IL‐33 production induced by cell lysates. Subsequently,
we evaluated the in vivo anti‐HCC effect of C188‐9, bevacizumab, and
pembrolizumab. The results showed that the anti‐HCC effect of triple‐combination
therapy was superior to that of single or dual treatments.
CONCLUSIONS
Humanized‐immune‐system HCC mouse models are suitable for identifying targets
from cancer and immune components and for testing combinational therapies.
Supported by the National Medical Research Council Singapore, the Virus‐Induced
Cancer: Translational Oncology Research & immunologY Programme
(NMRC/OFLCG/003/2018), the Senior Clinician Scientist Award
(NMRC/CSASI16nov006), the Eradication of HBV T‐cell receptor Program
(NMRC/TCR/014‐NUHS/2015), a Clinician–Scientist Individual Research Grant
(CIRG19may‐0051), and the National Research Foundation Singapore (NRF)
Fellowship (NRF‐NRFF2017‐03), an NRF–Israel Science Foundation joint grant
(NRF2019–NRF‐ISF003‐3127), an NRF–Competitive Research Programme grant
(NRF2016‐CRP001‐103), and the Agency for Science, Technology and Research
Industry Alignment Fund‐Pre‐positioning (H18/01/a0/022) to Q.C.
Potential conflict of interest: Dr. Chee is on the speakers’ bureau for Roche.
Dr. Lim advises, is on the speakers’ bureau for, and received grants from
Gilead, Abbott, and Roche. He advises AbbVie, Arbutus, Assembly, and Eisai. He
received grants from Merck Sharp & Dohme Corp and Grifols.
Hepatocellular carcinoma (HCC) remains one of the most common causes of
cancer‐related deaths and has a high recurrence rate.(1) HCC tumorigenesis is
impacted by chronic inflammation induced by liver injury,(2‐4) which promotes
HCC progression and development.(5‐8) However, the mechanisms that underlie the
crosstalk between human HCC and the human immune system remain poorly
understood. Therefore, examination of the interactions between the human immune
system and HCC, which may improve existing therapy and help to identify
strategies for HCC treatment, is warranted.
HCC cells attract various immune cells into the tumor microenvironment by
releasing multiple chemokines, including C‐X‐C motif chemokine ligand 12
(CXCL12), C‐C motif chemokine ligand 1 (CCL1), CCL22, CXCL16, CCL5, CXCL10, and
CXCL11.(9‐13) Furthermore, HCC cells can modulate the activities and functions
of immune cells and drive the acquisition of tumor‐associated phenotypes in
these cells.(14‐17) Tumor‐associated immune cells, including T‐helper (Th) type
2 (Th2) cells, type 2 innate lymphoid cells (ILC2s), tumor‐associated regulatory
T cells, tumor‐associated macrophages (TAMs), tumor‐associated neutrophils, and
myeloid‐derived suppressor cells (MDSCs) are responsible for producing various
cytokines (IL‐1, IL‐6, IL‐8, and IL‐10), growth factors (VEGF, platelet‐derived
growth factor [PDGF], EGF, HGF, FGF, and insulin‐like growth factor), matrix
metalloproteinase 2 (MMP‐2) and MMP‐9, and tissue inhibitor of metalloproteinase
1 (TIMP‐1) and TIMP‐2 to create an optimal environment for the proliferation,
survival, and metastasis of tumor cells.(18‐21) Previous studies have
demonstrated that numerous signaling pathways dysregulated in HCC were
associated with these HCC tumor–associated immune cells.(22‐24) For example,
IL‐8 released from TAMs may enhance the epithelial–mesenchymal transition (EMT)
in HCC through the Janus kinase 2 (JAK2)/signal transducer and activator of
transcription 3 (STAT3)/Snail pathway.(22) Similarly, activation of the
JAK2/STAT3 pathway, induced by IL‐6 from TAMs, also played a critical role in
HCC stem‐cell expansion.(23) In addition, increased functional activity in the
rat sarcoma/rapidly accelerated fibrosarcoma/mitogen‐activated protein kinase
(MAPK), phosphoinositide 3‐kinase (PI3K)/protein kinase B (AKT)/mechanistic
target of rapamycin and JAK/STAT pathways, caused by multiple growth factors
released from MDSCs, were also observed in human HCC.(24) Although this evidence
demonstrated the interactions between the human immune system and HCC, countless
other mechanisms remain unclear, particularly because of the lack of a robust in
vivo human cancer–immune system model. The absence of sufficient models also
limits the development of therapeutics targeting tumor‐associated immune cells
and their modulation pathways.
Over time, various monotherapies that target HCC proliferation, angiogenesis,
and immune resistance have been developed.(25,26) These include, for example,
treatments counteracting elevated IL‐6 signaling. Serum IL‐6 levels are elevated
in patients with HCC, compared with healthy individuals, which might enhance HCC
proliferation and angiogenesis through activation of the JAK2/STAT3 signaling
pathway.(27,28) Hence, tocilizumab (IL‐6 receptor blockade) and
N‐(1ʹ,2‐Dihydroxy‐1,2ʹ‐binaphthalen‐4ʹ‐yl)‐4‐methoxybenzenesulfonamide (C188‐9)
(STAT3 inhibitor) were developed and achieved optimistic results in reducing HCC
growth in vivo by impairing IL‐6 signaling from TAMs to HCC.(6,29)
VEGF is essential for tumor growth and angiogenesis. Bevacizumab, an anti‐VEGF
monoclonal antibody (Ab), has been applied to patients with HCC and has proven
to be effective in clinical trials.(30,31) Similarly, immune checkpoint blockade
therapies, such as nivolumab and pembrolizumab (programmed death 1 [PD‐1]
blockade) and atezolizumab (programmed death ligand 1 [PD‐L1] blockade) also
exerted certain levels of anti‐HCC effects by protecting and recovering T‐cell
function in animal models and patients.(32) Despite the development of different
monotherapies, patients with HCC only exhibit partial responses to these
treatments.(33) In recent years, combination therapy (polytherapy) has been
considered for synergistic efficacy, which may improve the overall survival of
patients with HCC by reducing their resistance to monotherapy.(33) Previous
studies have demonstrated that the combination of anti–IL‐6 and anti–PD‐L1
treatment could ameliorate the anti‐HCC efficacy in vivo.(34) In clinical
settings, a combination of bevacizumab and atezolizumab treatment led to
effective antitumor immune response in patients with HCC.(35) Furthermore,
combined blockade of IL‐6 and VEGF receptor also enhanced antitumor activity, as
was reported in another study.(36) Therefore, it is anticipated that the
combined therapy of anti–IL‐6–or IL‐6–related signaling pathways, anti‐VEGF, and
immune checkpoint blockade may be more efficacious.
We have shown that an HCC mouse model can be generated through the engraftment
of human HCC cell lines or patient‐derived xenografts (PDXs) into
immunodeficient mice bearing human leukocyte antigen (HLA)‐matched human immune
systems (humanized mice).(37) Intriguingly, some of the HCC‐PDX tumors regressed
in the humanized mice following pembrolizumab and ipilimumab treatment,
suggesting that the HCC humanized mice may represent an emerging platform for
the evaluation of cancer monotherapy or combination therapy.(37) In the present
study, we demonstrate that the human immune system in humanized mice may enhance
HCC proliferation and angiogenesis through a network involving damage‐associated
molecular patterns (DAMPs), Toll‐like receptors (TLRs), cytokines, and
intracellular protein phosphorylation. More importantly, triple‐combination
therapy targeting STAT3‐induced HCC proliferation, VEGF‐related angiogenesis,
and the PD‐1 immune checkpoint resulted in a combinational anti‐HCC effect in
our humanized mouse model.
MATERIALS AND METHODS
MICE
NOD.Cg‐PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice (The Jackson Laboratory) and
humanized mice were bred and generated, respectively, as described
earlier.(37,38) All manipulations with mice were approved by Institutional
Animal Care and Use Committee in Agency for Science, Technology and Research.
All animal experimental procedures were conducted in accordance to the approved
protocols and Guide for the Care and Use of Laboratory Animals. All human fetal
liver and HCC Patient tumor tissues with written consent were obtained from
guardians of donors, and in accordance with the ethical guidelines of Kandang
Kerbau (KK) Women’s and Children’s Hospital (Singapore) and National University
Hospital (Singapore). HCC humanized mice were generated by engrafting different
HCC cell lines or PDXs subcutaneously or orthotopically (intrasplenic injection
with 2 × 106 purified and live human tumor cells in 50 µL of saline) according
to HLA‐A (HCC‐PDX tumor 1# [A*02 and A*11] matched with hematopoietic stem cell
[HSC] 1# [A*02 and A*11]; HCC‐PDX tumor 2# [A*02 and A*11] matched with HSC 1#
[A*02 and A*11]; HCC‐PDX tumor 3# [A*02 and A*01] matched with HSC 2# [A*02 and
A*01]; HCC‐PDX tumor 4# [A*02 and A*11] matched with HSC 1# [A*02 and A*11]; and
HepG2 and LM3 cell lines [A*02 and A*24] matched with HSC 3# [A*02 and A*24])
(Supporting Table S1). To deplete specific immune‐cell subsets in immune
humanized mice, anti–human cluster of differentiation 45 (anti‐hCD45) (a human
leukocyte marker), anti‐hCD4 (a human Th cell marker), anti‐hCD8 (a human Tc
cell maker), anti‐hCD14 (a human monocyte marker), anti‐hCD19 (a human B‐cell
marker), and anti‐hCD56 (a human natural killer [NK] cell marker) (50 µg/mouse)
were given i.v. weekly. For the evaluation of drug efficacy, small molecules or
Abs were injected into the mice either alone or in combination. Briefly, C188‐9
dissolved in DMSO was injected intraperitoneally (75 mg/kg) on a daily basis,
whereas anti–human IL‐33 Ab (50 µg/mouse), bevacizumab, and pembrolizumab
(5 mg/kg) were injected i.v. on a weekly basis. Further methodological details
can be found in the Supporting Information.
RESULTS
THE HUMAN IMMUNE SYSTEM PROMOTES HCC PROLIFERATION AND ANGIOGENESIS
To explore the role of the humanized immune system with respect to HCC, we
engrafted HCC‐PDX tumor tissue into NSG humanized mice and hCD45‐depleted
humanized mice that were treated with anti‐hCD45 Ab to remove the humanized
immune system 2 weeks after engraftment. Interestingly, the size and weight of
the HCC tumors and spleens from humanized mice increased compared with those
from the NSG and hCD45‐depleted humanized mice (Fig. 1A). Similar results were
also observed in HCC‐PDX tumors from different donors, in both subcutaneous and
orthotopic models (Supporting Figs. S1A‐S6A). The expression of MKI67 (Ki67) on
the HCC‐PDX tumor was quantified by using immunohistochemical analysis, which
indicated a significant increase in the number of Ki67+ cells in the HCC tumor
from humanized mice (Fig. 1B and Supporting Figs. S1B‐S6B). Moreover, the
5‐ethynyl‐2′‐deoxyuridine (EDU) levels in isolated and purified HCC‐PDX tumor
cells from the three groups were analyzed using flow cytometry. Similarly, we
observed that the HCC‐PDX tumor cells isolated from humanized mice had the
highest EDU level among these groups (Fig. 1C). Furthermore, angiogenesis was
quantified in the vascular endothelium of the HCC‐PDX tumor by counting the
vessels with a lumen (CD31 immunohistochemical staining that was both negative
and positive) (Fig. 1D and Supporting Figs. S1C‐S6C). Both the microvessel
density (MVD) and the microvessel cross‐sectional area (VCSA) were calculated
(Fig. 1D and Supporting Figs. S1D‐S6D). More vascular invasion was observed in
HCC tumors in humanized mice than in both NSG and hCD45‐depleted humanized mice,
suggesting that the humanized immune system could augment HCC tumor
proliferation and angiogenesis. To dissect the underlying molecular mechanisms
that regulated the proliferation and angiogenesis affected by the humanized
immune system, the LM3 (HCC) cell line was selected because of its sharing the
HLA‐A type with the HCC‐PDX tumor (all are HLA‐A type 2). In concordance with
the results from HCC‐PDX tumors, LM3 tumors in humanized mice were larger than
those in NSG and humanized mice treated with anti‐hCD45 Abs (Fig. 1E). After 3
weeks of engraftment, the LM3 tumors were harvested, and the purified LM3 HCC
cells were subjected to RNA sequencing (Fig. 1F). Principal component analysis
(PCA) of all expressed genes (Fig. 1G) and heatmap analysis of differentially
expressed (DE) genes (Fig. 1H and Supporting Table S2) revealed that the
transcriptomic profiles among these groups were distinct and well separated,
indicating that LM3 cells were strongly influenced by the immune system. Results
from the hCD45‐depleted group indicated that the immune system had already
exerted some impact on the tumors even though it had been removed 2 weeks after
tumor implantation. Ingenuity pathway analysis revealed that the
acute‐phase‐response signaling pathways were highly modulated in LM3 cells from
humanized mice, including triggering receptor expressed on myeloid cells 1,
IL‐6, high mobility group box 1 (HMGB1), and IL‐10 signaling pathways, compared
with NSG and hCD45‐depleted humanized mice (Fig. 1I). Immunohistochemistry
staining of HCC‐PDX tumors and western blot analysis of isolated HCC‐PDX tumor
cells indicated that the JAK2/STAT3 of the tumor was highly phosphorylated in
humanized mice (Fig. 1J,K). Hence, we anticipated that the humanized immune
system in our model may enhance HCC‐PDX proliferation through the activation of
the JAK2/STAT3 intracellular signaling pathways in the HCC cells.
FIG. 1:
Human immune system–promoted HCC proliferation and angiogenesis in the Humice
model. (A) Representative images of HCC‐PDX tumor 1# and spleens, and the
statistical analysis of HCC‐PDX tumor 1# weight from NSG (n = 5), Humice
(n = 5), and Humice treated with anti–hCD45 Ab (50 ug/mouse/week for 4 weeks;
n = 5). (B) Immunohistochemistry staining of Ki67 in HCC‐PDX tumor 1# tissues
and the statistical analysis of the proportion of Ki67+ cells (n = 20, four
randomly selected photographs/each sample [total of five samples]). (C) The EDU
staining of the HCC‐PDX tumor 1# cells isolated from NSG Humice and Humice
treated with anti‐hCD45 Ab and the statistical analysis of EDU+ cells (n = 5).
(D) Immunohistochemistry staining of CD31 in tumor tissues and the statistical
analysis of the MVD and VCSA (n = 5 samples/group; four images were randomly
selected for each sample for quantification [total of 20]). (E) Five million
cells from the HCC cell line LM3 were engrafted into different groups. The tumor
weight was analyzed after 3 weeks (n = 4). (F) The methodology and workflow for
RNA sequencing of isolating LM3 tumor cells from different mice groups. (G) PCA
of LM3 tumor cells from different groups. (H) The heatmap of top DE genes in
RNA‐sequencing results. (I) The signal pathway analysis of DE genes from LM3
tumor cells between Humice and NSG mice or Humice and Humice treated with
anti‐hCD45 Abs. (J) Immunohistochemistry staining of p‐STAT3, p‐JAK2, p‐ERK1/2,
p‐p38, and p‐AKT using HCC‐PDX tumor 1#. (K) Western blot analysis of p‐STAT3,
p‐JAK2, p‐ERK1/2, p‐p38, and p‐AKT from isolated HCC‐PDX tumor cells from
different groups. Abbreviations: APC, allophycocyanin; ERK, extracellular
signal‐regulated kinases; GAPDH, glyceraldehyde 3‐phosphate dehydrogenase;
Humice, humanized mice; n.s, not significant; TREM1, triggering receptor
expressed on myeloid cells 1. *P < 0.05; **P < 0.01.
INTRATUMOR HCD14 CELLS CONTRIBUTE TO PROMOTING HCC PROLIFERATION AND
ANGIOGENESIS
To validate the functions of human immune cells from different organs on HCC in
vitro, hCD45+ cells were isolated from blood, spleen, bone marrow (BM), and
tumor‐infiltrating leukocytes (TILs) of humanized mice bearing HepG2 cells and
LM3 cells (with HLA‐A2, similar to HCC‐PDX tumors 1#‐4#), and the average
composition of immune‐cell subsets was analyzed (Fig. 2A). A colony formation
assay was performed by two‐dimensional co‐culturing of hCD45+ cells and HepG2
cells or LM3 cells for 10 days. The results showed that only TILs could strongly
stimulate HepG2 cell and LM3 cells proliferation when they were compared with
immune cells from other origins (Fig. 2B). Subsequently, hCD45+ cells were
isolated from blood and TILs from humanized mice bearing HCC‐PDX tumor 1#. The
mRNA expression levels of various chemokines, cytokines, and growth factors were
analyzed by RT–quantitative real‐time PCR; IL‐33, IL‐6, CCL15, VEGF, CCL16,
PDGF, IL‐8, IL‐10, and CXCR7 were highly expressed in hCD45+ TILs (Fig. 2C and
Supporting Table S3). To further identify the subtypes of hCD45+ TILs that
influenced HCC proliferation and angiogenesis, different immune‐cell subsets
were depleted in vivo using humanized mice bearing HCC‐PDX tumor 1# (Supporting
Fig. S7). The weight of each HCC‐PDX tumor 1# was measured 4 weeks after
treatment, and the results revealed that hCD14+ or CD19+ cell depletion could
reduce HCC tumor weight. In contrast, hCD8+ cell depletion increased tumor
weight (Fig. 2D). Immunohistochemical staining of Ki67 and EDU flow cytometry
assays showed a decrease in HCC proliferation after hCD14+ cell depletion
(Fig. 2E,F and Supporting Fig. S8). Moreover, angiogenesis in the HCC tumor,
indicated by the MVD and VCSA, was impaired by hCD14+ or hCD19+ cell depletion
(Fig. 2G,H and Supporting Fig. S8). The presence and protein expression levels
of phospho‐JAK2 (p‐JAK2) and p‐STAT3 in the HCC tumor and the purified HCC cells
were examined by using immunohistochemistry (Fig. 2I,J and Supporting Fig. S8)
and western blotting (Fig. 2K), respectively. Our results showed that only
hCD14+ cell depletion could significantly diminish the expression of JAK2 and
STAT3 in the tumor. In addition, hCD14+ or CD19+ cell depletion also altered the
composition of human immune‐cell subsets of TILs (Fig. 2L,M). After the
depletion of hCD14+ cells, the proportion of total CD8+ cells, central memory Th
cells (ThCMs), effector memory cytotoxic T (Tc) cells (TcEMs), and central
memory Tc cells (TcCMs) increased, whereas the proportion of effector memory Th
cells (ThEMs), type 1 macrophages (MØ1s) or type 2 macrophages (MØ2s), and
mononuclear MDSCs (M‐MDSCs) decreased (Fig. 2L). The total number of CD8+ cells,
CD19+ cells, ThCMs, TcEMs, and TcCMs increased per gram of tumor tissue, whereas
effector memory Th cells (ThEMs), MØ1s or MØ2s, and M‐MDSCs decreased in hCD14+
cell–depleted tumor tissues (Supporting Fig. S9A). Similarly, a depletion in
hCD19+ cells also led to an increase in the percentage of total CD8+ cells and
TcCMs and a decrease in the proportion of MØ2s (Fig. 2M). In terms of the cell
number per gram of tumor tissue, total CD8+ cells, ThCMs, TcEMs, TcCMs,
hCD14+hCD16− cells, and early‐stage MDSCs increased after hCD19+‐cell depletion
(Supporting Fig. S9B). Taken together, the intratumor hCD14+ cells could
stimulate HCC tumor proliferation and angiogenesis by modulating the profile of
the immune cells in the tumor and plausibly through the activation of the
IL6/JAK2/STAT3 signaling pathway.
FIG. 2:
hCD14+ TILs are one of the major players in HCC proliferation and angiogenesis.
(A) The average proportion of multiple human immune cells (hCD45+) in blood,
spleen, BM, and TILs from HepG2 or LM3‐engrafted Humice, which were used in an
HepG2 or LM3 co‐culture in vitro experiment. (B) The HCC clone‐formation
analysis. HepG2 or LM3 cells are co‐cultured with human immune cells from blood,
spleen, BM, and TILs of HepG2‐engrafted Humice for 10 days. The ratio was 1:10,
exchanging new medium and adding new human immune cells every two days. The
statistical analysis of the size of clone is shown (n = 50). (C) Total RNA was
extracted from blood or hCD45+ TILs from Humice without the HCC‐PDX tumor and
HCC‐PDX tumor 1#–bearing Humice. Gene expression profiles are analyzed using
RT–quantitative real‐time PCR (n = 3). A heat map of the gene expression is
shown. (D) HCC‐PDX tumor 1# was engrafted into NSG and Humice, which were
treated with saline, anti–hCD4 Abs, anti‐hCD8 Abs, anti‐hCD19 Abs, anti‐hCD14
Abs, and anti‐hCD56 Abs. (E) The HCC‐PDX tumor 1# cells from different groups
were analyzed using EDU staining (n = 5). (F‐J) Immunohistochemistry staining of
Ki67, CD31, p‐JAK2 and p‐STAT3 were performed in HCC‐PDX tumor tissues. The
statistical results of (F) Ki67+, (G) MVD, (H) VCSA, (I) p‐JAK2, and (J) p‐STAT3
are shown (n = 5 samples/group; four images were randomly selected for each
sample for quantification [total of 20]). (K) Western blot analysis of the
p‐STAT3 and p‐JAK2 level in isolated HCC‐PDX tumor cells from different groups.
(L‐M) The changes in human immune cells’ proportion in TILs after saline and (L)
anti‐hCD14 Ab or (M) anti‐hCD19 Ab injection (n = 5). Abbreviations: e‐MDSC,
early‐stage MDSC; Humice, humanized mice; k, thousand; PMN‐MDSC,
polymorphonuclear leukocyte–MDSC; TcE, effector Tc cell; TcN, naive cytotoxic T
cells; ThE, effector Th cell; ThN, naive T helper cells; Treg, regulatory T
cell; W, with; W/O, without. *P < 0.05; **P < 0.01.
INTRATUMOR HUMAN IMMUNE CELLS ARE STRONGLY MODULATED BY HCC TUMORS
To characterize the phenotypes and functions of the humanized immune system in
the absence or presence of an HCC tumor burden, we isolated multiple immune‐cell
subsets, including CD4+, CD8+, CD14+, CD19+, and CD56+ cells, from the spleen
and from among the TILs of humanized mice bearing an HCC‐PDX tumor and analyzed
their RNA profiles (Fig. 3A). Through PCA and heatmap analysis, it was found
that the profiles of CD4+ (Fig. 3B), CD8+ (Fig. 3C), CD14+ (Fig. 3D), CD19+
(Fig. 3E), and CD56+ (Fig. 3F) cells among the groups were distinct and well
separated. The list of DE genes was detected and calculated for CD4+, CD8+,
CD19+, CD14+, and CD56+ cells (Supporting Table S2). Despite minor differences
between splenic immune cells from humanized mice with and without HCC, the
intratumor human immune cells were significantly different, including in terms
of the expression of surface markers, chemokines, cytokines, and functional
proteins. For example, cell migration (CCL13 and CCL18), angiogenesis and
invasion (CCL2, CCL7, CCL9, CCL10, IL‐8, IL‐10, PDGFA, VEGFA, EGF, MMP7, MMP9,
and MMP19), and MØ2 type markers (CD163 and peroxisome proliferator–activated
receptor gamma genes) were found to be up‐regulated in hCD14+ TILs, whereas MØ1
type maker (CD86) and phagocytosis markers (neutrophil cytosol factor 1 [NCF‐1],
phosphatidylinositol 4‐phosphate 5‐kinase type‐1 gamma [PIP5K1C],
vasodilator‐stimulated phosphoprotein [VASP], hematopoietic cell kinase [HCK],
phosphatidylinositol‐4,5‐bisphosphate 3‐kinase, catalytic subunit gamma
[PIK3CG], spleen tyrosine kinase [SYK], actin related protein 2/3 complex
subunit 4 [ARPC4], AKT1, WASP family member 2 [WASF2], vav guanine nucleotide
exchange factor 1 [VAV1], actin related protein 2/3 complex subunit 1B [ARPC1B],
P21 (RAC1) activated kinase 1 [PAK1], cofilin 1 [CFL1] and AKT serine/threonine
kinase 2 [AKT2]) were down‐regulated. These results suggested that HCC tumors
could alter human immune cells in humanized mice, particularly on intratumor
human immune cells.
FIG. 3:
Human immune cells from TILs were modulated by HCC tumors. Multiple kinds of
human immune cells are isolated from spleen (in HCC‐PDX tumor 1#–bearing
humanized mice and non–HCC humanized mice) and HCC‐PDX tumor 1# tissue. PCA and
heatmap analysis are performed using RNA‐sequencing results. (A) The workflow of
isolation of multiple kinds of human immune cells for RNA sequencing. (B)
Results of hCD4+ cells (human Th cells). (C) Results of hCD8+ cells (human Tc
cells). (D) Results of hCD14+ cells (human monocytes). (E) Results of hCD19+
cells (human B cells). (F) Results of hCD56+ cells (human NK cells).
Abbreviations: W, with; W/O, without.
IL‐33 SECRETED FROM INTRATUMOR HCD14+ CELLS UP‐REGULATES IL‐6 EXPRESSION IN
MULTIPLE INTRATUMOR IMMUNE CELLS AND ENHANCES HCC PROLIFERATION
Previous studies have shown that serum IL‐33 levels are higher in patients with
HCC than in healthy donors.(39) Consistent with these clinical findings, our
results also verified the elevation of IL‐6 and IL‐33 expression in intratumor
hCD45+ cells (Fig. 2C). In our HCC‐PDX humanized mouse model, IL‐33+ cells were
only present in intratumor hCD14+ cells, and these HCC cells did not express
IL‐33 (data not shown), whereas IL‐6+ cells were detected among the CD4+, CD14+,
and lineage (Lin)− TILs (Fig. 4A‐C). Therefore, the correlation between the IL‐6
level in the captioned immune cells and the IL‐33 level in intratumor hCD14+
cells was analyzed in HCC samples from 10 patients. The results showed that the
IL‐33 level in intratumor hCD14+ cells was closely correlated with the IL‐6
level in intratumor hCD4+ and hCD14+ cells but was weakly correlated with the
intratumor hCD19+ cells and Lin− cells (Fig. 4A). Interestingly, ILC groups from
Lin− cells were found in our model, particularly in BM and among TILs
(Supporting Fig. S10A). The major ILC subtype in the BM and among TILs were ILC1
and ILC2, respectively (Supporting Fig. S10B). Meanwhile, the majority of the
ILC2s could express IL‐6, whereas other ILC subsets, such as ILC1, NCR+ILC3, and
NCR−ILC3, did not express IL‐6 (Fig. 4E). Interleukin 1 receptor‐like 1 (ST2) is
a member of the IL‐1 receptor family, which is the receptor of IL‐33. We found
that ST2 was highly expressed in intratumor CD4+, CD14+, and Lin− cells
(Supporting Fig. S11A). Furthermore, the proportion of ST2+ IL‐6+ cells was much
higher than that of ST2− IL‐6+ cells in CD4+, CD14+, and Lin− cells (Supporting
Fig. S11B), suggesting that IL‐33 could modulate IL‐6 expression through the ST2
receptor. To confirm the regulatory effect of IL‐33 on HCC in vivo, anti–human
IL‐33 Ab was injected into HCC‐PDX humanized mice to neutralize IL‐33. After 4
weeks of treatment, the tumor weight for these mice was drastically reduced
compared with that of their saline‐injected counterparts (Fig. 4F). Meanwhile,
human IL‐33 neutralization led to a decrease in the IL‐6 level in intratumor
CD4+, CD14+, and Lin− cells (Fig. 4G) and led to lower activation of JAK2 and
STAT3 in HCC cells (Fig. 4H). Furthermore, the MVD and VCSA suggested that IL‐33
was also involved in angiogenesis (Fig. 4I,J). After human IL‐33 neutralization,
the proportions of intratumor Th2 and regulatory T cells decreased, whereas the
proportion of TcEMs increased, suggesting that CD14+ monocyte–derived IL‐33 may
also be involved in regulating other immune‐cell types in the tumor environment
(Fig. 4K). These results suggested that IL‐33 from intratumor hCD14+ cells could
up‐regulate IL‐6 expression in multiple cell types, thereby enhancing HCC
proliferation.
FIG. 4:
IL‐33 from CD14+ TILs could up‐regulate IL‐6 expression in TILs’ multiple immune
cells and enhance HCC proliferation and angiogenesis. (A) Correlation of IL‐33
levels in monocytes and IL‐6 levels in CD4+, CD14+, CD19+, and Lin− TILs of
patients with HCC. (B‐D) Expression of IL‐33 and IL‐6 in hCD4+, CD8+, CD19+,
CD14+, and Lin− cells from blood, spleen, and BM and from among TILs in HCC‐PDX
tumor 1# humanized mice models. The statistical results of (C) IL‐33 and (D)
IL‐6 are shown. (E) IL‐6 expression in ILCs from spleen and TILs. The
statistical result is shown. (F) HCC‐PDX tumor 1# weight after 4 weeks of
treatment with saline and anti–IL‐33 Abs. (G) Changes in IL‐6 level in TILs’
multiple human immune cells after anti–human IL‐33 Ab treatment. (H) Western
blot analysis of p‐STAT3 and p‐JAK2 from isolated HCC cells from saline and
anti‐IL33 Ab treatment groups. (I‐J) Tumor angiogenesis analysis in HCC‐PDX
tumor 1# tissues from saline and anti‐IL33 Ab treatment groups. The statistical
results of (I) MVD and (J) VCSA are shown (n = 5 samples/group, four images were
randomly selected for each sample for quantification [total of 20]). (K) Changes
in the proportion of multiple human immune cells after anti‐IL33 Ab treatment in
TILs. Abbreviations: e‐MDSC, early‐stage MDSC; PMN‐MDSC, polymorphonuclear
leukocyte–MDSC; TcE, effector Tc cell; TcN, naive cytotoxic T cells; ThE,
effector Th cell; ThN, naive T helper cells; Treg, regulatory T cell. *P < 0.05;
**P < 0.01.
CO‐RECEPTOR CD14 IS ESSENTIAL FOR IL‐33 PRODUCTION THROUGH DAMP
(HMGB1)/TLR4/ACTIVATOR PROTEIN 1 PATHWAY
To clarify the mechanism of IL‐33 production from intratumor hCD14+ cells only,
we induced IL‐33 expression using primary human immune cells and U937 cells in
vitro. We attempted to detect IL‐33 expression induced by using different
reagents, including co‐culture with HepG2, Hep3B, Huh7, and PLC5 cell lines and
stimulation by lipopolysaccharide (LPS), IL‐33, IL‐6, HepG2 lysates, Hep3B
lysates, Huh7 lysates, and PLC5 lysates. We observed that only HepG2 lysates and
LPS could induce high levels of IL‐33 in primary human immune cells (Fig. 5A).
Meanwhile, we stimulated U937 cells using HepG2 lysates. However, no IL‐33
expression caused by the direct addition of HepG2 lysates to U937 cells was
observed (Fig. 5B). U937 is a monocytic cell line, and low levels of CD14 and
1,25‐dihydroxyvitamin D3 (VD3) may induce CD14 expression in U937; these are
results we validated (Supporting Fig. S12). We observed that VD3 could induce
CD14 expression and that HepG2 lysates stimulated the induction of IL‐33 in
VD3‐treated U937 cells (Fig. 5B). The flow cytometry plot also indicated that
only CD14+ cells expressed IL‐33 (Fig. 5B). In VD3‐treated U937 cells, HepG2
lysates, Hep3B lysates, PLC5 lysates, and LPS could induce high levels of IL‐33.
We also performed specific targeted hCD14 gene knockdown in U937 cells using
five short‐hairpin RNAs (shRNAs) (Supporting Fig. S13). TRC1.5 vector controls
and shRNAs expressing lentiviral particles were generated using third‐generation
lentivirus packaging systems. The results indicated that hCD14 shRNAs could
significantly impair CD14 expression induced by VD3 in U937 cells (Supporting
Fig. S13B). As a result, the intracellular level of IL‐33 induced by VD3 and
HepG2 lysates was down‐regulated in hCD14‐silenced U937 cells (Supporting
Fig. S13C). In conclusion, CD14 is an essential molecule for IL‐33 production.
By analyzing the network of highly expressed genes in intratumor CD14+ cells, we
found that activator protein 1 (AP‐1) was as a key transcription factor because
of its regulation of many of the up‐regulated genes. Similar results, including
activation of the AP‐1 pathway, can also be observed in the RT–quantitative
real‐time PCR heatmap of CD45+ TILs (Supporting Fig. S14A), U937 cells treated
with VD3, HepG2 lysates (Supporting Fig. S14B), and healthy donor CD45+ cells
treated with HepG2 lysates (Supporting Fig. S14C). To further validate the role
of AP‐1 signaling in IL‐33 expression, we treated primary hCD45+ cells with LPS,
HCC lysates (HepG2), (R)‐Ethyl 6‐(N‐(2‐chloro‐4 fluorophenyl) sulfamoyl)
cyclohex‐1‐enecarboxylate (TAK‐242) (inhibitor of TLR4) and
(E,E,Z,E)‐3‐Methyl‐7‐(4‐methylphenyl)‐9‐(2,6,6‐trimethyl‐1‐cyclohexen‐1‐yl)‐2,4,6,8‐nonatetraenoic
acid (SR‐11302) (inhibitor of AP‐1). The results showed that either blockage of
TLR4 or inhibition of AP‐1 can suppress LPS‐ or HCC lysate–induced IL‐33
expression (Fig. 5D). Additionally, we found that LPS and HCC lysates could
increase Jun family (JUNB, c‐JUN, and JUND) protein levels in hCD14+ cells.
However, TAK‐242 and SR‐11302 can mitigate the elevation of Jun Proto‐Oncogene
(JUN)‐family proteins (Fig. 5E). We also confirmed that AP‐1 can bind multiple
motifs in the promoter region of IL‐33 in U397 cells (Supporting Fig. S15A,B).
HCC lysates can enhance the binding ability of AP‐1 (JUN family) to the promoter
of IL‐33. TAK‐242 and SR‐11302 can mitigate the effect of HCC lysates (Fig. 5F).
Moreover, HMGB1 protein is a type of DAMP that is typically located in the
nucleus as a nuclear factor. However, it can also be translocated to the
cytoplasm and released into the extracellular matrix, linking inflammation and
HCC. HMGB1 may activate several intracellular signaling pathways (NF‐κB or AP‐1)
that regulate monocyte‐induced cytokine synthesis by binding TLRs 2, 4, 5, and
9. Earlier studies have also demonstrated that HMGB1 is highly expressed in HCC
tissues compared with paratumor and normal tissues and that it also promotes HCC
proliferation and angiogenesis. To determine the role of HMGB1 in IL‐33
synthesis, we treated primary hCD45+ cells with HCC lysates and anti‐HMGB1
neutralizing Abs. The results indicated that anti‐HMGB1 neutralizing Abs could
attenuate HCC lysate–induced IL‐33 levels in CD14+ monocytes (Fig. 5G).
Furthermore, increased supernatant HMGB1 levels were observed in
interferon‐gamma (IFN‐gamma)–treated HCC cells (Fig. 5H). Overall, IL‐33 could
be synthesized by CD14+ cells through the DAMP(HMGB1)/TLR4/AP‐1 pathway.
FIG. 5:
CD14 is an essential molecule for IL‐33 generation induced by DAMPs (HMGB1) from
HCC through the TLR4/AP‐1 pathway. (A) IL‐33 expression levels in hCD14+ cells
after stimulating hCD34− cells from three healthy donors with different reagents
(n = 3). (B) The IL‐33 level in U937 cells following stimulation by different
reagents with or without VD3 pretreatment (n = 3). (C) Network for highly
expressed transcription factors in hCD14+ TILs. (D) IL‐33 expression levels in
hCD14+ cells combinatorically treated with HepG2 lysates, TAK‐242 (TLR4
inhibitor), and SR‐11302 (AP‐1 transcription factor inhibitor). (E) JUN protein
levels, including JUNB, c‐JUN, and JUND, in U937 cells (pretreated with VD3)
following combinatorial treatment with HepG2 lysates, TAK‐242 and SR‐11302. (F)
ChIP analysis was performed in U937 cells using anti‐JUNB Ab, anti–c‐JUN Ab, and
anti‐JUND. ChIP DNA was analyzed using real‐time PCR (n = 4). (G) The effect of
HMGB1 neutralizing Ab on lysate‐induced IL‐33 expression (n = 3). (H) Western
blot analysis of HMGB1 levels from the supernatant after IFN‐gamma treatment of
LM3 cells for 24 hours. Abbreviations: ChIP, chromatin immunoprecipitation; MFI,
mean fluorescence intensity; n.s, not significant; Q, quadrant. *P < 0.05; **P <
0.01.
HCD14+ MONOCYTES AMONG TILS ARE CRUCIAL FOR COMBINATORIAL IMMUNOTHERAPY ON HCC
The above data proved that the presence of intratumor CD14+ cells enhances HCC
proliferation and angiogenesis by activating the JAK2/STAT3 pathway or releasing
angiogenic cytokines (VEGF and so on). HCC‐PDX humanized mice were treated with
C188‐9 (STAT3 inhibitor) or bevacizumab (VEGF inhibitor) alone or in combination
with pembrolizumab, and the additive effects were observed following treatment
(Fig. 6A,B). Next, the efficacy and safety of triple‐combination therapy using
C188‐9, bevacizumab, and pembrolizumab were evaluated and showed a more
significant anti‐HCC effect (Fig. 6C). Similar results were consistently
observed from subcutaneous (Supporting Figs. S1G, S2G and S3G) and orthotopic
mouse models reconstituted with PDXs from different donors (Supporting
Figs. S4D, S5D and S6D). The Ki‐67 immunohistochemical staining revealed that
HCC tumors treated with triple‐combination therapy had the lowest level of
proliferation (Fig. 6D and Supporting Fig. S15). Besides this, MVD and VCSA
results also indicated that triple‐combination therapy could reduce angiogenesis
(Fig. 6E,F and Supporting Fig. S15). Interestingly, the phosphorylation of STAT3
in HCC tumors was reduced after triple‐combination therapy, albeit with an
increase in the tumor size following pembrolizumab treatment (Fig 6G,I and
Supporting Fig. S16). Meanwhile, the expression of JAK2 was unchanged after
triple‐combination therapy (Fig. 6H,I and Supporting Fig. S16). To further
investigate the role of individual human immune‐cell types in this
triple‐combination therapy, we compared the anti‐HCC effect of
triple‐combination therapy when hCD14 and hCD8 cells were depleted separately in
both subcutaneous (HCC‐PDX tumor 1#) (Supporting Fig. S17) and orthotopic models
(HCC‐PDX tumors 1# and 2#) (Supporting Figs. S18 and S19). The results revealed
that the anti‐HCC effect of triple‐combination therapy were greatly hampered
without hCD8 or hCD14 cells in HCC humanized mice. It confirmed that these two
human immune‐cell types were both critical in this combination therapy. Taken
together, the results showed that triple‐combination therapy using C188‐9,
bevacizumab, and pembrolizumab could significantly increase the efficacy of the
anti‐HCC response in vivo compared with monotherapy or dual‐therapy.
FIG. 6:
hCD14+ myeloid cells from TILs are one of the potential target cells for
developing combinatorial HCC immunotherapy. (A) The HCC‐PDX tumor weight after 4
weeks of treatment with C188‐9 (n = 6), pembrolizumab (n = 6), and combination
treatment (n = 6). (B) The HCC‐PDX tumor weight after 4 weeks of treatment with
bevacizumab (n = 4), pembrolizumab (n = 4), and combination treatment (n = 4).
(C) The HCC‐PDX tumor weight after 3.5 weeks of treatment with saline (n = 6),
C188‐9 + bevacizumab (n = 6), pembrolizumab + bevacizumab (n = 6),
pembrolizumab + C188‐9 (n = 6) and combination treatment (n = 6). (D‐G)
Immunohistochemistry staining of Ki67, CD31, p‐STAT3 and p‐JAK2. The statistical
results of (D) Ki67+, (E) MVD, (F) VCSA, (G) p‐STAT3, and (H) p‐JAK2 are shown
(n = 5 samples/group, four images were randomly selected for each sample for
quantification [total of 20]). (I) Western blot analysis of p‐STAT3 and p‐JAK2
levels from different groups. Abbreviations: APC, allophycocyanin; n.s, not
significant. *P < 0.05; **P < 0.01.
In summary, our humanized‐immune‐system HCC mouse model provides a useful in
vivo platform for testing HCC combinational immunotherapy on the basis of the
dissection of molecular features of the human immune microenvironment and human
tumors. A general picture of tumor–immune‐cell interaction is proposed in our
study (Fig. 7). Initially, when the human immune system is exposed to an HCC
tumor, it becomes activated and releases proinflammatory cytokines, such as
IFN‐gamma. The HCC tumor senses the immune responses and generates resistant
reactions by releasing DAMPs, such as HMGB1, to immunomodulate CD14+ monocytes.
For example, this occurs through the binding of DAMPs to TLR4 and the subsequent
synthesis of IL‐33 through the TLR4/AP‐1 signaling pathway and VEGF, and so on.
IL‐33 stimulates CD4+ cells, CD14+ cells, and ILC2s to release IL‐6, stimulating
HCC proliferation through the JAK2/STAT3 pathway and VEGF‐related angiogenesis
to overcome the killing activity of the immune system. In this context, we
demonstrated that a triple therapy comprising C188‐9 to inhibit STAT3‐related
HCC proliferation induced by IL‐6, bevacizumab to block VEGF‐induced
angiogenesis from intratumor monocytes, and pembrolizumab to block
PD‐1–triggered T‐cell exhaustion induced by PD‐L1/2 has a combinational effect.
FIG. 7:
The DAMP/TLR4/AP‐1/IL‐33/IL‐6 model and combinational anti‐HCC effect of
triple‐combination treatment (immune checkpoint blockades, anti‐HCC
proliferation therapy, and angiogenesis inhibitors).
DISCUSSION
The human immune system is instrumental in modulating HCC progression. On the
one hand, cytotoxic effector cells eliminate HCC cells, whereas tumor‐associated
immune cells stimulate the proliferation, angiogenesis, EMT, invasion, and
metastasis of the HCC.(40‐42) In addition, several inflammatory signaling
pathways in HCC, namely JAK/STAT, MAPK, PI3K/AKT, and extracellular
signal‐regulated kinases1/2 pathways are induced by the immune
cells.(22‐24,43,44) In our humanized‐immune‐system HCC mouse model, increased
HCC proliferation was associated with activation of the JAK/STAT pathway in the
tumor cells, and VEGF‐induced angiogenesis was also triggered by the human
immune system. These results suggest that the human immune system could alter
HCC progression by changing the signaling pathways in our
humanized‐immune‐system HCC mouse model, in a way similar to that observed in
patients with HCC.
Different human immune‐cell subsets, such as T cells, B cells, monocytes, NK
cells, and NK T cells, were present in the HCC tumor microenvironment.(45) These
human immune cells may promote or inhibit HCC growth, depending on the immune
responses elicited. For example, depletion of CD4+ T cells and CD8+ T cells
could accelerate HCC progression,(46,47) which was also seen in our model. By
contrast, we also demonstrated that depletion of B cells, monocytes, and
macrophages could attenuate the growth and angiogenesis of HCC, consistent with
findings in relation to other models.(23,48) In our study, intratumor hCD14+
cells triggered HCC proliferation through IL‐33 and triggered angiogenesis
through VEGF. The angiogenesis seen in this model is likely of mouse origin;
however, human VEGF is highly conserved in mice and could thus stimulate mouse
endothelial cells and be validated in our model.(49) CD14 is a co‐receptor of
TLR4 and the TLR4/AP‐1 pathway, which has been reported to up‐regulate IL‐33
expression.(50,51) Consistent with findings from earlier studies, we found that
CD14+ cells could up‐regulate IL‐33 after stimulation with HCC lysates in vitro,
and we further proved that intratumor CD14+ cells are the only immune‐cell type
responsible for IL‐33–induced HCC proliferation in vivo. The AP‐1 (JUN and FOS
[Fos proto‐oncogene]) signaling pathway was activated in intratumor CD14+ cells
and HCC lysate–treated primary CD14+ cells, in which the expression of IL‐33 was
reduced after TLR4 and AP‐1 inhibition. Another study demonstrated that HMGB1
could induce IL‐33 expression by binding with TLR4.(52) Our results indicated
that the increased IL‐33 expression level induced by HCC lysates was hampered
after HMGB1 neutralization. On the basis of these results, we demonstrated that
the DAMP (HMGB1)/TLR4/AP‐1/IL‐33 pathway was critical for HCC survival and
proliferation. It also appeared that intratumor hCD14+ cells and their
associated pathways could serve as targets for anticancer treatment. Besides
CD14+ cells, other immune‐cell types in the tumor microenvironment all exhibited
significant differential RNA‐sequencing profiles compared with their
counterparts in peripheral organs, such as blood and spleen, suggesting that HCC
tumors have robust selection and learning capabilities regarding immune cells,
enabling them to escape immune surveillance, which is an interesting avenue for
further study of the individual functions of various immune subsets in tumors.
However, HCC intracellular signaling pathways were also significantly impacted
by the immune system, as evidenced by the comparison of tumors from mice with
and without the human immune system. These changes may contribute to the
evolution of the tumor, selection of mutations, and development of drug
resistance. Study of the pool of molecular changes in this model, whereby
different conditions could be created by manipulating immune components, could
facilitate enhanced understanding of the complexity of heterogeneity, mutation
burden, and drug resistance and may be further developed into potential
therapeutic targets. When combining the discoveries from the angles of the tumor
and immune system, our model may subsequently be used to validate the targets
and the interfering strategies developed against these targets in single or
combined approaches.
In addition to target identification, this model also demonstrated its
usefulness in testing existing anticancer and repurposed drugs without putting
patients at risk, particularly in combination‐therapy settings. A combination
therapy that targets HCC and the tumor microenvironment showed a synergistic
effect and has been identified as a promising treatment regimen for patients
with HCC.(25,26,33) Recently, the results of a phase III IMbrave150 trial (a
combination of atezolizumab [Tecentriq] and bevacizumab [Avastin]) indicated
that the therapy could markedly decrease the risk of progression or death in
patients with HCC, compared with treatment with sorafenib (Nexavar).(26,35)
Hence, there is an urgent need to validate existing combination therapies and to
explore therapies with the aid of preclinical animal models in HCC‐PDX and HCC
microenvironments that are similar to those encountered in patients with HCC.
However, the risk and cost of combining different drugs that possess various
toxicity levels have increased significantly. As such, it is difficult and
costly to conduct combinational clinical trials. Our results indicate that
monotherapy, dual therapy, and triple therapy could be used to validate the
anti‐HCC effects and side effects in humanized mice. Monotherapy, such as the
depletion of hCD14+ cells, neutralization of human IL‐33, and the use of C188‐9,
bevacizumab, and pembrolizumab, resulted in differential anti‐HCC effects. Dual
therapy using the combination of C188‐9 and pembrolizumab and the combination of
bevacizumab and pembrolizumab in humanized mice showed the additive effects
compared with the aforementioned monotherapy. Furthermore, triple therapy using
pembrolizumab, bevacizumab, and C188‐9 was evaluated in our HCC, immune
system–humanized mouse model and resulted in an improved combinational effect
compared with the monotherapy and dual therapy. This suggested that
triple‐targeting of HCC proliferation, angiogenesis, and the immune checkpoint
together may offer a combination therapy scheme for HCC treatment. In
conclusion, our HCC humanized‐immune‐system mouse model provides a platform for
studying the interaction between the HCC tumor and human immune cells and for
testing combination therapy that targets the molecular features of HCC and the
HCC immune‐system microenvironment.
AUTHORS CONTRIBUTIONS
Y.Z. designed and performed the experiments, analyzed and interpreted data, and
prepared the manuscript. J.W., S.Y.F., S.Y.T., J.Y.C., W.W.S.T., and M.L.
performed the experiments and analyzed data; W.N.L., T.W.H.S., S.H., J.K.Y.C.,
C.E.C., G.H.L., H.C.T., S.G.L., and Y.W. contributed research tools and reagents
and prepared the manuscript. Q.C. conceived the study, designed the experiments,
supervised the project, and prepared the manuscript.
ACKNOWLEDGMENT
We thank the KK Women’s and Children’s Hospital and National University Hospital
for provision of human fetal liver/cord blood and HCC tumor samples.
REFERENCES
1. Villanueva A. Hepatocellular carcinoma. N Engl J Med 2019;380:1450‐1462.
* Cited Here |
* Google Scholar
2. Bakiri L, Hamacher R, Graña O, Guío‐Carrión A, Campos‐Olivas R, Martinez L,
et al. Liver carcinogenesis by FOS‐dependent inflammation and cholesterol
dysregulation. J Exp Med 2017;214:1387‐1409.
* Cited Here |
* Google Scholar
3. Shalapour S, Lin XJ, Bastian IN, Brain J, Burt AD, Aksenov AA, et al.
Inflammation‐induced IgA+ cells dismantle anti‐liver cancer immunity. Nature
2017;551:340‐345.
* Cited Here |
* Google Scholar
4. Todoric J, Antonucci L, Karin M. Targeting inflammation in cancer prevention
and therapy. Cancer Prev Res 2016;9:895‐905.
* Cited Here |
* Google Scholar
5. Huang W, Chen Z, Zhang L, Tian D, Wang D, Fan D, et al. Interleukin‐8 induces
expression of FOXC1 to promote transactivation of CXCR1 and CCL2 in
hepatocellular carcinoma cell lines and formation of metastases in mice.
Gastroenterology 2015;149:1053‐1067, e14.
* Cited Here |
* Google Scholar
6. Wan S, Zhao E, Kryczek I, Vatan L, Sadovskaya A, Ludema G, et al.
Tumor‐associated macrophages produce interleukin 6 and signal via STAT3 to
promote expansion of human hepatocellular carcinoma stem cells. Gastroenterology
2014;147:1393‐1404.
* Cited Here |
* Google Scholar
7. Ma S, Cheng Q, Cai Y, Gong H, Wu Y, Yu X, et al. IL‐17A produced by
gammadelta T cells promotes tumor growth in hepatocellular carcinoma. Cancer Res
2014;74:1969‐1982.
* Cited Here |
* Google Scholar
8. Shao Y, Lo CM, Ling CC, Liu XB, Ng K‐P, Chu ACY, et al. Regulatory B cells
accelerate hepatocellular carcinoma progression via CD40/CD154 signaling
pathway. Cancer Lett 2014;355:264‐272.
* Cited Here |
* Google Scholar
9. Ghanem I, Riveiro ME, Paradis V, Faivre S, de Parga PM, Raymond E. Insights
on the CXCL12‐CXCR4 axis in hepatocellular carcinoma carcinogenesis. Am J Transl
Res 2014;6:340‐352.
* Cited Here |
* Google Scholar
10. Wiedemann GM, Rohrle N, Makeschin MC, Fesseler J, Endres S, Mayr D, et al.
Peritumoural CCL1 and CCL22 expressing cells in hepatocellular carcinomas shape
the tumour immune infiltrate. Pathology 2019;51:586‐592.
* Cited Here |
* Google Scholar
11. Chew V, Lee YH, Pan LU, Nasir NJM, Lim CJ, Chua C, et al. Immune activation
underlies a sustained clinical response to Yttrium‐90 radioembolisation in
hepatocellular carcinoma. Gut 2019;68:335‐346.
* Cited Here |
* Google Scholar
12. Chew V, Chen J, Lee D, Loh E, Lee J, Lim KH, et al. Chemokine‐driven
lymphocyte infiltration: an early intratumoural event determining long‐term
survival in resectable hepatocellular carcinoma. Gut 2012;61:427‐438.
* Cited Here |
* Google Scholar
13. Liang CM, Chen L, Hu H, Ma HY, Gao LL, Qin J, et al. Chemokines and their
receptors play important roles in the development of hepatocellular carcinoma.
World J Hepatol 2015;7:1390‐1402.
* Cited Here |
* Google Scholar
14. Sachdeva M, Chawla YK, Arora SK. Immunology of hepatocellular carcinoma.
World J Hepatol 2015;7:2080‐2090.
* Cited Here |
* Google Scholar
15. Flores‐Borja F, Irshad S, Gordon P, Wong F, Sheriff I, Tutt A, et al.
Crosstalk between innate lymphoid cells and other immune cells in the tumor
microenvironment. J Immunol Res 2016;2016:7803091.
* Cited Here |
* Google Scholar
16. Shi C, Chen Y, Chen Y, Yang Y, Bing W, Qi J. CD4+ CD25+ regulatory T cells
promote hepatocellular carcinoma invasion via TGF‐beta1‐induced
epithelial‐mesenchymal transition. Onco Targets Ther 2019;12:279‐289.
* Cited Here |
* Google Scholar
17. Zhou SL, Yin D, Hu ZQ, Luo CB, Zhou ZJ, Xin HY, et al. A Positive feedback
loop between cancer stem‐like cells and tumor‐associated neutrophils controls
hepatocellular carcinoma progression. Hepatology 2019;70:1214‐1230.
* Cited Here |
* Google Scholar
18. Budhu A, Wang XW. The role of cytokines in hepatocellular carcinoma. J
Leukoc Biol 2006;80:1197‐1213.
* Cited Here |
* Google Scholar
19. Wang X, Ding J, Feng Y, Weng L, Zhao G, Xiang J, et al. Targeting of growth
factors in the treatment of hepatocellular carcinoma: the potentials of
polysaccharides. Oncol Lett 2017;13:1509‐1517.
* Cited Here |
* Google Scholar
20. Chen R, Cui J, Xu C, Xue T, Guo K, Gao D, et al. The significance of MMP‐9
over MMP‐2 in HCC invasiveness and recurrence of hepatocellular carcinoma after
curative resection. Ann Surg Oncol 2012;19(Suppl. 3):S375‐S384.
* Cited Here |
* Google Scholar
21. Giannelli G, Bergamini C, Marinosci F, Fransvea E, Quaranta M, Lupo L, et
al. Clinical role of MMP‐2/TIMP‐2 imbalance in hepatocellular carcinoma. Int J
Cancer 2002;97:425‐431.
* Cited Here |
* Google Scholar
22. Fu XT, Dai Z, Song K, Zhang ZJ, Zhou ZJ, Zhou SL, et al. Macrophage‐secreted
IL‐8 induces epithelial–mesenchymal transition in hepatocellular carcinoma cells
by activating the JAK2/STAT3/Snail pathway. Int J Oncol 2015;46:587‐596.
* Cited Here |
* Google Scholar
23. Kong L, Zhou Y, Bu H, Lv T, Shi Y, Yang J. Deletion of interleukin‐6 in
monocytes/macrophages suppresses the initiation of hepatocellular carcinoma in
mice. J Exp Clin Cancer Res 2016;35:131.
* Cited Here |
* Google Scholar
24. Trikha P, Carson WE III. Signaling pathways involved in MDSC regulation.
Biochim Biophys Acta 2014;1846:55‐65.
* Cited Here |
* Google Scholar
25. Stotz M, Gerger A, Haybaeck J, Kiesslich T, Bullock MD, Pichler M. Molecular
targeted therapies in hepatocellular carcinoma: past, present and future.
Anticancer Res 2015;35:5737‐5744.
* Cited Here |
* Google Scholar
26. Kudo M. Targeted and immune therapies for hepatocellular carcinoma:
predictions for 2019 and beyond. World J Gastroenterol 2019;25:789‐807.
* Cited Here |
* Google Scholar
27. Bergmann J, Müller M, Baumann N, Reichert M, Heneweer C, Bolik J, et al.
IL‐6 trans‐signaling is essential for the development of hepatocellular
carcinoma in mice. Hepatology 2017;65:89‐103.
* Cited Here |
* Google Scholar
28. Shakiba E, Ramezani M, Sadeghi M. Evaluation of serum interleukin‐6 levels
in hepatocellular carcinoma patients: a systematic review and meta‐analysis.
Clin Exp Hepatol 2018;4:182‐190.
* Cited Here |
* Google Scholar
29. Jung KH, Yoo W, Stevenson HL, Deshpande D, Shen H, Gagea M, et al.
Multifunctional effects of a small‐molecule STAT3 inhibitor on NASH and
hepatocellular carcinoma in mice. Clin Cancer Res 2017;23:5537‐5546.
* Cited Here |
* Google Scholar
30. Siegel AB, Cohen EI, Ocean A, Lehrer D, Goldenberg A, Knox JJ, et al. Phase
II trial evaluating the clinical and biologic effects of bevacizumab in
unresectable hepatocellular carcinoma. J Clin Oncol 2008;26:2992‐2998.
* Cited Here |
* Google Scholar
31. Fang P, Hu JH, Cheng ZG, Liu ZF, Wang JL, Jiao SC. Efficacy and safety of
bevacizumab for the treatment of advanced hepatocellular carcinoma: a systematic
review of phase II trials. PLoS One 2012;7:e49717.
* Cited Here |
* Google Scholar
32. Scheiner B, Kirstein MM, Hucke F, Finkelmeier F, Schulze K, von Felden J, et
al. Programmed cell death protein‐1 (PD‐1)‐targeted immunotherapy in advanced
hepatocellular carcinoma: efficacy and safety data from an international
multicentre real‐world cohort. Aliment Pharmacol Ther 2019;49:1323‐1333.
* Cited Here |
* Google Scholar
33. Pinter M, Peck‐Radosavljevic M. Review article: systemic treatment of
hepatocellular carcinoma. Aliment Pharmacol Ther 2018;48:598‐609.
* Cited Here |
* Google Scholar
34. Liu H, Shen J, Lu K. IL‐6 and PD‐L1 blockade combination inhibits
hepatocellular carcinoma cancer development in mouse model. Biochem Biophys Res
Commun 2017;486:239‐244.
* Cited Here |
* Google Scholar
35. Medavaram S, Zhang Y. Emerging therapies in advanced hepatocellular
carcinoma. Exp Hematol Oncol 2018;7:17.
* Cited Here |
* Google Scholar
36. Eichten A, Su J, Adler AP, Zhang LI, Ioffe E, Parveen AA, et al. Resistance
to anti‐VEGF therapy mediated by autocrine IL6/STAT3 signaling and overcome by
IL6 blockade. Cancer Res 2016;76:2327‐2339.
* Cited Here |
* Google Scholar
37. Zhao Y, Shuen TWH, Toh TB, Chan XY, Liu M, Tan SY, et al. Development of a
new patient‐derived xenograft humanised mouse model to study human‐specific
tumour microenvironment and immunotherapy. Gut 2018;67:1845‐1854.
* Cited Here |
* Google Scholar
38. Zhao Y, Liu M, Chan XY, Tan SY, Subramaniam S, Fan Y, et al. Uncovering the
mystery of opposite circadian rhythms between mouse and human leukocytes in
humanized mice. Blood 2017;130:1995‐2005.
* Cited Here |
* Google Scholar
39. Zhang P, Liu XK, Chu Z, Ye JC, Li KL, Zhuang WL, et al. Detection of
interleukin‐33 in serum and carcinoma tissue from patients with hepatocellular
carcinoma and its clinical implications. J Int Med Res 2012;40:1654‐1661.
* Cited Here |
* Google Scholar
40. Makarova‐Rusher OV, Medina‐Echeverz J, Duffy AG, Greten TF. The yin and yang
of evasion and immune activation in HCC. J Hepatol 2015;62:1420‐1429.
* Cited Here |
* Google Scholar
41. Chen Y, Hao X, Sun R, Wei H, Tian Z. Natural killer cell‐derived
interferon‐gamma promotes hepatocellular carcinoma through the epithelial cell
adhesion molecule‐epithelial‐to‐mesenchymal transition axis in hepatitis B virus
transgenic mice. Hepatology 2019;69:1735‐1750.
* Cited Here |
* Google Scholar
42. Disis ML. Immune regulation of cancer. J Clin Oncol 2010;28:4531‐4538.
* Cited Here |
* Google Scholar
43. Capece D, Fischietti M, Verzella D, Gaggiano A, Cicciarelli G, Tessitore A,
et al. The inflammatory microenvironment in hepatocellular carcinoma: a pivotal
role for tumor‐associated macrophages. Biomed Res Int 2013;2013:187204.
* Cited Here |
* Google Scholar
44. Nikolaou K, Sarris M, Talianidis I. Molecular pathways: the complex roles of
inflammation pathways in the development and treatment of liver cancer. Clin
Cancer Res 2013;19:2810‐2816.
* Cited Here |
* Google Scholar
45. Garnelo M, Tan A, Her Z, Yeong J, Lim CJ, Chen J, et al. Interaction between
tumour‐infiltrating B cells and T cells controls the progression of
hepatocellular carcinoma. Gut 2017;66:342‐351.
* Cited Here |
* Google Scholar
46. Ma C, Kesarwala AH, Eggert T, Medina‐Echeverz J, Kleiner DE, Jin P, et al.
NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis.
Nature 2016;531:253‐257.
* Cited Here |
* Google Scholar
47. Endig J, Buitrago‐Molina LE, Marhenke S, Reisinger F, Saborowski A, Schütt
J, et al. Dual role of the adaptive immune system in liver injury and
hepatocellular carcinoma development. Cancer Cell 2016;30:308‐323.
* Cited Here |
* Google Scholar
48. He H, Wu J, Zang M, Wang W, Chang X, Chen X, et al. CCR6+ B lymphocytes
responding to tumor cell‐derived CCL20 support hepatocellular carcinoma
progression via enhancing angiogenesis. Am J Cancer Res 2017;7:1151‐1163.
* Cited Here |
* Google Scholar
49. Gerber HP, Wu X, Yu L, Wiesmann C, Liang XH, Lee CV, et al. Mice expressing
a humanized form of VEGF‐A may provide insights into the safety and efficacy of
anti‐VEGF antibodies. Proc Natl Acad Sci U S A 2007;104:3478‐3483.
* Cited Here |
* Google Scholar
50. He Z, Riva M, Björk P, Swärd K, Mörgelin M, Leanderson T, et al. CD14 is a
co‐receptor for TLR4 in the S100A9‐induced pro‐inflammatory response in
monocytes. PLoS One 2016;11:e0156377.
* Cited Here |
* Google Scholar
51. Ho JE, Chen WY, Chen MH, Larson MG, McCabe EL, Cheng S, et al. Common
genetic variation at the IL1RL1 locus regulates IL‐33/ST2 signaling. J Clin
Invest 2013;123:4208‐4218.
* Cited Here |
* Google Scholar
52. Chang J, Xia Y, Wasserloos K, Deng M, Blose KJ, Vorp DA, et al. Cyclic
stretch induced IL‐33 production through HMGB1/TLR‐4 signaling pathway in murine
respiratory epithelial cells. PLoS One 2017;12:e0184770.
* Cited Here |
* Google Scholar
View full references list
Author names in bold designate shared co–first authorship.
© 2021 The Authors. Hepatology published by Wiley Periodicals LLC on behalf of
American Association for the Study of Liver Diseases.
View full article text
SOURCE
Analysis and Validation of Human Targets and Treatments Using a Hepatocellular
Carcinoma–Immune Humanized Mouse Model
Hepatology74(3):1395-1410, September 2021.
* Full-Size
* Email
* + Favorites
* Export
* View in Gallery
Email to Colleague
Colleague's E-mail is Invalid
Your Name:
Colleague's Email:
Separate multiple e-mails with a (;).
Message:
Thought you might appreciate this item(s) I saw in Hepatology.
Your message has been successfully sent to your colleague.
Some error has occurred while processing your request. Please try after some
time.
RELATED ARTICLES
* MECHANISTIC RATIONALES GUIDING COMBINATION HEPATOCELLULAR CARCINOMA THERAPIES
INVOLVING IMMUNE CHECKPOINT INHIBITORS
* IMMUNE CHECKPOINT INHIBITORS IN COMBINATIONS FOR HEPATOCELLULAR CARCINOMA
* THE LIVER CANCER IMMUNE MICROENVIRONMENT: THERAPEUTIC IMPLICATIONS FOR
HEPATOCELLULAR CARCINOMA
* SPATIAL PROXIMITY OF TUMOR-IMMUNE INTERACTIONS PREDICTS PATIENT OUTCOME IN
HEPATOCELLULAR CARCINOMA
* SPONTANEOUS REGRESSION OF HEPATOCELLULAR CARCINOMA: WHEN THE IMMUNE SYSTEM
STANDS UP TO CANCER
* LETTER TO THE EDITOR: HEPATITIS B VIRUS REACTIVATION IN IMMUNE CHECKPOINT
INHIBITOR‐BASED COMBINATION THERAPIES FOR HEPATOCELLULAR CARCINOMA
READERS OF THIS ARTICLE ALSO READ
* TRANSCRIPTOMICS IDENTIFY THROMBOSPONDIN‐2 AS A BIOMARKER FOR NASH AND
ADVANCED...
* MACROPHAGE‐SPECIFIC FGF12 PROMOTES LIVER FIBROSIS PROGRESSION IN MICE
* ENDOTHELIAL NOTCH ACTIVATION RESHAPES THE ANGIOCRINE OF SINUSOIDAL
ENDOTHELIA...
* 11BETA‐HYDROXYSTEROID DEHYDROGENASE‐1 DEFICIENCY OR INHIBITION ENHANCES
HEPATIC ...
* HEPATOSTAT: LIVER REGENERATION AND NORMAL LIVER TISSUE MAINTENANCE
MOST POPULAR
* DIAGNOSIS, EVALUATION, AND MANAGEMENT OF ASCITES, SPONTANEOUS BACTERIAL
PERITONITIS AND HEPATORENAL SYNDROME: 2021 PRACTICE GUIDANCE BY THE AMERICAN
ASSOCIATION FOR THE STUDY OF LIVER DISEASES
* AASLD PRACTICE GUIDANCE ON THE CLINICAL ASSESSMENT AND MANAGEMENT OF
NONALCOHOLIC FATTY LIVER DISEASE
* AASLD PRACTICE GUIDANCE ON RISK STRATIFICATION AND MANAGEMENT OF PORTAL
HYPERTENSION AND VARICES IN CIRRHOSIS
* AASLD PRACTICE GUIDANCE ON PREVENTION, DIAGNOSIS, AND TREATMENT OF
HEPATOCELLULAR CARCINOMA
* DIAGNOSIS AND MANAGEMENT OF AUTOIMMUNE HEPATITIS IN ADULTS AND CHILDREN: 2019
PRACTICE GUIDANCE AND GUIDELINES FROM THE AMERICAN ASSOCIATION FOR THE STUDY
OF LIVER DISEASES
Back to Top
NEVER MISS AN ISSUE
Get new journal Tables of Contents sent right to your email inbox Get New Issue
Alerts
BROWSE JOURNAL CONTENT
* Register on the website
* Subscribe
* Get eTOC Alerts
CUSTOMER SERVICE
* Contact us at:
* Support:
Submit a Service Request
* TEL:
800-638-3030 (within the USA)
301-223-2300 (outside of the USA)
* Manage Cookie Preferences
* Privacy Policy
* Legal Disclaimer
* Terms of Use
* Open Access Policy
* Your California Privacy Choices
* Copyright © 2024
* American Association for the Study of Liver Diseases - Wolters Kluwer Health,
Inc. All rights reserved.
YOUR PRIVACY
To give you the best possible experience we use cookies and similar
technologies. We use data collected through these technologies for various
purposes, including to enhance website functionality, remember your preferences,
show the most relevant content, and show the most useful ads. You can select
your preferences by clicking the link. For more information about cookies,
please review ourPrivacy & Cookie Notice
Please note that we have recently updated our privacy notice for California
residents, which can be reviewed here.
Reject All Cookies Accept All Cookies
Manage Cookie Preferences
PRIVACY PREFERENCE CENTER
When you visit any website, it may store or retrieve information on your
browser, mostly in the form of cookies. This information might be about you,
your preferences or your device. Because we respect your right to privacy, you
can choose not to allow certain types of cookies on our website. Click on the
different category headings to find out more and manage your cookie preferences.
However, blocking some types of cookies may impact your experience on the site
and the services we are able to offer.
Privacy & Cookie Notice
Allow All
MANAGE CONSENT PREFERENCES
STRICTLY NECESSARY COOKIES
Always Active
These cookies are necessary for the website to function. They are usually set in
response to actions made by you which amount to a request for services, such as
setting your privacy preferences, logging in or filling in forms. You can set
your browser to block or alert you about these cookies, this may have an effect
on the proper functioning of (parts of) the site.
View Vendor Details
FUNCTIONAL COOKIES
Functional Cookies
These cookies enable the website to provide enhanced functionality, user
experience and personalization, and may be set by us or by third party providers
whose services we have added to our pages. If you do not allow these cookies,
then some or all of these services may not function properly.
View Vendor Details
PERFORMANCE COOKIES
Performance Cookies
These cookies support analytic services that measure and improve the performance
of our site. They help us know which pages are the most and least popular and
see how visitors move around the site.
View Vendor Details
ADVERTISING COOKIES
Advertising Cookies
These cookies may collect insights to issue personalized content and advertising
on our own and other websites, and may be set through our site by third party
providers. If you do not allow these cookies, you may still see basic
advertising on your browser that is generic and not based on your interests.
View Vendor Details
Back Button
VENDORS LIST
Search Icon
Filter Icon
Clear
checkbox label label
Apply Cancel
Consent Leg.Interest
checkbox label label
checkbox label label
checkbox label label
Reject All Confirm My Choices